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Abstract 
Introduction: Obesity and type 2 diabetes are leading causes of cardiovascular morbidity 
and mortality most commonly through accelerated atherosclerotic disease. Researchers have 
recognised clearly that there is a cardiac pathological process that is over and beyond any 
damage secondary to accelerated atherosclerosis or associated hypertension. There has 
been much research into the histological, genetic and functional changes that may underpin 
these specific processes; these demonstrate structural hypertrophic and fibrotic changes 
accompanied by changes in energy metabolism, nervous control, contractile performance 
and electrical conduction. To date, there is very little in the way of comparative study 
between animal diabetes and obesity models or of cardiac gene expression in the human 
type 2 diabetes phenotype, which in many individuals comprises both diabetes and obesity. 
Aim: To investigate cardiac genetic expression of proteins and ion channels in obesity and 
diabetes to identify changes underpinning the pathological processes and to characterise 
features common to both conditions, specifically features that may affect contractile 
performance and secondly, changes that may lead to increased arrhythmogenesis. 
Methods: A streptozocin rat model of type 1 diabetes was compared with a high fat diet rat 
model of obesity and finally a human group with type 2 diabetes to understand the gene 
expression changes in the left ventricle characterising the obesity and diabetic 
cardiomyopathy. Gene expression of left ventricle tissue was measured using qPCR and 
compared to a control group; followed by mathematical modelling to predict changes in the 
cardiac action potential. This was used to investigate specific changes to each condition and 
common changes between the groups to identify if there was a common genotype and 
action potential phenotype. 
In addition, echocardiography, the standard ECG and the signal averaged ECG were used to 
assess the human study group for early signs of cardiac dysfunction related to diabetes. 
Results: All three groups had gene expression changes likely to lead to action potential 
prolongation and higher rates of arrhythmias, with ERG (Human Ether Related a Go-Go) 
mRNA reduced in all 3 study groups responsible for I
K,r
. AP modelling, suggested that the 
likely functional change of the gene expression alterations would be to cause AP 
prolongation and in the human study, early-after depolarizations at the endocardial level. 
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As part of the confirmatory process for one of the more unexpected gene changes, up-
regulation in HCN4 gene expression in the obese rats was associated with a significant 
increase in HCN4 protein immunofluorescence in the ventricles. 
In addition, the human type 2 diabetes group had evidence of reduced ventricular 
contractile function, atrial changes and strain rate changes suggestive of myocardial 
fibrosis. No significant alterations were noted in the signal averaged ECG between groups 
but as has been seen in other studies, QT prolongation was found in the type 2 diabetes 
group. 
Conclusion: Diabetes and obesity lead to changes in cardiac gene expression that when 
modelled will prolong the action potential, possibly as a compensatory mechanism to 
maintain contractile function at the expense of an arrhythmogenic phenotype. 
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1. Introduction 
Diabetes and obesity are two of the leading health challenges in medicine across the world 
and specifically in cardiovascular medicine. They remain contributing factors to 
atherosclerotic disease which remains the number one killer in the western world 1. The 
prevalence of diabetes and obesity across the world has increased significantly over the 
years with some areas of the UK reporting a near 50% increase in diabetes prevalence over 
only a decade2 with similar rapid rises reported in obesity defined as a body mass index 
(BMI) greater than 30kg/m23. 
These epidemiological changes have led people to look at the effects that diabetes 
and obesity have on the heart beyond the well-recognised pathophysiological processes 
associated with atherosclerosis and hypertension; increasingly a specific pathological 
process is recognised for each entity with some degree of overlap.  In 1972, Rubler and co-
workers first described a diabetic cardiomyopathy in 4 patients with diabetes presenting 
with clinical heart failure in the absence of hypertension, coronary or structural heart 
disease4. As a result of this and further work on cardiomyopathic process and heart failure 
symptoms in the presence of diabetes and obesity, most authors now define a diabetic or 
obesity related cardiomyopathy as: 
Symptoms of heart failure or evidence of cardiac impairment in the presence 
respectively of diabetes or obesity without concomitant hypertension, structural or 
atherosclerotic heart disease5.  
This cardiomyopathy can present with impairment of contractile performance, 
arrhythmogenic complications or a combination of both.  
Before advanced imaging and specialised laboratory testing, the cardiomyopathic 
effect of diabetes alone was illustrated by UK studies revealing an estimated prevalence of 
diabetes of 4.3 percent but a disproportionate prevalence of diabetes in people with 
congestive heart failure quoted at between 20 and 35 percent reflecting the earlier work in 
Framingham6.   
In Figure 1 shown below is a graph illustrating the prevalence of diabetes in several 
large scale unselected heart failure trials in both ischaemic and non-ischaemic heart failure 
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in the over 65s, which shows prevalence levels much higher than the prevalence in the 
general population.                                                                                                      
 
Figure 1: Prevalence of diabetes in patients in several large scale commercial drug trials for 
heart failure treatment  showing a high percentage of patients with ischaemic and non-
ischaemic heart failure drawn from Bauters et al.7 
Similarly, with obese subjects, researchers noticed that the likelihood of developing 
heart failure was much higher even when adjusted for traditional risk factors such as 
smoking or age than in non-obese subjects as shown below in Figure 28. 
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Figure 2: Age adjusted cumulative incidence of heart failure for increasing weight bands 
over 10 years showing a marked increase for obese individuals compared to normal weight 
controls drawn from Kenchaiah et al.8 
 
What has become more evident in recent years is that as imaging has improved more 
people with diabetes and obesity have been found to have signs of cardiac dysfunction even 
at a preclinical/asymptomatic stage. The most common method of imaging the heart in 
routine clinical practice is echocardiography and in many departments the performance of 
the left ventricle (LV) as a pump is most commonly assessed and reported using the 
Simpson’s biplane ejection fraction9. Using echocardiography, children with type 1 diabetes 
have been found to have subtle changes suggestive of cardiac impairment including 
impaired myocardial relaxation patterns, a phenomenon that was previously confirmed in 
adult diabetes studies in patients with heart failure clinically and a normal ventricular 
ejection fraction10. In obese patients similar subclinical changes can be seen in cardiac 
performance and can be picked up using more detailed imaging techniques and these 
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patients also are often found to have a normal ejection fraction11. These findings would 
suggest that obesity and diabetes affect cardiac function at least initially in a fairly subtle 
manner. 
Once clinical heart failure symptoms occur even with a preserved ejection fraction as can be 
seen in many patients with diabetes and obesity there is a significant increase in mortality12. 
While contractile performance is a major area of concern for many clinicians the rate of 
cardiac rhythm disturbances as part of the cardiomyopathic process is increased in patients 
with diabetes13, 14 and obesity15 compared to matched controls. 
This epidemiological evidence supports the hypothesis that there is a specific 
cardiomyopathic process in diabetes and obesity and the scale of the potential problem 
merits further assessment.  
Reviewed below is the current pathological understanding of the subject and a short 
summary of left ventricular structure and action potential organisation pertinent to this 
study. 
 
1.1. Left ventricular structure 
The left ventricle is not a homogenous structure from outer to inner or from base to apex 
and this is important whenever measurements are made of its function, tissue character or 
gene expression. From inner to outer, the left ventricle is made up of three  distinct muscle 
layers, the endocardium, mid-myocardium and epicardium. 
The endocardium has fibres that run longitudinally, the mid-myocardium as the 
largest layer has circumferential running fibres and the epicardium at 45 degrees to the 
myocardium running spirally16. The relationship of muscle fibres is shown in Figure 3 below: 
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Figure 3: LV fibre orientation topographically from epicardium to endocardium, reflecting 
the changing orientation of fibres adaptive to changing mechanical and electrical stress 
drawn from Trew et al.17 
 
This is important because as layers differ in orientation from epicardium to 
endocardium and also in terms of their location from apex to base, they experience differing 
amounts of mechanical strain. As a result, there are differences in the fibre properties and 
their metabolic actions and therefore the genes that encode for these properties. 
Each of these layers contributes to myocardial performance but the mid-myocardium 
provides the largest amount of contractile force as the largest layer. The myocardium 
traditionally has been the easiest layer to assess echocardiographically as it is responsible 
for the classic lateral contraction picture seen in the apical 4-chamber view and is best 
represented using the Simpson’s method. 
 
1.2. Cardiac action potential 
Generation of the action potential (AP), is caused by a change in the electrochemical 
gradient across the sarcolemma which occurs through conductance of ions through 
channels. These channels characteristically have α and β subunits, α subunits normally 
represent the pore element of the channel and the β subunits accessory structures. 
Movement of ions across the sarcolemma, can be passive or active but in the passive state, 
where the electrochemical gradient is responsible for generating ion movement, current 
amplitude is expressed as: 
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Current amplitude=membrane potential x channel conductivity18 
 
Although for many channels in the body, this equation implies a linear relationship 
however for many cardiac channels conductivity is different at different membrane 
potentials, for example with the inward rectifier K+  rectifying current, I
K,1
 which generates an 
outward current at more negative membrane potentials18. Figure 4 summarises the 
movement in and out of the major ions involved in the cardiac ventricular action potential 
in humans. 
The cardiac action potential has distinct phases, initially, at rest (phase 4) there is 
comparatively high intracellular K+ , maintaining a resting potential of approximately -96 mV. 
This state is maintained by the I
K,1 
current and by an amount of constant active ion transport 
of Na+ /K+ via ATPase driven active exchangers. 
In response to a pacemaker stimulus, there is opening of the fast Na +  channels and a 
massive influx of positive Na+ ions, seen in the diagram below as phase 0, which is normally 
initiated by the depolarization of a nearby cell. I
Na, 
the main cardiac Na+ current responsible 
for phase 0, at normal negative phase 4 membrane potentials will be generated by the 
opening of all the Na
v
1.5 channels at a conduction velocity of 1m/s. The all-or-none 
principle of Na+  channel opening does not apply in disease states and at a higher resting 
potential not all channels will be activated, potentially being arrhythmogenic 19. As the 
membrane potential rises rapidly due to Na+ influx, there is closure of the fast Na+  channels 
and K+  and Cl- efflux (via the I
to
 current), leading to a small drop in voltage, seen as phase 1, 
classically in sub-epicardial cells. The I
to 
current, can be both a fast and slow current- I
to-F
 or 
I
to-s
 respectively and is generated by Ca2+ -dependent Cl - channels and K+   channels (K
v
4.3- I
to-f  
,K
v
1.5- I
to-s 
and to some degree K
v
1.4
-
I
to-s
)19. 
Next, is the longest phase, the plateau phase where the L-type channels- Ca
v
1.2 (I
C a-L 
current-which begin to open at -10mV (during phase 0) allowing initially a small influx of 
extracellular Ca2+  ions and due to voltage changes there is also an efflux of intracellular K+  
ions using the I
K,1,
 I
to
 and I
K,r
. In this phase the initially small amount Ca2+  ions influx which 
began in phase 0 increases and is balanced by K+ via the channels mentioned above, which 
helps to create the long plateau in membrane voltage. This inward current of Ca2+  allows for 
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activation of sarcoplasmic Ca2+ channels (RYR2) which when activated allow for Ca2+  release 
and excitation and contraction coupling. In the background, due to the more positive 
membrane potential, the forward mode of Na+ Ca2+ Exchanger (NCX1) is favoured with exit of 
Na+  for Ca2+  which helps to maintain the plateau phase, this current is termed the I
NaC a
 
current. 
Finally, there is repolarization, when the Ca2+  channels close and K+ rectifying 
channels stay open allowing exit of K+ , till the membrane potential reaches approximately -
80mV at which point only the inward rectifying K+  channel stays open, keeping the 
intracellular K+  concentration constant (phase 3 then 4).  
Important in this phase of repolarization, is the concept of equilibrium potential of 
K+ , which is calculated using the simplified Nernst equation, which is shown below for K+ : 
 
-61.5 log K+  intracellular/ K+  extracellular 
 
This gives an equilibrium potential of K+  of -96mV and this very negative equilibrium 
potential means that continuous K+  is required for a prolonged period to allow the cell to 
come back to a period of equilibrium prior to the next action potential and the separate K+  
channels involved are discussed below. 
 In the mid-myocardium, K+  currents, can be broadly broken down in to two main 
groups; voltage gated (I
to , 
I
K,ss 
I
K,r 
and I
K,s
) and rectifying currents (I
K,1 
and
 
I
K,AC h
). I
K,ss 
I
K,r 
and I
K,s 
are 
slowly activating rectifying channels that are active during phases 2 and 4  of the AP and 
control repolarization. The I
K,r 
current, created by the ERG channel, is a pivotal channel in the 
repolarization process being slowly activated and rapidly inactivated, beginning during 
initial depolarization but accelerating in phase 2 as the membrane potential drops, creating 
a large outward K+  current before closing quickly as K+ concentrations drop at the 
extracellular mouth of the channel. The next most important current in repolarization is I
K,s 
which, as a slow rectifying current created by the K
v
LQT1 channel, creates an outward K+  
current but unlike ERG as the membrane potential becomes more negative, K
v
LQT1 channels 
become inactivated slowly. I
K,s 
has two important features that are different to the other 
voltage gated channels, firstly that its expression is markedly reduced in the mid -myocardial 
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layer giving rise to the prolonged APD in the mid-myocardial layer and it is increased at 
higher heart rates helping to shorten the APD as the heart rate increases. The last of the 
voltage gated currents considered here is I
K,ss
 (also known as I
Kur
) which is an ultrafast voltage 
gated K+  rectifying current which is quickly activated but slowly inactivated and mainly 
found in the atria but has been shown in some studies to be found in the ventricle 20. I
K,AC h 
is a 
rectifying current that is activated by acetylcholine release from the vagal nerve and is best 
understood in terms of its role in the atria and conduction tissues where it helps regulate 
heart rate by shortening the action potential and delaying phase 4 depolarization, which 
causes firing of the sino-atrial node.  
A summary of the cardiac ventricular AP and ion movement is shown below in Figure 
4: 
 
 
Figure 4: The cardiac ventricular action potential and major ion movements in/out 
 
In addition to these main currents, there are several other proteins/currents that are 
important in the action potential of the ventricle. Firstly, is the role of gap junction protei ns 
which help transmit depolarization from one cell to the next cell on in ordered and 
regulated manner and secondly, the hyperpolarization activated cyclic nucleotide-gated K+  
channels (HCNs) which primarily are responsible for phase 4 depolarization in the 
pacemaker regions of the heart.  It does not occur in the normal ventricular myocyte AP, but 
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is important in the foetal/neo-natal phenotype21 and generation of the I
F 
current. While HCNs 
are predominantly seen only in specialist pacemaker and conduction tissue in the heart, 
studies have shown that there is low level ventricular expression and especially in disease 
states may generate ectopic beats and higher resting heart rates22. 
As mechanical orientation changes spatially across the left ventricle, so does the 
cardiac electrical activity (pacemaker cells and specialist conduction cells are not considered 
here), which stimulates myocyte muscle contraction. Initial electrical depolarization begins 
in the endocardial layer and this charge spreads towards the epicardial layer before 
repolarization spreads in reverse through the wall before the next sequence. This is borne 
out in the fact, that the endocardial action potential duration (APD) is much longer than the 
epicaridal APD (shown below in Figure 5), so as to prevent re-excitation before the 
epicardium and mid-myocardium have repolarized and are ready for the next beat. This 
physiological development is protective as it acts to prevent re-excitation ventricular 
arrhythmias and is largely controlled through a transmural gradient in re-polarising 
potassium channels which control the rate of repolarization and thus action potential 
duration23. 
 
 
 
Figure 5: Illustrations of the comparative action potential duration of the left ventricle wall, 
showing the longest APD for the mid-myocardial layer drawn from Colli Franzone et al.24 
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Importantly when it comes to the generation of arrhythmias, is the principle of 
refractoriness, whereby the cell after being depolarized cannot then be depolarized a 
second time and this is due to closure of the Na
v
1.5 channels, which is the principle 
depolarizing current in the human heart. This refractory period can either be absolute or 
relative, i.e. no depolarization at all possible or in the right circumstances depolarization is 
possible but does not occur normally. In the human ventricular myocyte, the absolute 
refractory period is from phase 1-2, due to Ca2+  influx and the relative refractory period is 
from late in phase 2 to phase 4. 
The roles of the main ion channels in relation to the human ventricular AP are 
summarised below in Table 1: 
 
Ion channel Current Main AP phase of 
action 
Ion movement  Physiological role 
Na
v
1.5 I
Na 
0 Na+  influx Cell depolarization 
K
v
1.5,
 
K
v
1.4, 
K
v
4.3 
I
to
 1-2 K+  efflux K+  efflux to balance Ca2+ 
influx and maintain plateau 
Ca
v
1.2 I
C a-L
 2 Ca2+  influx Ca2+  influx to allow for 
excitation/contraction 
K
v
LQT1  I
K,s
 2-4 K+  efflux Abbreviation of the plateau 
phase and repolarization 
ERG I
K,r 
 2-4 K+  efflux Abbreviation of the plateau 
phase and repolarization 
K
ir
2.1 I
K,1
 4 K+  efflux Setting of the resting 
membrane potential 
Table 1: A summary of the roles of the main ion channels in the human ventricular AP 
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1.3. The cardiac action potential: ion channels and arrhythmogenesis  
Arrhythmia generation in the heart considered only at a ventricular level can be thought of 
as falling into two main categories, abnormal impulse formation and abnormal impulse 
conduction and then these two categories can be then further subdivided. 
Firstly, abnormal impulse formation, which is broadly seen in clinical and scientific 
practice as either increased altered automaticity or triggered  activity. Altered automaticity 
normally is most commonly seen in atrial or pacemaker cell generated arrhythmias but at a 
ventricular level is also important where abnormal foci may develop increased automaticity 
in settings with increased sympathetic stimulation, classically seen with VT in 
ischaemia/reperfusion25. 
The most important type of abnormal impulse formation from the perspective of 
this study, is that of triggered activity where an abnormal impulse is generated during or 
after an existing action potential that reaches a threshold potential causing an after-
depolarization and a new AP. These can be either early- (EAD) or delayed after 
depolarization (DAD) depending on whether they occur in phase 2/3 or after repolarization 
is finished respectively, shown below in Figure 6: 
 
 
 
Figure 6: Ventricular AP’s with arrowed depolarizations. A, an early after depolarization 
occurring late in phase 2, B, an early after depolarization occurring in phase 3 but before 
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the completion of repolarization and C, a delayed after depolarization in phase 4 with 
repolarization complete. Drawn from Gaztanaga et al.26 
Firstly, the early after depolarization, this is caused predominantly by re-activation 
of the I
C a-L 
current which occurs during the end of phase 2, when there is AP repolarization 
and the membrane potential drops, I
C a-L 
can enter a window phase of 0 to-30mV (overlap 
between steady inactivation and activation) where the channel can re -open creating a new 
inward current and when large enough an EAD 23. In normal circumstances during the end of 
phase 2 to phase 3 there is high K+  conductance via I
K,r
 and I
K,s
 creating a high and fast 
outward current which repolarises and does not allow I
C a-L 
to self-amplify and create an 
EAD27. Multiple conditions exist where I
K,r
 and I
K,s
 may be reduced or have their function 
impaired including drug treatment with erythromycin, low Mg2+  levels and hypoxia. EADs 
tend also to be seen in bradycardic situations as the channels I
K,r
 and I
K,s
 are in more deeply 
closed states27. 
The second important current, involved in EAD formation is the I
NaC a 
current which 
helps to create EADs in tandem with I
C a-L 
by two main mechanisms, firstly when there is high 
and dyssynchronous Ca2+  release this stimulates NCX1s forward activity and generation of 
an inward current, prolonging the AP and allowing enough time for I
C a-L 
to reactivate which 
then increases Ca2+  forming a positive feedback loop and EADs. The second method, is 
conditions such as heart failure where there is increased NCX1 levels, as the AP repolarises, 
there is increased NCX1 forward activity and generation of a current to oppose outward 
repolarization, prolonging the AP, which may create enough time for I
C a-L
 to reactivate. Both 
mechanisms, lead to AP prolongation and are common in inherited channelopathies but the 
EAD can only form a clinical arrhythmia if the EAD can be transmitted to enough 
neighbouring myocytes to interrupt repolarization and form a waveform. 
DADs predominantly occur as a result of oscillations in Ca 2+  levels in late phase 3 or 
phase 4 predominantly thought by many groups to stem from an inability of the 
sarcoplasmic reticulum to store the Ca2+  which, when released in an oscillatory fashion can 
then stimulate NCX1 to create a late inward Na2+
 
current, I
Ti
 and this can then lead to a DAD 
and an abnormal AP. This situation can occur as a result of abnormalities in the ryanodine 
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receptor, which controls SR Ca2+  release, digoxin toxicity, catecholamine related arrhythmias 
and AP prolongation as it allows excess Ca2+ influx28. 
This study has focussed on the effects of obesity and diabetes and the experimental 
groups involved are not likely to have structural ventricular abnormalities likely to cause 
conduction block. This is an important point as when discussing arrhythmia generation 
secondary to abnormal impulse conduction, we are reviewing functional impulse conduction 
abnormalities due to alterations in current/channel function. 
Abnormal impulse conduction occurs when heterogeneous expression of  ion 
channels lead to conduction slowing or block allowing a waveform to return29 or a 
unidirectional conduction block preventing waveform dissipation23 which then can re-enter a 
non-depolarised area forming a circuit. This can be seen with loss of gap junction proteins 
and in Brugada syndrome with loss of I
Na 
particularly in the epicardium leading to late phase 
2 re-entry30. 
After consideration of ionic generation of arrhythmias and based on the structure of 
the LV discussed earlier, it is important to note that there is a transmural gradient of ion 
channels. Specifically, a gradient from epicardium to endocardium exists predominantly of 
rectifying K+  channels and if this fine balance is lost, there is increased conduction block 
and re-entrant arrhythmias31. Also, transmural heterogeneity, away from the normal smooth 
gradient may lead, in combination with normal beat to beat AP alternans, to an increase in 
arrhythmogenic potential as seen in animal models32.  
Much of what is known about the ion currents and channels discussed in this section comes 
from work on inherited cardiac conditions and a selection of the genes/currents and 
conditions are described below in Table 2: 
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Condition Occurrence  Gene  Protein Function Current Change  
Long QT 1 42-54% KCNQ1 K
v
LQT1 I
K,s
 current I
K,s
 decrease 
Long QT 2 35-45% KCNH2 ERG I
K,r  
current I
K,r  
decrease 
Long QT 3 <8% SCN5A Na
v
1.5 I
Na 
current I
Na 
decrease 
Long QT 4 <1% ANK2 Ankyrin-B Adaptor  None 
Long QT 5 <1% KCNE1 MinK Β-subunit I
K,s
  I
K,s
 decrease 
Long QT 6 <1% KCNE2 MiRP1 Β-subunit I
K,r
  I
K,r  
decrease 
Long QT 7 <1% KCNJ2 K
ir 
2.1 I
K,1
 current I
K,1
 decrease 
Long QT 8 <1% CACNA1C Ca
v
1.2 I
C a-L
 current I
C a-L
 increase 
Short QT 1 Rare KCNH2 ERG I
K,r  
current I
K,r  
increase 
Short QT 2 Rare KCNQ1 K
v
LQT1 I
K,s
 current I
K,s
 increase 
Short QT 3 Rare  KCNJ2 K
ir 
2.1 I
K,1
 current I
K,1
 increase 
Brugada 10-30% SCN5A Na
v
1.5 I
Na 
current I
Na 
decrease 
Brugada <8.5% CACNA1C Ca
v
1.2 I
C a-L
 current I
C a-L
 decrease 
Familial AF Family linkage KCNE3 MiRP2 Β-subunit I
to-f
 I
to-f 
increase 
Familial AF Family linkage KCNA5 K
v
1.5 I
K,ss
 current I
K,ss
 increase 
Familial AF Family linkage KCNH2 ERG I
K,r  
current I
K,r
 increase 
Familial AF Family linkage KCNH2 MiRP1 Β-subunit I
K,r  
 I
K,r  
increase 
Familial AF Family linkage KCNQ1 K
v
LQT1 I
K,s
 current I
K,s
 increase 
Familial AF Family linkage KCNJ2 K
ir 
2.1 I
K,1
 current I
K,1
 increase 
Table 2: A summary of inherited cardiac rhythm disorders and their gene and ion current 
basis drawn from Amin et al.18 
 
Using this information and the earlier review of the AP phases a summary of AP phase and 
currents and the most common arrhythmia generation mechanisms is presented in Table 
333: 
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Arrhythmia mechanism AP Phase Channel Current change 
Reduced conduction propagation 
leading to functional block and re-
entry 
0 Na
v
1.5 I
Na
- decrease 
Creation of a transmural 
repolarization gradient leading to 
triggered activity with phase 2 re-
entry 
1-2 K
v
1.5,
 
K
v
1.4, K
v
4.3 I
to
- increase 
Prolongation of the AP leading to 
triggered activity with EADs 
2 Na
v
1.5 
Ca
v
1.2 
NCX1 
ERG 
K
v
LQT1 
K
ir 
2.1 
I
Na
- increase
 
I
C a-L
- increase 
I
Ti
- increase 
I
K,r
- decrease 
I
K,s
- decrease  
I
K,1
- decrease 
Prolongation of the AP leading to 
triggered activity with EADs 
3 Na
v
1.5 
Ca
v
1.2NCX1 
ERG 
K
v
LQT1 
K
ir 
2.1 
I
Na
- increase
 
I
C a-L
- increase 
I
Ti
- increase 
I
K,r
- decrease 
I
K,s
- decrease  
I
K,1
- decrease 
Prolongation of the AP leading to 
Ca2+  oscillation and triggered activity 
with DADs 
4 NCX1 
RYR2 
K
ir 
2.1 
I
Ti 
-increase 
SR Ca2+  increase 
I
K,1
- decrease 
Resting membrane potential 
hyperpolarisation and increased 
automaticity 
4 K
ir 
2.1 I
K,1
- increase 
Table 3: A summary of the major mechanisms of arrhythmia generation by phase of the AP 
and channel/current 
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1.4. The action potential: ion channels and heart failure 
Effective organisation of the action potential and its transmural variation is important for 
co-ordinated electro-mechanical activation and therefore good contractile pump function 
and relaxation from apex to base and from endocardium to epicardium. The key step in the 
excitation-contraction coupling (ECC) pathway, is during phase 2 (plateau phase), where the 
intracellular flow of Ca2+  (down a high gradient) leads to Ca2+  induced Ca2+ release from the 
sarcoplasmic reticulum. Free Ca2+  released from the sarcoplasmic reticulum via RYR2 binds 
to troponin C which then changes then shape of the entire troponin complex removing 
troponin I from the myosin head binding site on actin filaments. The exposed  myosin head 
can then in ATP dependent be used to pull the actin filament in a linear fashion, shortening 
the sarcomere shortening. This procedure is repeated across multiple filaments all 
shortening leading to cardiac contraction. As the phase 2 of the AP ends and Ca2+  influx 
drops, SERCA2A pumps Ca2+  back into the sarcoplasmic reticulum and there is an overall 
reduction in cytosolic Ca2+ which leads to Ca2+  being removed from troponin C and the 
inactivated state is gradually returned to with the myosin binding site being covered by 
troponin I. The excitation-contraction coupling pathway is summarised in Figure 7 below: 
 
 
 
Figure 7: Ca2+  handling and contraction in the cardiomyocyte drawn from Andersson and 
Marks34 
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There are three key changes in the action potential shape in heart failure linked to 
reduced excitation-contractile performance and they are: 
1. Increased phase 0, fast upstroke, amplitude 
2. Reduced or absent phase 1, notch, early repolarization 
3. Prolongation of the action potential35  
 
The first two problems appear to be mainly due to a reduction in outward rectifying 
K+  channels, I
to
36 while prolongation of the action potential mainly seems to involve reduced 
inward rectifying channel density and altered function, such as a reduction in I
K,1
37. 
In terms of direct contractile performance, the main problem seems to stem from 
impairment of the Ca2+  induced Ca2+ release and hence, impairment of troponin binding and 
contraction. In the early stages of myopathic or hypertrophic processes it seems that 
prolongation of the action potential maybe an early adaptive response with reduced I
to 
function enhancing Ca2+  entry and reducing Ca2+  extrusion38. While this may result in a 
positively inotropic phenotype early on, this does lead to a change in gene expression before 
there is a maladaptive response and eventually reduced expression of Ca 2+  entry handling 
proteins and enzymes39. 
Once the compensatory phase is passed, heart failure and reduced excitation-contraction 
coupling mediated by Ca2+ release occurs through 4 main actions: reduced sarcoplasmic Ca2+ 
release40, functional defects in the L type Ca2+  channel41, increased space between the L type 
channel and  RYR242 and abnormalities of RYR243 
In almost all models, human and animal, there is reduced function of SERCA2A and 
often reduced mRNA expression leading to a reduction in the amount of Ca 2+  taken up into 
the sarcoplasmic reticulum and thus available for Ca 2+  induced Ca2+ release43. This is in part 
due to alterations in phospholamban which regulates SERCA2A and may alter the real time 
dynamics of the enzyme to make it less sensitive to Ca 2+   and therefore unable to pump it in 
to the sarcoplasmic reticulum44. In a previous study reduced contractile function assessed 
using the force-frequency method was associated with reduced SERCA2A and the observed 
contractile impairment is thought to be due to reduced accumulation of Ca2+  in the 
sarcoplasmic reticulum  45.  
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Functional defects in the L-type Ca2+   channel have long been suggested to potentially 
contribute to reduced contractile function because there is a loss of response of the channel 
to stimulation in heart failure41. L--type channels are important for Ca2+  influx and 
generation of a Ca2+  spike that is sufficient to trigger secondary release from the ryanodine 
receptor and thus when the distance between the L-type channel and RYR2 is increased 
there is less effective activation of RYR242. 
RYR2 is affected in several ways in heart failure; firstly, there may be a reduction in 
receptor numbers leading to reduced calcium release. There is also phosphorylation of the 
receptor which leads to removal of calstabin (which stabilises the receptor by promoting it 
in its closed state) leading to a constant leak of Ca2+  with reduced peak Ca2+ release and 
reduced contractility34. Damage to the receptor also seems to leave some RYR2 proteins 
spatially disconnected and thus there may be dyssynchronous activation of RYR2 and thus 
ineffective ECC46. 
After contraction, relaxation of the ventricle is very important as this has been 
shown to form a vortex twist which encourages optimal ventricular filling for effective 
cardiac output after contraction. High diastolic levels of calcium due to up-regulation of 
NCX1 and enhanced Ca2+  influx through its reverse mode lead to an inability of ventricular 
relaxation, high passive tension requiring more energy for the next contractile beat and poor 
relaxation and impaired filling47. 
These changes seen above provide a general link from cardiac structure, to the 
action potential and to the development of arrhythmias/heart failure in general and now we 
can look at how diabetes and obesity may specifically cause a cardiomyopathy. 
 
1.5. Cardiac pathological changes in diabetes 
As has been seen in many other organs affected by diabetes, changes occur to the heart in a 
wide variety of structures and in many different ways. As part of the background to this 
study, it is important to look at the major areas that have been studied. 
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1.5.1. Cardiac energy usage and consumption 
The heart is one of the most energy demanding organs in the body and uses between two-
thirds to one-third ratio of free fatty acids (FFAs) to pyruvate (from glucose and lactate) for 
energy metabolism. This delicate balance is altered in people with diabetes and leads to a 
reduction in the heart’s ability to meet its energy requirements and thus leads to heart 
failure48. Glucose utilisation is vital in maintaining efficient energy production and also in 
protecting against periods of ischaemia49 and in diabetes glucose utilisation is impaired.  
Glucose transporter-4 (GLUT-4) is the major membrane glucose transporter in the 
heart and allows transport of glucose into the cardiac myocyte for metabolism and ATP 
production. In many patients with heart failure there is a reduction in the expression of the 
GLUT-4 transporter, which causes reduced energy production. Down regulation of GLUT-4 
expression in diabetes occurs through a reduction in the expression of myocyte enhancer 
factor 2C (MEF2C), which is a regulatory factor for GLUT-450. In diabetes glucose metabolism 
seems to be reduced due a reduction in the translocation of GLUT-4 from the cytoplasm to 
the cell membrane, which seems to be the main difference between people with diabetes 
and heart failure and those without49. If the myocyte cannot make significant use of glucose, 
energy metabolism is shifted to the less efficient and more toxic fatty acid pathway. 
Oxidation of FAs is less efficient than glucose metabolism for the production of ATP 
as it requires more oxygen and as micro and macrovascular ischaemia is common in 
patients with diabetes this means that there is less energy reserve during periods of 
ischaemia51. These processes lead to a build-up of glucose 6 phosphate within the myocyte 
which then in turn inhibits hexokinase which prevents utilisation of any further glucose by 
the myocyte52. In animal models, the response to this excess of fats has been to increase 
CD36 and fatty acid transport protein (FATP) expression and their relocation to increase FA 
uptake and oxidation53.  
Peripherally in diabetes, adipocytes that generate the excess of offending free fatty 
acids become resistant to negative signalling and help down regulate insulin mediated 
glucose uptake in other cells, worsening the situation in the heart54. 
Impaired glucose metabolism secondary to up-regulation of FFA metabolism means 
the heart’s energy demands are not met. FAs have affects other than just on glucose usage; 
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they are toxic in themselves. In patients with diabetes and diabetic animal models, an excess 
of FAs and triglycerides leads to the creation of toxic substrates which have a wide range of 
negative effects53, 55. Excess FA metabolism and accumulation leads to the formation of 
ceramide which up-regulates caspases causing cell apoptosis56 and in a structure like the 
heart with very low levels of cell replication this loss of myocytes is not replaced by new 
myocytes. 
Furthermore, the pathological changes that lead to impaired glucose utilisation and 
excess lipotoxic fatty acid production in diabetes activate the peroxisome proliferator 
activated receptor-alpha system (PPARα). PPARα is a nuclear transcription factor present 
commonly in areas of high metabolic activity such as the liver and skeletal muscle and its 
key role being is the in the regulation of genes that control FA utilisation. 
PPARα up regulation leads to inhibitory effects on cardiac metabolism through 
increased pyruvate dehyrdrogenase kinase 4 levels which inhibits glucose oxidation in the 
mitochondria57. Up regulation of PPARα which controls gene expression changes via the 
peroxisome proliferator response element leads to an increased fatty acid uptake and 
oxidation via reduced malonyl CO-A expression58. Carnitine palmitoyltransferase I, is an 
enzyme which controls entry across of the mitochondrial membrane of FAs and in turn 
binds to and is inhibited by malonyl CO-A. In normal people CPT-I levels and activity are 
strictly controlled but with PPARα activation in type 2 diabetes, it is up-regulated allowing 
the excess fatty acid oxidation to continue unhindered 59. PPARα activation is seen as a 
common process in other cardiomyopathies in patients without diabetes and this would be 
suggestive that increased PPARα activity has a negative effect on cardiac function 60. 
The long term effect of these changes is to impair contractile function, isovolumetric 
relaxation and diastolic filing through insufficient energy supply and subsequently a 
reduction in the diabetic heart’s ability to cope with metabolic stress/ischaemia53.  
 
1.5.2. Reactive oxygen species  
One of the major factors in diabetic cardiomyopathy, as opposed to other cardiomyopathies, 
is the constant production of damaging oxygen free radicals and their effects on the heart.  
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In times of free radical generation, the body responds in various ways, including free radical 
absorption (via NADPH [Nicotinamide Adenine Dinucleotide Phosphate] and glutathione), 
repair to damaged structures and through planned apoptosis. This is a carefully balanced 
and well-adapted mechanism that helps the body in situations of infection, inflammation 
and damage from sunlight. It is becoming clear that the diabetic state results in a 
continuous stream of free radicals that overwhelm natural free radical absorption systems 
in the body leading to cardiac damage. 
The three main pathological mechanisms by which reactive oxygen species (ROS) are 
created in diabetes are via hyperglycaemia, increased fatty acids and fatty acid oxidation 
(outlined earlier) and mitochondrial uncoupling61. 
The hypothesised first step in the hyperglycaemia pathway is excess sugar forced 
into the polyol pathway which oxidises NADPH to NADP removing glutathione, a very 
important anti-oxidant from the system. Loss of glutathione impairs free radical absorption 
making it difficult for the body to deal with normal levels of free radical not just the 
increased free radical levels seen in diabetes62. In addition to this, as a by-product there is 
excess generation of the superoxide free radical which is damaging in its own right and now 
has less glutathione to correct it63. In addition hyperglycaemia also leads to increased 
expression of inducible nitric oxide synthetase (iNOS) which leads to increased superoxide 
and peroxynitrite free radical levels63. These free radicals are directly damaging to DNA and 
DNA repair mechanisms, which leads to cardiac myocyte apoptosis57. 
Hyperglycaemia also up regulates the activity of protein kinase C (PKC), which while 
having a plethora of deleterious effects on vessels, up-regulates the pro-inflammatory NF-κB 
pathway and causes an increase in ROS generation via NADPH oxidase (Nox-1)64. Excess 
glucose can also be forced into the hexosamine pathway, which increases production of two 
inflammatory cytokines, TGFβ and plasminogen activator inhibitor type one 65.  
Hyperglycaemia thus forces excess glucose into pathways producing harmful effects 
on the heart and a self-propelling cycle of hyperglycaemia induced ROS, forcing more 
glucose into these pathological pathways62, 66, 67. 
A review of the metabolic pathways linked to hyperglycaemia is shown below in 
Figure 8:  
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Figure 8: An overview of the metabolic pathways linked to increased glucose and their 
relationship to diabetic cardiomyopathy 
 
Mitochondria as the key energy creator are vitally important in all areas of human 
physiology and especially to areas of high-energy usage such as the heart. In diabetic mouse 
models, increased ROS generation resulted in an increase in mitochondrial uncoupling 68 and 
impairment of cardiac mitochondrial function, through changes in the genetic expression of 
proteins involved with mitochondrial respiration69, 70. Abnormal function of mitochondrial 
respiration due to ROS also in turn leads to further ROS generation. 
Mitochondria in diabetes, due to the effects of long-term reactive oxygen damage express 
less ATP synthase, which means that energy production is markedly reduced57. 
This means that the diabetic heart simply cannot generate enough energy to perform as 
needed in normal conditions and under stress. 
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Using the free radical damage model outlined above, we can begin to view 
cardiomyopathy in diabetes as a problem with cellular defence, repair and renewal. In 
knockout diabetic mouse models where the P66 (a pro-apoptotic gene) gene had been 
deleted there was an improvement in telomere length and in cardiac progenitor cell 
numbers and therefore the number of myocytes71. P66 is predominantly activated by excess 
untreated ROS in diabetes and again lends credence to ROS generation being important to 
the pathogenesis of diabetic cardiomyopathy. P66 has been shown to be increased in other 
animal models of heart failure and may be one of the missing links in terms of explaining 
why a cardiomyopathy related to diabetes carries such a poor prognosis72. The activation of 
P66 by ROS is also dependent on angiotensin two binding and this may explain some of the 
benefits in heart failure of angiotensin converting enzyme inhibitors (ACEi) particularly in 
people with diabetes above and beyond the haemodynamic benefits73.  
 
1.5.3. Ca2+ signalling and the ryanodine receptor  
Ca2+  is the principal signalling molecule that activates the contractile machinery of the 
ventricular myocyte.  
RYR2 as an important component of the contractile machinery is impaired by diabetes in a 
variety of ways. 
In age matched rats with diabetes there are higher basal cardiac levels of Ca2+  and 
this may be due to altered function of the NCX1 74. Surprisingly higher basal rates of Ca2+ , 
does not lead to better contractile function. Damage to SERCA2A, a key sarcoplasmic 
ATPase, leads to reduced calcium uptake and the rate of rise to peak Ca2+  levels75. This may 
then be insufficient to generate a spark causing Ca2+  induced Ca2+ release (via RYR) or 
slower/fewer contractile activations. 
So while receptor numbers maybe reduced as with other cardiomyopathies, receptor 
function is also reduced thought principally to be due to ROS induced damage to the 
receptor and also through a change in the receptor structure because of advanced glycation 
that renders the receptor less sensitive to its ligands76.  
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Chronic damage in diabetes to the receptor means that there is often dyssynchronous 
release and a persistent diastolic leak (evidenced by a high basal level of Ca2+) impacting on 
contractility and increasing arrhythmia rates77. 
 
1.5.4. Cardiac autonomic neuropathy  
Long before the pathological mechanisms could be understood clinicians had noticed that 
diabetic patients had reduced cardiac autonomic function initially described by 
investigators as a reduction heart rate variability78. Eventually heart rate variability was 
largely realised to be a factor of heart rate 79  and not really a reflection of autonomic 
function. However autonomic dysfunction in diabetes remained an area of interest for many 
researchers and current major findings are discussed below. 
Eventually it was realised that diabetes affected neuronal function in the heart and 
this can be through many of the already discussed metabolic problems such as ROS derived 
damage and AGEs. These processes at the cellular level cause direct damage to cardiac 
nerves and to the blood supply to these nerves resulting in reduced cardiac neuronal 
function80. Confirmation of a direct loss of nerve function within the heart of patients with 
diabetes was confirmed using MIBG (a radioactive tracer similar to noradrenaline) with 
reduced uptake even in patients with normal autonomic function tests81, 82. 
In addition to direct damage, indirectly a depletion of ATP, leads to activation of 
polyADP ribosylation, which leads to cell necrosis and release of neuronal toxic factors83. 
Long term diabetes leads both peripherally and centrally, to a reduction in neuronal growth 
factor (NGF) which results in reduced nerve function and potentially a loss in replacement of 
damaged and dead fibres 84.  
Patients with cardiac autonomic neuropathy (CAN) during normal conditions exhibit 
normal coronary artery flow85 but under stress there is a reduction in coronary blood flow 
reserve; leading to regular periods of small but significant ischaemia causing cardiac 
injury86. This is seen elegantly in the heart in labelled perfusion imaging with noradrenaline 
analogues and in patients with CAN, there is exaggerated proximal retention with proximal 
vessel constriction and distal hypoinnervation leading to reduced blood flow reserve under 
sympathetic stress86.  
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As the autonomic neuropathy progresses there is over production of catecholamines 
and increased beta-adrenergic receptor production in the heart. These two factors combine 
to cause an increase in calcium related myocyte apoptosis via endonucleases,87 which 
progressively leads to heart failure. High sympathetic activity and reduced parasympathetic 
function is a key common pathway in many types of heart failure and important because 
increasing vagal derived parasympathetic activity leads to reduced inflammatory cytokine 
production, reduced heart rate, reduced iNOS, anti -inflammatory cytokine production and 
improved baroreflexes88.  
While CAN has many effects on vessels and myocytes, the neuronal damage also 
leads to the loss of calcitonin gene related peptide function, which is released directly from 
nerves.  In diabetes this peptide’s receptor is down regulated and the peptide itself is not 
released from the nerve in normal quantities and this is important as this peptide causes 
vessel relaxation and increases cardiac contractility89. 
Many of the processes discussed above potentially overlap with heart failure caused 
by other syndromes or are seen as heart failure develops but CAN seems to be very specific 
to diabetes, especially in the early stages, with close correlation to glycaemic control and 
some regression with tight glycaemic control 90.  
 
1.5.5. Cardiac Structure 
Diabetes and the prolonged effect of hyperglycaemia have metabolic effects on the heart 
and some of these as described previously lead to changes in cellular function but they also 
produce changes in the structure of the diabetic heart. Endomyocardial biopsies from 
diabetic patients show thickening of the capillary basement membrane, myocellular atrophy 
and hypertrophy with interstitial and myocardial fibrosis and collagen deposition, all of 
which reduce myocardial function91.  
The most common structural problems seen with diabetes are cardiac fibrosis and 
left ventricular hypertrophy (LVH) which we will now look at in turn. 
In diabetes, up-regulation of the protein kinase C (PKC) system produces increased 
TGFβ and connective tissue growth factor (CTGF) expression leading to fibrosis and 
consequently poorly relaxing and poorly contractile hearts92. This increased fibrosis may 
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also be secondary to a variety of elevated circulating proteins such as angiotensin and 
endothelin caused by inflammatory metabolic and cellular changes93. 
One of the central pathological mechanisms in diabetes is the formation of advanced 
glycation end products (AGEs). AGEs are a heterogeneous group of molecules formed non-
enzymatically, when reducing sugars react with the free amino groups of proteins94. These 
products cause cross-linking between myocardial collagen fibres leading to a decrease in 
compliance and heart failure95. AGEs up-regulate the genetic expression of NF-ĸβ, endothelin 
and fibronectin which have been linked with myocardial fibrosis, inflammatory change and 
increased apoptosis93.  
This occurs because receptors of advanced glycosylation end products (RAGEs) on 
the cell surface are activated by the high levels of AGEs and they cause downstream 
intracellular activation of various transcription factors, such as NF-ĸβ96. AGEs are also now 
thought to cause immune complex formation, in a similar fashion to a variety of other 
autoimmune diseases, these complexes then activate the complement system and 
complement mediated cellular inflammation97. 
Patients with diabetes commonly have left ventricular hypertrophy (LVH) and two causal 
mechanisms have been investigated widely. Primarily, hyperinsulinaemia acts as a local 
growth factor causing increased left ventricular mass via insulin receptor substrate -1 (IRS1) 
and activation of IRS1-associated phosphatidylinositol-3 kinase (PI3K)98. The other 
postulated mechanism is that obese patients with type 2 diabetes have high interleukin six 
levels99 and high leptin levels100 which, stimulate growth factors increasing left ventricular 
mass. 
 
1.6. Pathological changes in obesity cardiomyopathy 
Obesity is a major risk factor for the development of type 2 diabetes and it is clear from 
previous studies, that there is an overlap in some of the downstream effects of both 
conditions e.g. LVH101 and although key aspects of the pathology have already been 
discussed, the obesity specific changes are reviewed below.   
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1.6.1. Unique changes 
In obesity without the development of diabetes there is an infiltrative deposition of 
triglycerides within the myocardium as the body aims to store the excess caloric intake102. 
This mechanism leads to LVH and to a myocardium that is not lean muscle but stiffer with 
high levels of fat deposition and is similar in mechanism to the observed obesity related 
non-alcoholic steatohepatitis. This myocardial fat deposition is not a benign process and 
has been shown in animal models to cause myocyte apoptosis103. 
One of the key hypertrophic mechanisms in obesity, is via leptin, a satiety and 
appetite regulatory hormone which is found in high circulating levels in obesity but with 
increasing levels produces increasing receptor resistance. It has been shown that while the 
predominant action and role of leptin is in the central nervous system it is also produced 
within the heart104. 
Leptin is directly hypertrophic via 3 main mechanisms, which begin with activation 
of the Janus kinase 2 (JAK2) tyrosine kinase and then a series of downstream activations105. 
Firstly, leptin activates JAK2, which stimulates the release of signal transducer and activator 
of transcription (STAT3) from the cell membrane and relocation of the cell nucleus where it 
can dock with its transcription targets and cause hypertrophy, predominantly by myocyte 
elongation106. Secondly, high levels of leptin increase rhoA/ROCK pathway activity which 
causes an increase in the F-actin to G-actin ratio and an enlargement in the cardiac 
myocyte107.The final method is via JAK2 activated up-regulation of the PI3K/AKT 
transcription pathway which is known to cause cell growth and hypertrophy and also actin 
rearrangement causing hypertrophy105, 108. Also indirectly hyperleptinaemia has been shown 
to enhance endothelin and angiotensin 2 mediated cardiac myocyte hypertrophy in an 
autocrine manner109. 
Adiponectin, is a key cytokine that is down regulated in obesity probably by 
adiposity related excess TNFα release and adiponectin has been shown to prevent α-
adrenergic mediated LVH110. LVH is not a benign adaptive process and represents an early 
subclinical phase with reduced energy kinetics before overt LV impairment visible on 
echocardiography. In LVH there is a reduction in the PCr/ATP ratio compared to normal 
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controls and also reduced creatine kinase which helps maintain high ADP levels in the 
mitochondria for metabolism to ATP111.  
Obesity is thought to represent a chronic inflammatory condition with whole -body 
effects some which are thought to be driven by pathological white adipose tissue function. 
White adipose tissue gene expression has been shown to generate increased inflammatory 
cytokines and in a mouse model this led to LV fibrosis and hypertrophy112. 
 
1.6.2. Overlap with type 2 diabetes 
In obesity there is activation of the sympathetic nervous system with similar effects to 
diabetic autonomic neuropathy leading to up-regulation of the renin-angiotensin system 
(RAAS) which stimulates cardiac fibrosis, hypertrophy and myocyte apoptosis113.  
Obesity and type 2 diabetes both represent a hyperinsulinaemic state with insulin 
resistance and this phenotype results in augmented white adipose tissue function, 
overproduction of angiotensin 2114 and increased hepatic renin production115. 
A major area of overlap between types 2 diabetes and obesity is the switch from 
predominantly cardiac glucose metabolism to fatty acid metabolism with down regulation of 
GLUT-4, increased fatty acid uptake and oxidation116, 117.  
As mentioned earlier the excess myocardial deposition of fatty acids and their metabolism 
leads to deposition of toxic lipid metabolites which cause myocardial apoptosis and seems 
to be a key overlap mechanism between type 2 diabetes and obesity118.  
In addition to the observations above, free radical damage is an important component of the 
ongoing pathological process in diabetes and similarly in obesity there is an excess of free 
radical generation which causes myocardial injury and helps promote the myopathic 
process119. 
 
1.7. Arrhythmogenesis in diabetes and obesity 
Apart from changes that lead to a reduction in contractile performance, the other important 
aspect of the cardiomyopathy linked to diabetes and obesity is the change to an 
arrhythmogenic phenotype, with obese patients having higher rates of atrial120 and 
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ventricular arrhythmias15 and type 2 diabetes  also linked to an increased incidence of many 
arrhythmias13, 121.  
In patients with type 2 diabetes, episodes of hypoglycaemia (defined as a blood 
glucose of 3 mmol/l or less) were associated with a large increase in the number of 
ventricular couplets and episodes of ventricular tachycardia compared to a control 
population122. The exact mechanism by which hypoglycaemia contributes to arrhythmias is 
uncertain but seems to be independent of changes in the QT interval.122 Hypoglycaemia is 
thought to be arrhythmogenic by two mechanisms; a large sympathetic adrenergic surge in 
the context of a high prevalence of autonomic neuropathy plus an abnormal responses to 
catecholamines123 and through inhibition of the human ether related a go-go channel (ERG), a 
key K+  repolarising channel. In type 2 diabetes episodes of hypoglycaemia are often caused 
by medications such as sulphonylureas and insulin which can affect electrophysiological 
channels with sulphonylureas in particular thought to affect cardiac K+ channels124.   
Autonomic neuropathy is a complication that can occur in patients with d iabetes and 
this can extend to CAN confirmed in patients with type 2 diabetes125. CAN is associated with 
higher resting heart rates which are associated with worse cardiovascular outcomes and 
higher rates of cardiac arrhythmias. CAN, specifically in patients with diabetes, is related to 
an increase in the corrected QT interval and higher rates of sudden cardiac death126. 
Another purported mechanism of arrhythmogenesis in patients with type 2 diabetes 
is a reduction in the number of ryanodine receptors in the sarcoplasmic reticulum of the 
myocyte, which is very important for Ca2+  release127 and excitation-contraction coupling. 
Chronic damage, or a reduction in RYR2 numbers, in diabetes often leads to a situation 
where there is not organised synchronous Ca2+  release and a persistent diastolic leak which 
may cause delayed after-depolarizations (DADs) increasing the incidence of arrhythmias77. 
Other novel mechanisms have been identified by which arrhythmias may be induced 
through RYR2 receptor induced Ca2+ sparks and abnormal waveform generation leading to 
re-entrant arrhythmias128. 
In diabetes studies have shown that an increase in dispersal of the action-potential 
has the propensity to form re-entrant circuits leading to sustained arrhythmias129. Diabetes 
has also been shown in a variety of animal models to affect the abundance of rectifying 
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potassium channels that are important in myocyte repolarization and reduction of these 
channels can lead to prolongation of the action potential and arrhythmias130. 
Although the mechanisms of arrhythmogenesis in obesity are not fully understood 
some putative theories have been published. In several studies an increase in the corrected 
QT interval in obese individuals has been observed and it was suggested this may be due to 
high levels of circulating fatty acids interfering with myocyte repolarization131. An excess of 
fatty acids also, as discussed in the section on contractile function, affects cardiac energy 
production in a negative manner and this can impair active ion exchangers by reducing the 
amount of ATP production. An excess of fatty acids leads to increased oxidative stress 
within the myocardium and this in turn increases the reverse mode function of NCX1, 
leading to a delay in inactivation of the late sodium current, prolonging phase 2 of the AP 
and leading to triggered and ectopic activity132. 
In obese individuals with sudden cardiac death, it was noted that were was an 
increase in ventricular ectopy, which in many cardiac disease states is linked to prolonged 
ventricular arrhythmias and death133. Obesity is linked to an increase in resting heart rate 
through increased sympathetic tone and reduced parasympathetic control 134 and increased 
circulating levels of norepinephrine135. 
In obesity apart an increase in myocardial adipocyte density may alter electro -
mechanical coupling leading to reduction in conduction propagation/conduction block and 
an increase in the incidence of arrhythmias136.  
In obese individuals, as discussed above, there is an increase in leptin expression 
and increased leptin resistance at the receptor level. This may be important as obesity 
progresses, as the following potential anti-arrhythmogenic actions of leptin may be lost: 
1. Leptin reduces NCX1 forward activity which leads to a reduction in the I
Ti
 
current in phase 3/4 and less chance of DADs 
2. Leptin inhibits the I
K,ss
 ultra-rapid delayed rectifier channel and thus shortens 
the APD in the 90% phase of repolarization which has been shown to 
cardiovert atrial fibrillation137 
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1.8. Cardiac fibrosis: downstream effects of diabetes and obesity 
Myocardial fibrosis is a common pathological endpoint in diabetes and obesity and is 
caused by various changes in gene and protein expression. Fibrosis commonly results from 
transformation of fibroblasts to myofibroblasts with deposition of type 1 collagen and in 
comparatively smaller volumes of type 3 collagen, induced by inflammatory cytokines, most 
importantly by TGFβ. This results in disruption of the extracellular matrix and 
transformation of a smooth muscle with normal cell to cell connections to a fibrotic muscle 
with poor cell to cell connections. 
Fibrosis has been shown to be pro-arrhythmogenic via several mechanisms including: 
slowed conduction and re-entrant arrhythmias, increased automaticity, reduced ability to 
prevent early after depolarizations transferring from one myocyte to another and a 
reduction in the number of myocytes required to promote an ectopic beat138 
Fibrosis as a common endpoint of obesity and diabetes is very important in 
arrhythmogenesis and this has been confirmed in many other cardiac disease processes 
such as post myocardial infarction and in hypertrophic cardiomyopathy. There is 
experimental evidence that correction of fibrosis without any treatment of ion channels or 
electrophysiological proteins directly attenuates the arrhythmogenic phenotype 139.  
 
1.9. Summary 
The left ventricle is organised topographically with fibre orientation gradually changing 
from epicardium to endocardium with corresponding differences in the action potential and 
potassium repolarising channels. 
Optimal organisation of the action potential is required for optimal excitation-contraction 
coupling and thus cardiac output. When there is abnormal AP activity this ac ts as a 
substrate for arrhythmias either as triggered activity or a re-entrant circuit. The contractile 
performance of the heart is predominantly activated by Ca 2+ release and binding with 
troponin/tropomyosin complex. In heart failure changes in L type channels, ryanodine 
receptor, SERCA2A activity and NCX1 lead to abnormal Ca2+  handling and poor excitation-
contraction and poor myocardial performance. Abnormal Ca 2+  handling also impairs 
ventricular relaxation and may contribute to poor ventricular filling and cardiac output. 
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Diabetes causes several specific cardiomyopathic processes including left ventricular 
hypertrophy, fibrosis, reduced glucose metabolism and a switch to increased fatty acid 
metabolism with apoptotic myocardial steatosis. Diabetes, while causing a peripheral 
autonomic neuropathy, also leads to a cardiac autonomic neuropathy with up-regulated 
sympathetic action. Diabetes is a disease characterised by inflammatory ROS generation 
which is cardiotoxic and may lead to myocyte apoptosis. Diabetes also reduces RYR2 levels, 
impairs RYR2 function and SERC2a function which all lead to higher rates of arrhythmias 
and heart failure. Diabetes can also, through the formation of AGEs, directly impair cardiac 
structure or the RYR2 and both impairments may contribute to the overall cardiomyopathic 
process. 
Obesity shares many of the same processes with diabetes in terms of impairing 
cardiac function such as higher rates of fatty acid metabolism, LVH, lipotoxicity and high 
sympathetic activity. A major difference between diabetes and obesity, appears to centre on 
leptin, which as a transcription factor causes myocyte hypertrophy via several mechanisms. 
Obesity causes a release of inflammatory cytokines from adipose tissue which may cause 
cardiac fibrosis, LVH and down regulation of adiponectin which might be protective against 
LVH. 
These changes in both diabetes and obesity result in a phenotype that is pro -
arrhythmogenic and results in contractile dysfunction and heart failure with experimental 
evidence that suggests these effects are independent of traditional cardiovascular risk 
factors. 
It is the working hypothesis of this study that there are common gene expression changes 
between type 1 diabetes, type 2 diabetes and obesity that may explain the cardiomyopathy 
seen in these conditions and that the most important area of investigation will be around 
key electrophysiology genes. 
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2. Aims and objectives 
Given the rapid increase in patients suffering with obesity and diabetes and the cardiac 
complications caused by the two conditions, a better understanding of the changes in gene 
expression in the ventricles may help guide the development of future treatments.  
qPCR is a well-established technique for understanding the genetic expressional 
changes in a wide variety of species and disease states and has been used to great effect to 
understand many aspects of obesity and diabetes. Using qPCR, our aim was to analyse the 
left ventricular gene expression of a series of key cardiac genes to gain a better 
understanding of the pathophysiology of diabetes and obesity related cardiomyopathy. 
These gene changes have then been combined with mathematical modelling software to 
produce modelled action potential curves. This information has been combined with 
echocardiographic and ECG/signal averaged ECG results in the human study to look for 
confirmation of a clinical phenotype and to see if the genetic changes are associated with 
specific phenotypic changes. 
Key aims of the project are: 
 To characterise the changes in left ventricular gene expression in type 1 diabetes, 
type 2 diabetes and obesity 
 To look for areas of commonality between the three disease states 
 To model the effects of these gene changes on the ventricular action potential  
 To look for clinical correlation in a human type 2 diabetes group using 
echocardiography and the ECG 
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3. Methods 
 
3.1. Animal tissue preparation and isolation- experiment 1: streptozocin (STZ) 
ratsThis part of the study was primarily undertaken as a reference point for the 
other two qPCR studies and for practice and refinement of experimental pathology given the 
fact that Pandit et al.140 have previously published on this topic using AP modelling. 
Animal preparation and experiments were licensed under the UK Animals (Scientific 
Procedures) Act 1986 and undertaken at the University of Manchester.  
Diabetes was induced in 8 Adult male Wistar rats (Charles River, Margate, UK) via 
intraperitoneal injection of freshly dissolved streptozocin (55mg/kg in sterile saline).  This 
was performed after an overnight fast and confirmation of diabetes induction was made 
with tail vein blood monitoring. A minimum of blood glucose level of greater than 15mmol 
at day 4 post injection was considered diagnostic of the induction of diabetes. The STZ 
model is a well validated model of diabetes typically behaving more like the autoimmune 
human type 1 disease than what is thought of the more lifestyle related, type 2 disease 141. 
Issues with the STZ rat model as a specific type 1 diabetes model have previously been 
raised including the fact that STZ is eliminated within 48 hours and that the effects of STZ 
can be reversed partially with insulin142. Acknowledging these facts, the STZ model has years 
of historical data and experimental familiarity and was felt to be an initial useful starting 
point for this study. 
All animals were fed a standard chow diet to and water ad libitum. All animals were 
kept on a standard 12 hour on/off light cycle. 8 age, weight and sex matched rats were used 
as controls and kept in identical conditions. After 8 weeks, all rats were terminally 
anaesthetised with isoflurane (2% in oxygen) and killed by cervical dislocation. The whole rat 
heart was dissected and removed and placed in freshly made Tyrode solution143 on ice.   
The rat ventricles were then pinned and a full thickness piece of the left ventricular 
free wall was cut out measuring approximately 5mm long. This piece was then embedded in 
OCT mounting matrix (VWR, Lutterworth, UK) with the endocardium facing up. The same 
area was used in all rats and distance from anatomical markers such as the apex, left atrium 
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and atrial appendage and aorta were used to maintain accuracy. The tissue was then snap 
frozen in liquid nitrogen at –800C and stored at –800C for future use. 
The topographically orientated piece was then placed in a cryostat machine at –260C and 15 
x 10m slices taken of the endocardial layer. After this 20 x 10m slices were taken and 
discarded before the procedure was repeated for the mid myocardial and epicardial layers. 
Visual confirmation was used to confirm that the appropriate layers were being sectioned 
and approximately a third of the tissue was removed for each section. Each group of 15 
slices were placed in a separate labelled cryotube for future use. 
Our group have previously used this method locally and it has been used by other groups to 
look at differential topographical mRNA expression with good reproducibility and has been 
published in peer-reviewed journals and considered to be experimentally acceptable144. 
 
3.2. Animal tissue preparation and isolation- experiment 2: high fat diet (HFD) rats 
Animal preparation and experiments were licensed under the UK Animals (Scientific 
Procedures) Act 1986. Animal husbandry and tissue sample collection was undertaken at 
the University of Liverpool and experiment analysis at the University of Manchester.  
16 age matched male Wistar rats (Charles River, Margate, UK) with approximate 
starting weights of 250 g were split into two groups and one subgroup was fed a diet 
enriched with saturated fats (lard) for 8 weeks (Research Diets, Inc., New Brunswick, USA). 
The control group were fed a standard chow diet with 10% calories as fat and the 
experimental group were fed 40% calories as fat with equal concentrations of the 
antioxidant tBHQ and protein. All rats had free access to the food sources and water ad 
libitum. All animals were kept on a standard 12 hour on/off light cycle. This model was 
used as previous work has shown confirmed induction of obesity in the HFD group with 
hyperinsulinaemia and islet dysfunction which are both important in insulin resistance and 
in type 2 diabetes145. 
A breakdown of the percentage diet compositions is shown below in Table 4: 
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Group Protein  Carbohydrate Fat Kcal per gram 
Control 20 70 10 3.85 
High Fat 20 40 40 4.58 
Table 4: Percentage composition breakdown of the two experimental diets in the obesity rat 
experiment 
 
Weekly weights were measured, with total weight gain and  terminal weight gain 
recorded. At eight weeks, all animals were terminated with rising carbon dioxide 
concentration and cervical dislocation. The animals then had a single epididymal fat pad 
dissected and weighed before dividing this by the final weight as a measure of adiposity as 
used previously146.  
The rat hearts were in an identical manner to experiment one, dissected out and a 
section from the left ventricular free wall removed and mounted in OCT with the 
endocardial layer facing up and the tissue was then snap frozen in liquid nitrogen at –800C 
and stored at –800C for future use. 
The topographically orientated piece was then placed in a cryostat machine 
identically to experiment 1 and 15 x 10m slices were taken of the endocardial layer and 
discarded. After this 20 x 10m slices were taken and discarded before once at the mid 
myocardial layer a single 10m section was taken and mounted on labelled poly L-lysine 
coated microscope slides (Sigma-Aldrich, Poole, UK). Slides were then frozen at -800C for 
future use. Then as in experiment one, 15 x 10m slices were taken from the mid-
myocardium and stored in a labelled cryotube at -800C for future use. 
 
3.3. RT-PCR for gene expression-rat experiments 
 
3.3.1. RNA Isolation 
RNA was isolated from the tissue using proprietary RNeasy™ mini spin column kit (Qiagen, 
Manchester, UK). This kit uses tissue lysis to bind RNA to a guanidine salt section on the 
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column before sequential washing, drying and elution steps to purify and remove RNA from 
the tissue.   
Briefly, buffer RLT and -mercaptoethanol warmed with carrier RNA was added to 
the sectioned tissue to inhibit RNase and stabilise the tissue and this tissue mixture was 
homogenised for 2 minutes using a polytron rotor homogeniser. At the end of 2 minutes 
RNase free water and proteinase K were added and mixed which digested any remaining 
protein. The sample was heated at 55°C for 10 minutes until the sample was completely 
clear and centrifuged for 5 minutes at 13,000 rpm at room temperature. 455l of the 
supernatant was placed in a 1.5ml Eppendorf tube and mixed by pipetting with 227.5l of 
100% ethanol and transferred to an RNeasy mini spin column and collecting tube and 
centrifuged for 15 seconds at 10,000 rpm.  The flow through was discarded and 350l of 
buffer RW1 added to the column and centrifuged again for 15 seconds at 10,000 rpm with 
the flow through discarded. 80l of an RDD/DNase I mixture was added to the silica gel area 
in the centre of the column to allow digestion of genomic DNA on the gel before a repeat of 
the wash step with the RW1 solution. Next, 500l of buffer RPE was added to each column 
and centrifuged for 15 seconds at 10,000 rpm and the flow through discarded. 
To dry the RNA on the columns 80% ethanol was added to each tube before 
centrifuging for 2 minutes at 10,000 rpm and discarding the flow through before opening 
the column lid and centrifuging again for 5 minutes at 13,000 rpm. 
Finally, the column was placed into a final collection tube and RNA free water was 
added and the tube is centrifuged to remove all the purified RNA, this step being repeated 
twice to ensure maximal yield. 
 
3.3.2. RNA quantification and quality assurance 
RNA quality was measured using the NanoDrop™ (Thermo -Fisher, West Sussex, UK) 
spectrophotometry system as previously described147. In summary, after blanking the 
machine with 1.2l of RNase free water, 1.2l of the RNA solution was added and a machine 
derived curve is obtained with an absolute total RNA detected value in ng/nl, a 
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260nm/280nm spectrophotometry and a 260nm/230nm spectrophotometry absorbance 
ratio value. 
Good quality RNA occupies the spectrum between 260nm: 280nm with a ratio of 
around 2 (less than 1.9 suggestive is of contamination and over 2.1 suggestive of RNA 
degradation) consistent with local protocols and data from other centres148. An example 
curve and values from a good quality sample is shown below with 260nm: 280nm ratio of 
2.07 in Figure 9: 
 
Figure 9: Example of a NanoDrop curve and reading for a good quality RNA sample  
 
3.3.3. Reverse transcription 
RNA was then reverse transcribed to cDNA using high capacity RNA to cDNA master mix 
and a 9800 Fast Thermal Cycler with 96-well aluminium sample block module (both Applied 
Biosystems, Paisley, UK). 
This system uses purified reverse transcriptase from e.coli with the pol gene from the 
Moloney Murine Leukaemia Virus which encodes reverse transcriptase. Using this system, a 
variety of primers bind to the Poly A tail 3 end of the mRNA and after this reverse 
transcriptase was added which uses the primer end to form a complementary strand of 
DNA. This system is widely used in RT-PCR and gene expression studies149. 
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Briefly, to allow for accurate quantification comparing more than 1 sample, to make 
a total sample volume of 20µl, 4µl of the high capacity master mix was added to a mix of 
nuclease free water and a volume of the diluted RNA sample, to make a total of 16 µl. The 
volume of RNA solution added was altered depending on the amount of RNA per µl to 
ensure that the amount of RNA per sample for RT-PCR in each tube was identical. This was 
done to prove that quantitative expression changes were not a result of differing amounts 
of RNA extracted in each sample. The experimental mixture was then centrifuged for 10 
seconds at 10,000rpm before being put in the thermocycler at 25 0C for 5 minutes, 420C for 
30 minutes and then 850C for 5 minutes before the mixture was held at 40C for 15 minutes. 
Finally, the sample was diluted with nuclease free water to a total volume of 100 µl. The 
mixture was then stored at -200C. 
 
3.3.4. Quantitative PCR 
Quantitative PCR was then performed using a custom loaded Taqman™ low density array 
card and a 7900 HT PCR machine (Applied Biosystems, Paisley, UK). This technology uses 5’ 
nuclease chemistry with VIC dye and minor groove binding probe with a non-fluorescent 
quencher on the 3’ end, to allow for specific gene expression measurement and no primer-
dimer amplification as seen with SYBR green technology. Using specific sequence probes, 
there is specific binding to cDNA only. 
In this technique, the DNA mixture is denatured at high temperature and the 
quencher binds to the 5’ end Taqman gene specific probe. After this, the reaction is cooled 
and the Taqman gene specific probe can bind to its target and then DNA polymerase and 
primers loaded in the reaction mix allow formation of a complimentary DNA strand and in 
the process cleave the dye at the 5’ end giving off measurable fluorescence. With each PCR 
cycle, more dye can be released depending on the amount of DNA available. 
Results are reported in terms of threshold cycles (C
t
), which is the machine 
calculated number of PCR cycles for the amount of fluorescence to reach greater than 10 
times the standard deviation of the baseline fluorescence.  If after 40 cycles of 
amplification, the target has not amplified it is considered that it is not present in the 
tissue.  
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To summarise after thawing on ice 30µl of the cDNA solution was added to 20 µl of 
water and then 50µl of TAQMAN™ universal PCR mastermix (Applied Biosystems, Paisley, 
UK) to make a reaction volume of 100µl. The contents were vortexed and then centrifuged. 
Next, custom 384 well TAQMAN™ probe loaded microfluidic cards (Applied Biosystems, 
Paisley, UK) with 48 gene targets in replicates of 8 were removed from the fridge and 
allowed to reach room temperature. The reaction mix was loaded into the respective loading 
port of the card and when all ports were filled, the card was centrifuged for 1 minute twice 
at 1200 rpm. 
 
3.3.5. Gene targets 
The target genes for this study were chosen on the basis of the department’s previously 
published work on the cardiac action potential 150-152, key energy production genes and some 
neuronal proteins, hypothesised to be involved in cardiac dysfunction. 
The gene symbol, full gene name, the context sequence for the RNA and the 
chromosomal location of the gene for both rat experiments are shown below in Table 5 
using the national centre for biotechnology information (NCBI) gene database as a reference 
source153: 
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Gene  Gene Name  Context Sequence Chromosome 
18-S Eukaryotic 18-S CCATTGGAGGGCAAGTCTGGTGCCA 14 
ATP1A1 Na+/K+ ATPase 1a1 AGTGAACCAGGTGAACCCCAGAGAT 2q34 
ATP1A2 Na+/K+ ATPase 1a2 AGCAGGGCATGAAGAACAAGATCCT 13q24-q26 
ATP1A3 Na+/K+ ATPase 1a3 GGTGACAATCTGTACCTGGGCATAG 1q21 
ATP2A2 Cardiac Sarcoplasmic Reticulum Ca2+Activated- ATPase 2a GGAAATTGCTGTTGGTGACAAAGTT 12q16 
CACNA1C L-type Voltage-Gated Ca2+ Channel Alpha Subunit 1c GCCCGGCTTGCCCACCGGATCTCCA 4q42 
CLCN2 Cl- Channel 2 TTCTTTGCACAAGACCCACACCATC 11q23 
CLCN3 Cl- Channel 3 GAGACCTGACAATTGCAATAGAAAG 16p12 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase AGGAGTCCCCATCCCAACTCAGCCC 4 
GJA1 Gap Junction Alpha 1 GTGAAAGAGAGGTGCCCAGACATGG 20q11 
HCN1 Hyperpolarisation Activated Gated K+ Channel 1 AAATGAAATGGTTAATGATTCATGG 2q15 
HCN2 Hyperpolarisation Activated Gated K+ Channel 2 AACATGGTGAACCACTCGTGGAGCG 7q11 
HCN4 Hyperpolarisation Activated Gated K+ Channel 4 ATGGCTCCTATTTTGGAGAGATCTG 8q24 
KCNA4 K+ voltage-gated channel, shaker-related subfamily, 4 AACAGCACACGATTCCTGCTTTAAA 3q33 
KCNA5 K+ voltage-gated channel, shaker-related subfamily, 5 GGGGGCAAGATCGTGGGTTCACTGT 4q42 
KCND2 K+ voltage-gated channel, Shal-related subfamily, 2 GGAGAAAACCACGAACCATGAGTTT 4q22 
KCND3 K+ voltage-gated channel, Shal-related subfamily, 3 GCTGACCGGCACCCCAGAAGAGGAG 2q34 
KCNH2 Human Ether Related a Go-Go channel TACTGACAAGGACACAGAGCAGCCA 4q11 
KCNIP2 K
v
 channel-interacting protein 2 TGTCAACAGGACGAGAACATCATGA 1q54 
KCNJ2 K+ inwardly-rectifying channel, subfamily J, 2 ATCTCCACAACCAGGCGAGCGTGCC 10q32.1 
KCNJ3 K+ inwardly-rectifying channel, subfamily J, 3 GCTGCTCAAATCTCGGCAGACACCT 3q31-q35 
KCNJ5 K+ inwardly-rectifying channel, subfamily J, 5 TCTACGACTATGGCCGGTGATTCTA 8q21 
KCNQ1 K+ voltage-gated channel, KQT-like subfamily 1 TGTGTCACAGCTGCGGGATCACCAT 1q41 
MT-ATP6 Mitochondrially Encoded ATP Synthetase 6 CCCCCACAATAATAGGTCTACCAAT N/A 
MT-ATP8 Mitochondrially Encoded ATP Synthetase 8 AATCATCTCCTCAATAGCCACACTA N/A 
NGF Nerve Growth Factor TGGCCACTCTGAGGTGCATAGCGTA 2q34 
RYR2 Ryanodine Receptor 2 ACAAGAAAAGTTTCAGGAGCAGAAG 17 
SlC2A4 Glucose Transporter 4 TCTGCTGCTGCTGGAGCGGGTTCCA 8q32 
SLC8A1 Na+/Ca2+ Exchanger AAAGATGTATGGCCAACCTGTCTTC 10q24 
SCN5A Na+ Channel, Voltage-Gated Type Vα  TTTGAGGGCATGCGGGTGGTGGTCA 6q12 
TAC1 Tachykinin 1 CAAATCAAGGAGGCAATGCCGGAGC 4q21 
TACR1 Tachykinin Receptor 1 TATGAGAAAGCGTACCACATCTGCG 4q34 
TH Tyrosine Hydroxylase CAAGGACAAGCTCAGGAACTATGCC 1q41 
TTYH1 Tweety Homolog 1 TGCCGCAGTCTGCACAAGGACTATG 11 
TTYH3 Tweety Homolog 3 GTCCCCACCGCCCTCATACACCTCC 12 
UCHL1 Ubiquitin Carboxyl-Terminal Esterase L1  GGCCCAGCATGAAAACTTCAGGAAA 14p11 
Table 5: Gene targets in both rat experiments 
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3.3.6. Gene expression 
In an experiment such as this with multiple runs of different tissue samples for multiple 
gene targets a method is required to reference results obtained from different samples/runs 
and make them comparable. In this study we used the relative quantification method where 
an abundant gene known to be highly expressed is used as a housekeeper gene to reference 
the expression of other genes to. This allows the expression of a target gene to be compared 
from one tissue sample to another even where the total amount of RNA may have been 
vastly different. In this method, the abundance of a transcript was measured against the 
housekeeper gene abundance value to establish a C
t
 value. The cards were then sealed and 
placed in the PCR machine and the PCR run was begun. 
Based on the local laboratory experience, poor tissue quality and unreliable 
experimental results have been found when a sample recorded an absolute threshold cycle 
value of greater than 20 for 18-s (the commonly used housekeeper gene in the laboratory 
and a very abundant target). Any sample recording threshold cycle values beyond 20 for 18-
s were therefore excluded. Inappropriate amplification was then confirmed by analysis of 
the PCR curves to prove that there had been inefficient amplification likely due to human 
error at some point in the experiment. 
An example PCR plot, with nuclease free water used as a control sample plotted 
against the endogenous housekeeper 18-s with normal amplification is shown below in 
Figure 10: 
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Figure 10: PCR curves for 18-S from nuclease free water (bottom) and 18-s from a control 
tissue sample (top) 
 
3.3.7. Choosing the endogenous control 
Currently there is no definitive housekeeper used in gene expression studies and the choice 
of housekeeper is normally chosen depending on local experience and the tissue type 
analysed. Commonly used endogenous controls are 18-S, 28-S and GAPDH and in this 
experiment 18-S, GAPDH and Cx43 were provisionally identified as housekeepers that could 
be used in final expression calculations.  
Using automated geNORM™ (Statminer, Intergromics, Granada, Spain) analysis 
software, we were able to compare the raw C
t 
values for a variety of potential housekeeper 
genes with each other and use the standard deviations of logarithmically transformed 
expression ratios, to give an M value- or stability measure. The lowest M value suggests the 
most stable housekeeper154. This method was then checked by looking grossly at the 
distribution and standard error bars of the raw C
t
 values for each potential housekeeper 
seen (Figure 11): 
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Figure 11: Raw C
t 
distribution with bars for the 3 genes selected as potential housekeeper 
genes with the median, 10th, 25th, 75th and 90th percentiles with error bars 
 
Here we can see that the smallest distribution of values is for 18-S, this gene codes 
for part of the ribosome and has been widely used in cardiac genetic expression 
experiments and has not previously been demonstrated to be differentially expressed in 
diabetes or obesity155, 156. A selection of the gene expression results were then repeated with 
GAPDH and Cx43 to make sure that any changes seen with 18-s were along similar lines 
with the other housekeepers to give confidence to the existing results obtained using 18 -S 
as our housekeeper. Whilst different values were obtained, there were no significantly 
different trends. 
 
3.3.8. Conversion to relative abundance  
As each single decrease in the number of cycles required for replication, equates to a 
doubling of the amount of mRNA, all values were logarithmically transformed to reflect the 
fact that a small change in C
t
 value translates into a large change in mRNA expression. 
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Increasing C
t
 values suggest a smaller amount of mRNA present as more replication cycles 
are required to amplify up to a detectable level. For the entirety of the study the results are 
presented in arbitrary units based on target gene expression referenced to 18 -s. 
 
3.4. Immunofluorescence (IF)  
This technique is based on the use of specific antibodies to target proteins and then 
secondary multiple secondary antibody binding to the primary antibody with labelled 
fluorophores which can then be detected with microscopy. 
The 10m cryosection microscope slides were fixed in buffered 10% formalin. 
Sections were then washed in 1x phosphate buffered saline (PBS) before permeabilisation 
with 0.1% Triton-X 100 and non-specific blocking with bovine serum albumin (bSA) diluted 
in PBS (all, Sigma-Aldrich, Poole, UK).  
Sections were then incubated overnight at 4C in the dark with 1:100 primary 
antibody (rabbit anti-HCN4, Alomone, Jerusalem, Israel) in 1% bSA in PBS before washing 
with PBS and incubation in the dark at room temperature with 1: 500 secondary antibody 
diluted (donkey anti rabbit IgG, rhodamine, Millipore, Watford, UK) in 1% bSA in PBS for 2  
hours. A negative control was undertaken using a section from a control animal incubated 
with secondary but no primary antibody based on previously reported specificity from this 
group and others 157, 158. 
Sections were then washed with PBS before mounting with vectashield and analysis 
with confocal microscopy and quantitative signal intensity measurements in arbitrary 
manufacturer units.  
 
3.5. Mathematical modelling of the action potential 
Mathematical modelling has been used for some years in electrophysiological studies and is 
based on data recorded in myocytes with reconstruction of the currents and action potential 
using equations developed by Hodgkin and Huxley159. In this study we have used the model 
developed by Pandit et al.160 and which can be used to look at the following ion currents and 
then to generate action potential curves for the epicardium and endocardium, thus 
reflecting a depolarization gradient: 
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 I
C a-L
-Long lasting Ca2+  Current 
 I
F
-Funny Current 
 I
K,1
-Inward K+  Rectifying Current 
 I
K,ss
-Slowly Activating K+  Rectifying Current 
 I
Na
- Na+  Current 
 I
Na/C a
-Na+- Ca2+  Exchanger Current 
 I
to
-Transient Outward Current 
 I
Na-K 
-Na+- K+ ATPase Current 
 SR Ca2+  Release 
 
This model while not exhaustive has been very widely used and validated 140, 161 and 
does provide useful modelling data based on mRNA expression as seen previously 162.  
Before specific modelling of the funny current (I
f
), the original model in Pandit et 
al.160 was modified to incorporate experimental data models from Cerbai et al.163 more 
specifically. The activation curve from Cerbai et al.163, was fitted using the Boltzmann 
distribution (V
H
 = -87.74mV, k = -10.12):  
𝑦∞ =
1.0
1.0 + 𝑒(𝑉+87.74)/10.12
 
Where 𝑦∞, is the steady-state value of the activation variable, y and v is the 
membrane potential. The time constant of I
f
 activation was reformulated based on data from 
Cerbai et al.163: 
𝜏𝑦 =
1.0
0.1177 ∗ 𝑒(𝑉+86.78)/29.5
+ 0.8141 ∗ 𝑒−(𝑉+86.78)/14.75  
Where τ
Y
. The rate of change in the activation variable, y, was calculated from: 
𝑑𝑦
𝑑𝑡
=
𝑦∞ − 𝑦
𝜏𝑦
 
Finally, I
f
 was calculated assuming that it is carried by a mixture of Na+  and K+ : 
𝐼𝑓 = 𝑔𝑓𝑦[𝑓𝑁𝑎(𝑉 − 𝐸𝑁𝑎) + 𝑓𝐾(𝑉 − 𝐸𝐾)] 
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Where g
f
 is the conductance ƒ
Na 
and ƒ
K
 are the fractions of I
f
 carried by Na+  and K+ , E
Na
 
and E
K
 are the equilibrium potentials of Na+  and K+  and 𝑓𝑁𝑎 = 0.2 and 𝑓𝐾 = 1 − 𝑓𝑁𝑎.  
The maximum conductance, g
f
 (0.0043μS), was obtained by matching simulated 
current traces of I
f
 to experimental data.  
As the original Pandit et al.160 model for I
f
, was altered to incorporate more closely 
experimental data from Cerbai163 we have shown below our modelled values compared to the 
original data from Cerbai163, with the activation curve shown in Figure 12a, voltage-
dependence of the time constant of I
f
 activation in Figure 12b and finally the modelled I
f 
current density in Figure 12c. 
 
Figure 12: (A), I
f
 activation curve with experimental modelling and original data points from 
Cerbai et al.163, (B), voltage-dependence of time constant of I
f
 activation with experimental 
modelling and original data points from Cerbai et al.163 and (C), Experimental recordings 
from Cerbai et al.163(top) and simulation (bottom) of I
f
 during the protocol. 
 
For the rest of the ion channels, the Pandit et al.160 model was used unchanged. In 
normal and obesity conditions, the models were run for a 5s period to obtain a stable state 
condition before a sequence of external stimulus pulses (with an amplitude of 0.8 nA, 
duration of 6 ms and frequency of 1 Hz) were applied to evoke an action potential. Ion 
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current density was scaled from the normal model based on a percentage change in mRNA 
expression compared in the obese model. In order to evaluate the relative role of each of the 
remodelled ionic currents, simulations were also performed by considering changes to each 
individual ionic current alone. 
 
3.6. Human study 
 
3.6.1. Patient recruitment 
Written informed consent was obtained from all patients taking part in the study and the 
study was ethically approved by the Liverpool East Ethics Committee with subsequent NHS 
site approval at University Hospital Aintree and Liverpool Heart and Chest Hospital prior to 
the initiation of recruitment. 
Subjects were male and females all aged 18 years and above diagnosed with types 2 
diabetes and a control group without type 2 diabetes who were able to give informed 
consent. Criteria for inclusion were patients referred for aortic valve replacement for aortic 
stenosis with a normal left ventricular function being defined according to the definition of 
a preserved ejection fraction of greater than 50% as stated by the European Society of 
Cardiology 164. 
Exclusion criteria for the study comprised of atrial fibrillation due to the effect on LV 
function, the presence of other conditions which may affect LV function (non-ischaemic 
causes of heart failure, untreated thyroid disease, anaemia with a Haemoglobin (Hb) of less 
than 10, history of alcohol abuse, presence of AV fistula, significant regurgitant valvular 
heart disease or hypertensive heart disease (clinical history of uncontrolled hypertension 
with echocardiographic criteria of left ventricular hypertrophy). Other exclusion criteria 
were chronic renal failure with an eGFR less than 30 mls/min/1.73m2, requirement for 
additional surgery to CABG/AVR, the use of insulin in the treatment of their diabetes and 
patients with type 1 diabetes 
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3.6.2. Rationale for patient selection 
The main factor for the choice of our patient population was the safety and surgical 
availability to obtain samples. The surgical team at our local centre perform a large amount 
of coronary bypass surgery off cardiopulmonary bypass i.e. with the heart moving so a safe 
biopsy would not be able to be taken. The surgeons at our centre perform aortic valve 
replacements on cardiopulmonary bypass and thus the heart is relatively static and a safe 
biopsy which is paramount can be taken. By minimising any confounding factors which may 
cause electrical remodelling or heart failure such as eliminating patients with atrial 
fibrillation we tried to find a group where any experimental change could be as closely 
linked to diabetes as possible.  
Key pathological effects of type 2 diabetes and obesity in the myocardium, are the 
induction of LV hypertrophy165 and myocardial fibrosis166 both of which are associated with 
higher rates of arrhythmias138, 167.  There are many potential mechanisms of 
arrhythmogenesis related to hypertrophy and fibrosis including slowed conduction, early 
after-depolarizations and enhanced automaticity138 as mentioned previously. Cardiac 
hypertrophy and fibrosis in the absence of other causes such as high blood pressure or 
ischaemic heart disease can be seen in other cardiac diseases such as valvular aortic 
stenosis168 again with increased rates of arrhythmias169. It is unclear how much of the 
arrhythmic potential seen in diabetes/obesity relates to hypertrophy and fibrosis and how 
much is due to specific genetic changes related to diabetes or obesity. In preparation for 
this study we have reviewed many studies which while researching changes in diabetes and 
obesity have tended to use normal animals/patients as the control while not addressing the 
potential concern that much of the arrhythmogenic potential is related to hypertrophy and 
fibrosis. We chose to compare our group with diabetes with a control group of patients with 
aortic stenosis, which causes pressure overload and results in LV hypertrophy and fibrosis 
and so hopefully will help prove that any changes are related to a diabetic process 
specifically and not just due to hypertrophy/fibrosis. We have also taken into account the 
fact that type diabetes is closely associated with the metabolic syndrome and obesity and 
again have tried to match our control group closely in terms of average BMI and central 
adiposity so that the control group would be similar to the diabetes group so that again this 
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would give us the best chance of showing that the changes seen are related specifically to 
diabetes and not obesity. 
In our study we have chosen not to include patients on insulin treatment as insulin 
has been shown to have a wide range of effects within the myocardium including positive 
inotropy, reduced oxidative stress, improved metabolism and reduced apoptosis170. It was 
felt that these effects may suppress the pathological process and ameliorate any changes 
seen in our group with diabetes. As a large part of the clinical burden of cardiomyopathies 
is arrhythmogenic, we felt that when looking at the gene expression changes underlying this 
including patients with insulin would not be appropriate. This is due to the fact that insulin 
has been shown to activate a voltage-dependent, nonselective cation channel with 
prolongation of the action potential171. Insulin has also been shown to alter cardiac calcium 
levels and action of NCX1172. Previous studies have shown that experimental differences seen 
in animal models of diabetes, specifically in cardiac potassium channel gene expression can 
be reversed with the administration of insulin173, and for this reason and the other reasons 
mentioned above, we did not include any patient who was receiving insulin treatment. 
By selecting a control group that unlike many other studies is subject to similar 
hypertrophic/fibrotic changes and by omitting insulin usage in our group with diabetes, we 
feel that our results should reflect changes related to diabetes as specifically as possible. 
 
3.6.3. Patient characteristics 
Patients then had their height, weight and waist circumference measured, BMI calculated 
and patients with diabetes had their most recent glycated haemoglobin recorded. All 
patients had the use of statin drugs, beta blockers, ACE inhibitors/angiotensin receptor II 
blockers (ARBs) and patients with diabetes had their diabetes treatments recorded. We also 
recorded if any of the patients with diabetes were known to have any complications of 
diabetes such as retinopathy, neuropathy or nephropathy. 
 
3.6.4. ECG protocol 
All patients had their resting standard 12 lead ECG reviewed for their corrected QT interval 
(QTc) as measured by automated computer software installed with each ECG machine.  
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Standard electrocardiography is limited to frequencies up to 150Hz and many of the 
highest amplitude signals of the heart are above this. Therefore, standard 
electrocardiography may miss some of the higher frequency signals whereas signal averaged 
electrocardiography allows for a much broader bandwidth and therefore the ability of these 
higher frequency cardiac electrical signals. The signal averaged ECG also allows for 
processing over a prolonged period with noise reduction filtering to remove skeletal muscle 
noise and allow for a more accurate averaged measure of the QRS. 
The signal averaged ECG has been shown to be superior to the standard ECG for the 
detection of a variety of cardiac electrocardiographic abnormalities compared to a standard 
electrocardiogram including for the detection of coronary ischaemia 174. 
All patients underwent signal averaged ECG monitoring following a period of rest for 
10 minutes in the supine position for 10 minutes using a MAC 500 machine (GE healthcare, 
Amersham, UK) prior to cardiac surgery.  
Electrodes were placed in the standard position for the procedure as described 
previously175.  
Digital filtering was performed with a 40-250HZ band pass bidirectional filter and 
averages were taken over 250 beats with maximum acceptable noise of 0.5V. 
All ECGs were analysed for late potentials using previously reported values consisting of 
two of the following three criteria: filtered QRS greater than 114ms, voltage of the root 
mean square of the terminal 40 msec of the vector QRS less than 20ms and/or low 
amplitude signals greater than 38ms176 
 
3.6.5. Echocardiography 
Echocardiography is a well-known and well-validated method of assessing cardiac structure 
and performance in a non-invasive way, quickly and reproducibly. Echocardiography is 
based on the use of transducer generated sound waves reflected through the body and 
processed through a computer to generate images of the heart.   
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3.6.5.1. Strain analysis  
Using the Doppler principle, echocardiography can be used to measure myocardial 
deformation and therefore strain by tracking areas of the heart muscle and measure their 
movement over a distance and thus strain using the formula, as an example for longitudinal 
strain. 
L
strain
%= L
start
-L
end 
 L
end 
 
This will give a negative percentage for contraction and positive for elongation, 
except when measuring radial contraction, where the value will be positive. This method 
allows for a degree of measurement of the actual myocardium and thus an inference about 
the contractile performance. 
Using a suppression software to ignore the higher velocity signals from blood flow, 
the machinery can pick up the lower velocity signal from the myocardium and track the 
process of the muscle either by tracking of the unique speckle pattern (speckle tracking 
imaging-STI) or by placing a region of interest (ROI) cursor over a specific muscle area 
(tissue velocity imaging-TVI). 
An example of speckle tracking is shown below in Figure 13: 
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Figure 13: Echocardiographic speckle tracking of the myocardium in the apical 4 chamber 
view 
 
This then allows for production of strain curves and strain values in a variety of 
different directions including longitudinal, radial and circumferential covering the different 
fibre orientations and contractile directions of the heart. 
An example of strain curves is shown below for circumferential strain using speckle 
tracking in Figure 14: 
 
 
Figure 14: Strain curves and values using speckle tracking in the parasternal short axis for 
circumferential strain 
 
3.6.5.2. Speckle vs. tissue velocity imaging 
Both methods can be used to measure myocardial strain and accurately assess the 
contractile performance of the left ventricle and share some common methodologies and 
some important differences which are reviewed below. 
TVI, measures myocardial deformation by measuring in a region of interest between 
two frames, the instantaneous velocity of a point and the acquisition time of one frame to 
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another, which then can be used to infer the displacement of that point between frames. 
This region of interest is placed by the operator and normally is placed in the mid -
myocardium but may capture epi- or endocardium depending on image quality. TVI uses 
high frequency pulse wave repetition to enable capture at high heart rates and frame rates. 
STI, tracks the unique myocardial speckle pattern and by measuring the time between two 
frames, myocardial speckle velocity can be calculated and this is then averaged across the 
epi-to endocardium.  
Because the myocardium accelerates and decelerates and is not at a constant velocity 
with a sudden stop, the two methods are not interchangeable 177 but comparable for general 
trends. Also due to the complexity of the methodology, STI cannot be used at very high 
frame rates or heart rates as tracking of the speckles, is not possible which is not an issue 
using TVI. TVI can be performed online while acquiring images which is useful in time 
limited clinical situations and STI can only be performed offline.  STI, by comparison 
because it is not dependent on the angle of a pulse wave signal does not become less 
accurate if the insonation beam is not in line with the deforming myocardium178. STI 
therefore can be used to assess radial strain in a way that TVI cannot reliably be used due to 
issues with the angle of insonation. STI, has one important area of superiority in diseased 
states compared to TDI in that it is not subject to the tethering effect whereas TVI is 179. The 
tethering effect is caused when non-moving fibrous/scar tissue is pulled by the adjacent 
moving myocardium. In this situation TVI derived strain assumes the pulled area of 
myocardium to have contracted appropriately and assigns strain to it despite the fact it 
does contract itself. As STI measures speckles directly, it sees the non-moving speckle and 
accordingly assigns it to a zero strain value, signifying a diseased piece of myocardium. In 
this study we have predominantly used speckle tracking as measurements are being made 
offline and for superior reliability we believe based on the information above and because of 
the variability in curve analysis and region of interest placement. 
 
3.6.5.3. Correlation with myocardial fibrosis 
Myocardial fibrosis can be assessed commonly by two methods, cardiac MRI or histological 
examination but there have been studies in hypertrophic cardiomyopathy 180, Fabry’s 
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disease181, aortic stenosis168 and diabetes182 looking at the correlation of 2d speckle tracking 
strain rate using echocardiography with fibrosis.  
In many studies a global contrast-enhanced myocardial T
1
 mapping time on MRI of 
less than 500ms has been shown to correlate clearly with fibrosis183 and a T1 mapping time 
of less than 500ms has been correlated with a global longitudinal strain of less than -18% 
using 2D speckle tracking echocardiography182.  In this study as we unfortunately did not 
have access to cardiac MRI imaging or potentially enough human tissue for full histological 
analysis, the use of strain analysis has been used to infer fibrosis within the ventricle in 
both our human groups. By showing that both groups have probable evidence of fibrosis, we 
hope to show that whatever changes we see in terms of gene expression are not a 
consequence of fibrosis and not a common final pathway but changes specific to diabetes. 
In this study to show that there was subclinical dysfunction that could not be seen 
using standard method such as an ejection fraction, we compared our global longitudinal 
strain values to published normal reference values184 to try and show clear evidence of a 
myopathic phenotype. 
 
3.6.5.4. Echocardiography protocol 
All patients underwent 2-dimensional echocardiography prior to cardiac surgery using 
commercially available vivid Q, vivid 7 (GE healthcare, Amersham, UK) and IE 9 (Phillips, 
Guilford, Surrey) systems and a 3.5 MHz transducer.  
Patients were studied in the left lateral decubitus position following a 15-minute rest 
period. Conventional imaging allowing M-mode and two-dimensional assessment of left 
ventricular dimension and function was performed according to published guidelines and 
using the 16 segment model 185. All images were acquired over three successive cycles and 
all measurements averaged over the three cycles. Images were taken with a narrowed sector 
width and with a frame rate of 50-100 fps and then at 100 fps and above. 
Images were taken in the following positions for the following measurements 
summarised in Table 6: 
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Echo window Measurement 
Parasternal long axis view 
Parasternal short axis view-mitral level 
Parasternal short axis view-basal level 
Apical 4 chamber 
 
 
Apical 2 chamber 
 
Apical 3 chamber 
Measurement of LV septal width, end systolic  and diastolic  diameters, 
WMSI 
WMSI and speckle track strain 
WMSI and speckle track strain 
M mode of the lateral mitral annulus systolic  excursion, Simpson’s 
biplane ejection fraction, WMSI, speckle track strain, TVI strain, left 
atrial size and left atrial volumes 
Simpson’s biplane ejection fraction, WMSI, TVI strain, left atrial size, 
left atrial expansion index, speckle track strain and left atrial volumes 
Simpson’s biplane ejection fraction, WMSI, speckle track strain and TVI 
strain 
Table 6: Standard echocardiographic measurements used in this study 
 
Wall motion scoring index (WMSI) was calculated as 1 for a normal segment, 2 for a 
hypokinetic segment, 3 for an akinetic segment, 4 for a dyskinetic segment and 5 for an 
aneurysmal segment with 16 being a normal score as previously published186. 
Filling and diastolic function was assessed using pulsed-wave Doppler imaging of 
mitral inflow at the mitral valve leaflet tips at a frame rate of 80-100 fps for calculation of a 
maximal E velocity, A velocity and E: A ratio. Tissue velocity imaging was then performed of 
the lateral mitral valve annuluses for E/E’ ratios as a measurement of LV filling pressures 
and diastolic function. 
Measurements of LV end diastolic, systolic and septal width diameter were all made 
using a cursor placed across the LV septum with a straight line just in front of the tips of 
the mitral valve leaflets in accordance with published guidelines187. 
M mode of the lateral mitral valve systolic annulus excursion (MAPSE) was measured 
with the standard M mode cursor at angle of less than 150 of insonation and measured from 
the top of the baseline to the peak of the curve. 
Measurement of left atrial pathology was made in several ways with calculation of 
left atrial (LA) area made by free hand outlining of the left atrial area in the apical four 
chamber position just before the opening of the mitral valve. The left atrial volume was 
calculated using the area/length method in the apical 2 and 4 chamber views185. 
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Active atrial function was measured in three ways using the respective formulae: 
 
Left atrial expansion index (LAEI)= left atrial maximal volume—left atrial minimal 
volume/ left atrial minimal volume x 100. This measures the ability of the left atrium 
to acts as a reservoir for blood. 
Left atrial passive emptying fraction (LAPEF)=maximal left atrial volume -- left atrial 
volume on the ECG P wave/maximum left atrial x100. This represents the left atrial 
conduit function. 
Left atrial active emptying fraction (LAAEF)= left atrial volume on the ECG P wave – 
left atrial minimal volume/ left atrial volume on the ECG P wave x 100. This assess 
the pure pump function of the left atrium188. 
Offline measurement of strain (ECHOPAC™, GE healthcare, Amersham, UK) was 
made predominantly using speckle tracking software but with a comparison of 
measurements using TVI strain. All speckle measurements were made over a single cycle 
using the commercially available automated software. 
Offline images were analysed using automated border tracking software and systolic 
yo-yo tool for confirmation visually of appropriate speckle tracking. When the operator was 
satisfied with image / tracking quality, the automated tracking software, would then 
attempt to measure speckle movement for each region and if successful would visually 
represent this with a green tick. If the tracking quality was poor the segment would be 
rejected and the operator could manually readjust the border tracking to attempt to 
improve the speckle tracking, depicted below in Figure 15. 
 
70 
 
 
Figure 15: Automated confirmation of appropriate speckle tracking 
 
Once complete, the automated software would then generate an automatic set of 
peak systolic strain timed to aortic valve opening as seen in Figure 15 as the peak S value. 
Measurements were made in apical 2, 3 and 4 chamber for global longitudinal strain 
with values from each segment being averaged from 6 segments for a mean score. 
Circumferential and radial strain was measured using a mean score from 6 segments in the 
parasternal short axis at the mid wall level as previously described189.  
Tissue Velocity measurements were made in apical 2, 3 and 4 chamber and in the 
parasternal short axis at the mitral valve leaflet level for longitudinal strain and 
circumferential strain respectively. Measurement of strain was made offline with the pre -
recorded 3 cycle TVI loops at which point a ROI cursor was placed over the respective region 
to be interrogated using the 16 segment model. A strain curve was obtained  and the peak 
systolic value recorded and this repeated over the three cycles for an average value. 
An example curve is shown below in Figure 16: 
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Figure 16: An example of TVI strain curves  
 
For evaluation of the methods used, 5 selected patients (with the clearest image 
quality) had a selection of the echocardiographic measurements re-measured for intra-
observer variability, inter-observer variability by a second blinded British Society of 
Echocardiography accredited echocardiographer and for a comparison of TVI vs. speckle 
tracked strain. The repeated standard measurements investigated at for variability were 
ejection fraction, septal width and lateral MAPSE  
For analysis of methodology, a visual Bland-Altman plot was used based on its 
widespread as the predominant measurement of observer variability in echocardiography 
studies190, 191 and due to the fact that there is no recommendation from the expert consensus 
groups in echocardiography. All measurements were also compared using a t-test. 
 
3.6.6. Left ventricular biopsy 
All patients had their biopsy sample taken by an experienced consultant cardiothoracic 
surgeon at the LV apex in the anatomical position normally used for puncture of the LV in 
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transapical aortic valve implantation. The biopsy was performed using a single TRUCUT™ 
biopsy needle (Cardinal Health, Dublin, Eire) just prior to the insertion of cardioplegia 
solution. The sample was then taken and immediately placed in physiological Hartman’s 
solution (Baxter, Newbury, UK) before immediate transfer to the lab for processing. Initially, 
the experimental plan was to take all the samples and process them topographically as in 
the streptozocin rat experiment but unfortunately due to the variable quality and size of 
samples, it could not always be confirmed a full  thickness sample encompassing all layers 
was taken. All samples were placed in OCT before flash freezing liquid nitrogen. 
 
3.6.7. RT-PCR for human samples 
 
3.6.7.1. Left ventricle RNA isolation 
The left ventricle tissue was processed in a similar manner to the rat tissue  for RNA 
isolation but with the proprietary mirVana™ RNA isolation kit (Invitrogen, Paisley, UK) 
which uses a slightly different filter method to enable capture of very small amounts of 
RNA. 
The left ventricular tissue was taken from the freezer and added to 300µl of lysis 
buffer to the sample and homogenised for 2 minutes using a polytron rotor homogeniser. 
To this 30µl of miRNA homogenate additive was added and mixed by vortexing before 300µl 
of acid-phenol: chloroform was added and mixed by vortexing for 1 minute. The solution 
was centrifuged at 10,000 rpm for 5 minutes and the supernatant removed to a fresh tube 
and 375µl of 100% ethanol added and mixed by pipetting. This mixture was then transferred 
to a filter cartridge in a collection tube and centrifuged at 10,000rom for 15 seconds and the 
flow through discarded before 700µl of wash solution 1 was added to the cartridge and 
centrifuged for 15 seconds and the flow though discarded again. The mixture was washed 
twice with 500µl of wash solution 2/3 and centrifuged at 10,000 rpm for 30 seconds with 
the flow through discarded. 
The cartridge was placed in a new collection tube and 100µl of heated elution 
solution (950C) added and centrifuged at 10,000rpm for 30 seconds. The resulting RNA was 
then frozen at -800C. 
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3.6.7.2. RNA processing and qPCR 
The obtained RNA samples were processed for qPCR using similar laboratory techniques as 
the two rat experiments and identical laboratory supplies. The qPCR probe information is 
shown below in Table 7 again using the NCBI gene database as a reference153. 
Gene  Gene Name Context Sequence Chromosome  
18-S Eukaryotic 18-S CCATTGGAGGGCAAGTCTGGTGCCA 22p12 
ANO1 Anoctamin 1 GTTCTTCAAAGGCCGGTTTGTTGGA 11q13.3 
ATP1A1 Na+/K+ ATPase 1a1 GTATCCCCTCAAACCTACCTGGTGG 1p21 
ATP1A2 Na+/K+ ATPase 1a2 GACCTGTCCAAGGGCCTCACCAACC 1q23.2 
ATP1A3 Na+/K+ ATPase 1a3 GTTAACCCCCGGGATGCCAAGGCCT 19q13.31 
ATP2A2 Cardiac Sarcoplasmic Reticulum Ca2+Activated- ATPase 2a AGATGTCTGTCTGCAAGATGTTTAT 12q24.11 
BEST1 Bestrophin 1 GGAAAACAGGGATGAAGCACATTCC 11q13 
BEST2 Bestrophin 2 CTTCGTGCTTGGCTTTTATGTGACG 19p13.2 
BEST3 Bestrophin 3 ACCACGTGGTTGAAGCAGGTTTTAT 12q14.2-q15 
CACNA1C L-type Voltage-Gated Ca2+ Channel Alpha Subunit 1c ACCAATTCCAACCTGGAACGAGTGG 12p13.3 
CACNA1D L-type Voltage-Gated Ca2+ Channel Alpha Subunit 1d GAATGGAAACCATTTGACATATTTA 3p14.3 
CLCN2 Cl- Channel 2 AGACCCTGATGTATGGCCGGTACAC 3q27.1 
CLCN3 Cl- Channel 3 GTGACACTGCAGTTGGAACTCATTA 4q33 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase GACCAGTGGTGCGCTGAGCCCTGCC 12p13 
GJA1 Gap Junction Alpha 1 GAGGAGGAAAAGAAGCAGAAGTTTT 6q22.31 
GJA5 Gap Junction Alpha 5 CTTACAGTGATTTCAGGTTTTACTG 1q21.1 
HCN1 Hyperpolarisation Activated Gated K+ Channel 1 ATCAGTGGGAGGAGATCTTCCACAT 5p12 
HCN2 Hyperpolarisation Activated Gated K+ Channel 2 CCCTACAGTGACTTCAGATTTTACT 19p13.3 
HCN4 Hyperpolarisation Activated Gated K+ Channel 4 ATGATGGCTTATTACAGTGGCAATG 15q24.1 
KCNA4 K+ voltage-gated channel, shaker-related subfamily, 4 ATGGGAGGCTTGCTGAACATGGATA 11p14 
KCNA5 K+ voltage-gated channel, shaker-related subfamily, 5 TCTAACAGCCGATCCAGTTTAAATG 12p13 
KCND2 K+ voltage-gated channel, Shal-related subfamily, 2 CACAACCAGTCGCTCCAGCCTTAAT 7q31 
KCND3 K+ voltage-gated channel, Shal-related subfamily, 3 CTCTGGCTCTGAGGAGCTGATCGGG 1p13.3 
KCNH2 Human Ether Related a Go-Go CAGTTCTTTCCTCAAGGAGACTCCA 7q36.1 
KCNIP2 K
v
 channel-interacting protein 2 CCTGCGCCAGCAACAGGACATGTTC 10q24 
KCNJ2 K+ inwardly-rectifying channel, subfamily J, 2 AAGCTGCTCAAATCTCGGCAGACAC 17q24.3 
KCNJ3 K+ inwardly-rectifying channel, subfamily J, 3 GTGGAAGCCACAGGCATGACCTGCC 2q24.1 
KCNJ5 K+ inwardly-rectifying channel, subfamily J, 5 CACCCACATCTCACAGCTGCGGGAA 11q24 
KCNQ1 K+ voltage-gated channel, KQT-like subfamily, 1 CATTACTGCAGGCCACCTACTCATG 11p15.5 
MT-ATP6 Mitochondrially Encoded ATP Synthetase 6 GGCCCACCATAATTACCCCCATACT N/A 
MT-ATP8 Mitochondrially Encoded ATP Synthetase 8 CTCAAAGCAGCAGGAGCAGATCCCC N/A 
NGF Nerve Growth Factor CTCTCTATTTGTGGACAACTGAGAC 1p13.1 
RYR2 Ryanodine Receptor 2 CCCGCCAGACACGACCACGCCATCG 1q43 
SLC2A4 Glucose Transporter 4 ACAGATAGGCTCCGAAGATGGGGAA 17p13 
SLC8A1 Na+-Ca2+ Exchanger TCACTGTCAGTGCTGGGGAAGATGA 2p22.1 
SCN5A Na+ Channel, Voltage-Gated Type Vα  TGAGAAAGTGTACCACATCTGTGTG 3p21 
TACR1 Tachykinin Receptor 1 GATTCGGCGGGACGGGCTGCTCCTG 2p12 
TH Tyrosine Hydroxylase TGGCCCAGGCAGTCAGATCATCTTC 11p15.5 
TTYH-1 Tweety Homolog 1 CTCCCCTCCGCCTACGTACTCTCCC 19q13.4 
TTYH-2 Tweety Homolog 2 TCCCCGCCGCCCTCATACACCTCCA 17q25.1 
TTYH-3 Tweety Homolog 3 ACAGGAAGGCCAATGTCGGGTAGAT 7p22 
Uchl1 Ubiquitin Carboxyl-Terminal Esterase L1  CCATTGGAGGGCAAGTCTGGTGCCA 4p14 
Table 7: Gene targets in the human study 
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Between the human and rat experiments some gene targets were changed, this was 
on the basis of poor results with some targets and positive results with other which 
suggested expansion of a particular gene group of interest (e.g. extra Cl-  channels in the 
human experiment). 
 
3.6.8. Mathematical modelling of the action potential 
In the human experiment, we again used mathematical modelling to look at the putative 
effects of our qPCR results on the AP and to try and infer how these changes may prove 
arrhythmogenic. Similar to our obesity experiment, we used a previously published system 
the O’Hara-Rudy dynamic model which uses experimental data based from non-diseased 
human ventricular cells and then mathematical analysis to generate  a mathematical model 
of the human AP192. Mathematical modelling is very important in electrophysiological study 
of human subjects as the obtainment of multiple tissue samples to perform multiple patch 
clamp experiments can be very difficult to justify from a safety point of view.  
The O’Hara-Rudy dynamic model is able to model 14 currents and incorporate 41 
different equations to model effects on the human AP but we have chosen to use it because 
it illustrates the effect of I
Kr 
blockage more effectively than other AP models. Using this 
model, channel conductance was scaled according to the measured average ratio of mRNA 
between the control and the diabetes groups. In the control and the diabetes groups, the 
models were run for a 5 s period to obtain a stable state condition before a sequence of 
external stimulus pulses (with an amplitude of 0.8 nA, duration of 5 ms and frequency of 1 
Hz) were applied to evoke an action potential and record the change globally. In a similar 
manner to our rat experiment, we used scaled mRNA expression changes in our diabetes 
group compared to control in order to scale changes in current expression. In order to 
evaluate the relative role of each of the remodelled ion channels, simulations were also 
performed by looking at the change to each individual ion channel alone.  
 
3.7. Statistical analysis 
Prior to the study beginning, a decision was made to set up this project as an exploratory 
project which may then identify areas of interest for further work with larger sample sizes. 
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We then reviewed the published research output of department in terms of gene expression 
studies and the number of subjects previously used in these experiments which suggested 
groups of a minimum of six were required for useful data to be obtained and compared 193. 
As we were dealing with small groups in an exploratory fashion, a power calculation was not 
undertaken with the knowledge that any findings in this project would not be definitive and 
would need larger samples for confirmation. 
All experimental work was analysed using SigmaPlot™ version 12.5 (Systat, San Jose, 
USA). Significant results were taken as being with a p value of <0.05. All statistical 
methodology was chosen after consultation with a statistician at the University of Liverpool. 
Grouped mean data are reported as mean ± standard error of the mean (SEM).  
The STZ rat experiment was analysed using a two-way ANOVA to look for significant 
differences across the LV wall by region and then between the overall mean in the STZ 
group and control group. To identify where specifically the differences were located by 
region, a Tukey’s honestly significant difference (HSD) post hoc multiple pairwise 
comparison test was applied. All single variable experimental work was analysed for 
significance using an unpaired student’s t-test again if the data passed a Shapiro-Wilk test of 
normality and if not then a rank sum test was applied. Analysis of categorical variables for 
significant differences between the two groups was undertaken using a Fischer exact test. 
Results were taken as being significant with a p value of <0.05.  
Methodological comparison was undertaken using the well -established Bland-Altman 
(BA) method which is often used as the gold standard in medical methodological 
comparison in cardiac imaging studies194. The BA method allows for the sample visual 
representation of how well two methods agree without the difficulties encountered using 
the correlation coefficient or regression analyses. Methods are considered to agree if when 
plotted, the difference between the methods and their mean fall with 1.96 standard 
deviations (representing the 95% confidence interval (CI)). If there is poor agreement 
between the two methods, multiple scatter dots will be seen outside the 95% CI bars. 
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4. STZ rat: Type 1 diabetes model  
 
4.1. Animal characteristics 
Baseline and terminal weights with weight gain are shown below for control and STZ 
animals with significantly poorer weight gain in the STZ group and lower final weight 
(p<0.01). Results are shown in Table 8: 
Group Base Weight (G) Final Weight (G) Gain (G) Glucose (mmol) 
STZ 362.78(5.51) 383.44(16.71) 20.66(12.66) Unrecordable (above 25mmol/l) 
Control 358.38(7.01) 579.75(13.65)** 221.37(8.32)** 5.33 (0.28) 
Table 8: Baseline and final rat characteristics showing means ± SEM shown (n=8/group). 
**Significantly different from the control group (p<0.01). 
 
4.2. STZ rat RT-PCR results 
 
4.2.1. Major ion channels active during the action potential 
Expression of the major ion channel genes in the left ventricle were measured in all three 
myocardial layers for the STZ rat (n=8) and for the control group (n=8). Primary analysis was 
made looking at a difference of the mean for STZ group vs. the control with a post-hoc 
analysis to look for a specific regional difference. 
Expression of SCN5A responsible for the primary cardiac Na+ current (I
Na
) was significantly 
lower in its expression in the STZ group with this reduction located in the mid -myocardial 
layer (p<0.01 Figure 17). Expression of the L-type Ca2+  channel, Ca
v
1.2 (CACNA1c), 
responsible for the L-type Ca2+  current (I
C a-L
) was not significantly different between the two 
groups (p=0.175). Expression of K
v
1.4 (KCNA4) which is responsible for the slow transient 
outward K+  current (I
to-s
) was significantly increased in the STZ group in all three layers of the 
LV (P<0.01) but K
v
1.5 (KCNA5), the ultra-rapid delayed rectifier K+  current (I
K,ss
) was not 
statistically altered in its expression between groups(p=0.357). Expression of K
v
4.2 (KCND2) 
and K
v
4.3 (KCND3) which are responsible for the fast transient outward K+  current, were not 
significantly different in the two groups but the auxiliary subunit KChIP2 (KCNIP2) was 
significantly reduced in the STZ, predominantly in the mid and epicardial layers (P<0.01 and 
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0.026 respectively). In the STZ group, there was significantly reduced (P<0.01) expression of 
ERG responsible for the rapid delayed rectifier K+  current (I
K,r
) with this change located in the 
mid-myocardial layer, as was expression of K
v
LQT1 (KCNQ1) responsible for the slow 
delayed rectifier K+  current (I
K,s
) (p<0.01).  
 
Figure 17: Expression of mRNA for major ion channels active during the action potential in 
the left ventricle of the control and STZ groups for each section of the myocardium 
displayed in arbitrary units referenced to expression of 18-s (housekeeper gene). C=control 
STZ=streptozocin, Endo=endocardium, Mid=mid-myocardium and Epi=epicardium. Means ± 
SEM shown (n=8/group). *Significantly different from the control group (p<0.05). 
**Significantly different from the control group (p<0.01). 
 
4.2.2. Major ion channels active during diastole 
Three channel isoforms, HCN1, HCN2 and HCN4, are responsible in varying amounts for the 
funny current (I
F
), an important pacemaker current, both cardiologically and neurologically. 
Expression of all three isoforms tended to be lower in the STZ group, but only the decrease 
in HCN2 (predominantly expressed in the nervous system 195) was significant with the 
78 
 
reduction primarily in the endocardium and mid -myocardium with a smaller reduction in 
the epicardium (p<0.01, p<0.01 and p=0.021 respectively; Figure 18). There was no 
significant change in expression (p=0.413) of K
ir
2.1 (KCNJ2) responsible for the background 
inward rectifier K+  current (I
K,1
). Expression of K
ir
3.1 (KCNJ3), primarily an atrial channel 
responsible for the ACh-activated K+  current (I
K,AC h
) (in conjunction with and K
ir
3.4 (KCNJ5) as 
a tetrameric channel) was significantly reduced in the STZ group compared to control with 
the difference focussed in the mid-myocardial layer (p<0.01). We did not observe any 
significant difference in K
ir
3.4 (KCNJ5) expression between groups which composed the 
other half of the channel (p=0.081) but expression tended to be similarly lower in the mid -
level. 
 
 
 
Figure 18: Expression of mRNA for major ion channels active largely during diastole in the 
left ventricle of the control and STZ groups for each section of the myocardium displayed in 
arbitrary units referenced to expression of 18-s (housekeeper gene). C=control 
STZ=streptozocin, Endo=endocardium, Mid=mid-myocardium and Epi=epicardium. Means ± 
SEM shown (n=8/group). Means ± SEM shown (n=8/group). *Significantly different from the 
control group (p<0.05). **Significantly different from the control group (p<0.01). 
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4.2.3. Intracellular Ca2+ handling transcripts 
Intracellular Ca2+  plays an important role in arrhythmogenesis and contractility and three 
important intracellular Ca2+ -handling genes were investigated in this study: NCX1 (the Na+ -
Ca2+  exchanger), SERCA2A (ATP2a2, the sarcoplasmic reticulum’s Ca2+ pump) and RYR2 (the 
ryanodine receptor, the SR’s Ca2+  release channel).  
No significant variation between the STZ animals and control group was observed for NCX1 
or RYR2 but a significant decrease in SERCA2A gene expression was noted in the STZ group, 
with this mainly in the mid-myocardium (p<0.01) and to a lesser degree in the endocardium 
(p=0.018; Figure 19). 
  
 
 
Figure 19: Expression of mRNA for intracellular Ca2+  handling proteins in the left ventricle 
of the control and STZ groups for each section of the myocardium. C=control 
STZ=streptozocin, Endo=endocardium, Mid=mid-myocardium and Epi=epicardium displayed 
in arbitrary units referenced to expression of 18-s (housekeeper gene). Means ± SEM shown 
(n=8/group). *Significantly different from the control group (p<0.05). **Significantly 
different from the control group (p<0.01). 
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4.2.4. Other electrophysiological channels and associated proteins/enzymes 
Of all the ions so far discussed and investigated Cl - channels are the least investigated and 
poorest understood from a cardiac AP perspective and so to investigate from a preliminary 
perspective if they are affected by diabetes, 4 Cl - channels were chosen: CLCN-2, CLCN-3, 
TTYH-1 and TTYH-3. CLCN-2 is a hyperpolarization-activated inward-rectifier Cl - channel, 
which is sensitive to changes in cell volume and extracellular pH 196 and it generates a current 
(I
C l,ir
) which is similar to I
f
 and CLCN-2 has also been shown to be involved in pacemaking 196, 
197 but the exact role of this is not fully understood. CLCN-3 is thought to be responsible for 
the I
C l,v ol 
196 current which is a volume sensitive current and is thought to have some 
pacemaking activity as well. TTYH-1 potentially encodes a Ca2+-independent volume-
sensitive Cl- channel and TTYH-3 may encode a Ca2+ -activated Maxi-Cl- channel198. 
Of all four Cl - channels onlyCLCN-2 was significantly different with a reduction in 
expression, focussed in the mid-level (p=0.031; Figure 20). There was no clear pattern that 
emerged in terms of expression for the other Cl -  channels (p=ns for all).  
The three isoforms of the Na+ -K+ pump: 1 (ATP1a1), 2 (ATP1a2) and 3 (ATP1a3) had 
significantly reduced expression levels in the STZ group vs. control group with each isoform 
reduced in expression in the mid-layer but 2 and 3 also had reduced expression in the 
endocardial layer (Figure 20). 
Connexin43 (Cx43; GJA1) is the major connexin/gap junction isoform in the heart and is 
responsible for electrical coupling between myocytes. Expression of Cx43 was significantly 
reduced in the STZ group with this change primarily in the mid-myocardial layer (p<0.01; 
Figure 20) 
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Figure 20: Expression of mRNA for Cl -  channels, Na+ -K+  ATPases and Cx43 in the left 
ventricle of the control and STZ groups for each section of the myocardium. C=control 
STZ=streptozocin, Endo=endocardium, Mid=mid-myocardium and Epi=epicardium displayed 
in arbitrary units referenced to expression of 18-s (housekeeper gene). Means ± SEM shown 
(n=8/group). *Significantly different from the control group (p<0.05). **Significantly 
different from the control group (p<0.01). 
 
4.2.5. Cardiac energy production 
As the heart is a major area of energy consumption and diabetes significantly alters energy 
production, GLUT-4, the major cardiac glucose transporter and two major mitochondrial 
ATPases, 6 and 8 were selected for analysis. Expression of the primary cardiac glucose 
transporter GLUT-4 was significantly reduced in the STZ group across all 3 layers of the 
myocardium but maximally in the endo- and mid-myocardium (p<0.01; Figure 21). No 
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significant difference in expression or pattern change was noted for the mitochondrial 
encoded ATPases 6 and 8. 
 
 
Figure 21: Cardiac energy production gene expression in the left ventricle of the control and 
STZ groups for each section of the myocardium. C=control STZ=streptozocin, 
Endo=endocardium, Mid=mid-myocardium and Epi=epicardium displayed in arbitrary units 
referenced to expression of 18-s (housekeeper gene). Means ± SEM shown (n=8/group). 
*Significantly different from the control group (p<0.05). **Significantly different from the 
control group (p<0.01). 
 
4.2.6. Neuronal genes 
The final area of analysis in this study was expression of genes that relate to neuronal 
function given the evidence we have seen of a diabetes related cardiac autonomic 
neuropathy and analysis was undertaken of nerve growth factor (NGF1), the pain receptor 
(TACR1), tyrosine hydroxylase (TH), key in production of neurotransmitters and UCHL1 
which is important in the prevention of neurodegeneration199. 
For unclear reasons, we were unable to measure TH expression in both groups and the most 
likely explanation for this is probably related to experimental error at some point, given that 
the same cards were used successfully in identical animals/settings in our HFD vs. control 
group. Expression of NGF1, TACR1 and UCHL1 were not significantly different between 
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groups but there did appear to be a trend towards higher UCHL1 in the STZ group (Figure 
22). 
 
 
Figure 22: Cardiac neuronal gene expression in the left ventricle of the control and STZ 
groups for each section of the myocardium. C=control STZ=streptozocin, 
Endo=endocardium, Mid=mid-myocardium and Epi=epicardium displayed in arbitrary units 
referenced to expression of 18-s (housekeeper gene). Means ± SEM shown (n=8/group).  
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4.3. Discussion 
 
4.3.1. STZ Rat: Whole animal data 
Similar to many other STZ experiments on rats, we observed severe hyperglycaemia in our 
experimental group and failure to thrive compared to the control, with significantly reduced 
weight gain at 8 weeks200. Ideally in this study we would have had a weight matched control 
for the STZ rat in addition to our other control, as there is the possibility that the low 
weight and failure to thrive have affected mRNA expression. Whilst this is an issue, lower 
weight is a trend commonly seen in human studies, where children with type 1 diabetes 
have been observed to have a lower BMI at diagnosis on average compared to matched 
controls at diagnosis201.  
Whilst the STZ model has been extensively used in research on diabetes and the 
heart, there are important limitations to its use, firstly STZ as used in our experimental 
protocol induces diabetes at a rate that is not similar to the long process observed in human 
and so global changes over and above pancreatic β cell destruction may not be initially 
observed. STZ, is very effective at destroying pancreatic β cells leading to hypoinsulinaemia 
and hyperglycaemia but it does this without the global autoimmune effects of type 1 
diabetes in the human202. This does mean that there is the possibility that we may not have 
seen all the changes possible from type 1 diabetes in this study as a result of this lack of 
autoimmunity.  
 
4.3.2. STZ: Arrhythmogenesis 
Before analysis of the changes we observed in our STZ model, it is useful to look at the 
modelled ventricular AP in the original STZ paper by Pandit et al.140 to then explain how the 
changes we saw may be pro-arrhythmic or affect contractility. 
In this study the team modelled an elongation of phase 2 and 3 of the AP. This had 
also been experimentally confirmed in previous work203. As already discussed this can lead 
to re-entrant circuits and arrhythmias.  
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4.3.2.1. Na
v
1.5 down-regulation in type 1 diabetes 
In our experiment we were able to see a marked reduction in Na
v
1.5 in the STZ group with 
the change being localised to the mid-myocardial wall layer of our STZ rats and has 
previously been reported in the diabetic ventricle in animal models204. SCN5A, encodes the 
main alpha subunit of the cardiac sodium channel protein Na
v
1.5 which forms the I
Na 
current 
which is the predominant cardiac sodium channel in humans. These channels (99% of them) 
open briefly for less than 1ms in phase 0 of the action potential resulting in rapid 
depolarization19 and have rapid deactivation and inactivation kinetics.  The I
Na 
current and 
the Na
v
1.5 protein that creates the channel producing the current is voltage inactivated. 
While predominantly open during phase 0, a tiny number of channels may reopen 
during the plateau phase creating a later transient inward current, I
Ti
. 
Lots of work has previously been done on the effect of a reduction in Na
v
1.5/I
Na
 in the heart 
and its effect of arrhythmogenesis and a short list of conditions where Na
v
1.5/I
Na
 is reduced 
include Brugada syndrome linked to ventricular fibrillation and sudden death, conduction 
disorders such as AV block205, sick sinus syndrome with bradycardia206 and atrial standstill207 
Similarly to what has been shown in the Pandit experiment140, a reduction in I
Na 
can 
experimentally be induced using class 1c anti-arrhythmic agents such as sotalol and 
flecainide with marked prolongation of the ventricular myocyte AP208. 
From a purely ventricular perspective reduced I
Na 
leads to reduced conduction 
velocities across the ventricle204 and alterations in the transmural electrical gradient 
affecting repolarization. Firstly, as slowed conduction, a wave front leaving one zone of 
slowed conduction and travelling faster through normal areas of the heart may have enough 
time to reach back to the area of slowed conduction that gave rise to the original wave front 
and if it is not fully refractory, re-excite this area forming a stable circuit. This method of 
ventricular arrhythmia generation has previously been confirmed in SCN5A-/-mice209. 
Further evidence for reduced SCN5A/Na
v
1.5 and abnormal repolarization comes 
from the Brugada syndrome which is one of the most widely studied SCN5A/Na
v
1.5 
disorders. In the Brugada syndrome, there is loss of the ‘dome’ encompassing phase 2 of the 
AP, due to Na
v
1.5 down-regulation/loss of function with accentuation of I
to
 which creates a 
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transmural gradient in repolarization and increased dispersion in the epicardium which can 
then allow phase re-entry and with the right trigger VT/VF210.  
Both mechanisms described above due to reduced I
Na 
are powerfully pro-arrhythmic 
and potentially could explain the higher incidence of ventricular arrhythmias in patients 
with type 1 diabetes. Further support for a role of Na
v
1.5 in arrhythmogenesis in diabetes 
comes indirectly as cardiac PI3k is reduced in diabetes211 and reduction of PI3k signalling 
reduces I
Na
 and this causes AP and QT prolongation212. 
 
4.3.2.2. K
v
1.4 up-regulation in type 1 diabetes 
K
v
1.4 is thought to be responsible for the I
to-s
 current within the human endocardial layer 
and to represent the slower I
to-s 
current, which is active during phase 1 of the AP and creates 
a transient outward K+  current activated by rapid depolarization in phase 0 creating a flow 
of K+  out, reducing the membrane potential and determining the level of the plateau phase. 
This channel also affects the activity of I
C a-L
 and I
K,r 
which is important in the regulation of the 
overall APD213. 
K
v
1.4 and the slower I
to-s 
current are preferentially expressed in the mid and 
epicardial layers of the ventricle and help to regulate the duration of the AP to allow for the 
correct duration of transmural depolarization and repolarization, with differing AP duration 
as discussed in the introduction. In our experiment we saw an increase in all three layers of 
the ventricle wall of K
v
1.4, a factor which is common in left ventricular hypertrophy and 
leads to prolongation of the AP, a consistently pathological change in many ventricular 
arrhythmias214. Also, as discussed when we reviewed down regulation of I
Na
, there is a 
compensatory increase in I
to  
increasing transmural dispersion and allowing for re-entrant 
circuits and arrhythmia formation. In part this may be due to the fact that in diabetes, there 
is a switch from I
to-F 
to I
to-S
, encoded by K
v
1.4 with a prolongation of the AP due to the slower 
inactivation recovery of K
v
1.4215.
 
 
Our results are supported by other experimental work confirming an increase in 
K
v
1.4 expression in diabetes animal models, both type 1 and type 2 173, 216. 
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4.3.2.3. KChiP2 down-regulation in type 1 diabetes 
KChIP2 is an important regulatory subunit helping predominantly to stabilise and regulate 
expression of K
v
4.2, the I
to-F
 current217 without particularly having any effect on the AP on its 
own218. While we did not observe a significant reduction in the I
to-F 
genes in our STZ animals 
we did see a large increase in the expression of in K
v
1.4 which encodes for the I
to-S 
current 
and this has been previously reported in response to reduced KChIP2 217. The switch in I
to 
phenotype is arrhythmogenic as discussed above although conversely in a heart failure 
knockout mice model without KChiP2, arrhythmia susceptibility was markedly reduced 219. 
Overall, a reduction in KChip2 would be consistent with the increase observed in K
v
1.4, 
though a specific role in arrhythmia prevention or generation is difficult to prove 
definitively with the available data. 
 
4.3.2.4. ERG down-regulation in type 1 diabetes 
In our diabetes group we saw a reduction in the expression of ERG, which encodes for the I
K,r 
current which in the rat has very little effect on the AP but in humans is the key outward 
delayed rectifying potassium current and vital in prevention of ventricular arrhythmias.  
Reduced ERG function and prolongation of the AP and thus the QT on the surface 
electrocardiogram has been seen previously and can be caused by ROS damage, insulin 
deficiency and hypoglycaemia130, 220. The risk of sudden arrhythmogenic death in patients 
with type 1 diabetes is thought primarily to centre on dysfunction of the ERG and the I
K,r 
current from lots of potential mechanisms, three of which are mentioned above. We know 
that the mid-myocardial layer of three ventricular wall layers has the longest AP duration 
and that a specific reduction here in I
K,r 
will lead to an increase in transmural dispersion of 
repolarization (TDR)221 through an increase in the gradient between the endocardium and 
mid-myocardium. When the TDR is increased previous experimental work has shown that 
this leads to EADs in late phase 2 and re-entry mediated polymorphic VT222. 
Whilst, not potentially clinically important in the rat model, the data derived from 
this are strongly suggestive of an arrhythmogenic phenotype in diabetes and particularly 
based on the location of change in the mid-layer. 
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4.3.2.5. K
v
LQT1 down-regulation in type 1 diabetes 
K
v
LQT1 is the channel responsible for the I
K,s
 delayed rectifying K+  current in the ventricle of 
humans and is not modelled in the Pandit et al. system160. This current is a voltage gated 
slowly inactivating and deactivating current that seems to only be expressed in very small 
amounts in the mid-myocardium helping to prolong the AP at this level 223 but at the expense 
of an increase in TDR. The other important physiological element specific to this c urrent is 
that compared to other rectifying currents, it is the only one that is up-regulated by 
increased sympathetic activity224 and increased at higher heart rates. The combination of I
K,s
 
I
K,r 
and I
K,1 
form the majority of the repolarization reserve in the human ventricle and act in a 
synergistic manner. 
Clinically and electrophysiologically, I
K,s 
when reduced or dysfunctional is associated 
with long QT syndrome, 1 which is associated with ventricular arrhythmias and sudden 
death, commonly on exercise or with emotional stress. Previous experimental work has 
shown that current activity is increased at higher heart rates or with sympathetic drive 225 
which would be in keeping with the clinical features described above. In animal studies I
K,s 
seems to have a role as a compensatory mechanism when ERG/ I
K,r
 is reduced to prevent 
ventricular arrhythmias225. The reduction we have observed of both I
K,s
/ I
K,r 
in combination 
would based on animal work and clinical Long QT syndromes to be proarrhythmic.
  
The specific reduction we have seen in the mid-myocardium, an area where 
expression is already low, may be of extra significance due to the increase in AP duration it 
will cause and the increase in TDR, which has been shown to lead to EADs and re-entry226.  
 
4.3.2.6. K
ir
3.1 down-regulation in type 1 diabetes 
K
ir
3.1 and the respective current I
K,AC h 
is an acetylcholine activated rectifying atrial channel 
predominantly227 with very little described ventricular expression. What has been shown 
before in the human is that activation of this channel in the ventricle shortens the APD 228 
though whether this is clinically significant given the small levels of ventricular expression 
is unclear.  
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4.3.2.7. HCN2 down-regulation in type 1 diabetes 
HCN2 is one the isoforms that contributes to the generation of the I
f  
current which forms a 
pacemaking current in the heart and brain. HCN2 in cardiac tissue predominantly is found 
in the contractile tissue and not in the conduction tissue surprisingly, where the major HCN 
isoform is HCN4. Previous experimental studies have suggested that while HCN4 is 
primarily responsible for the pacemaker current in the human, HCN2 may form part of a 
heteromeric channel with HCN4 that is important for normal functioning of the sinus node 
and conduction through the contractile tissue 229. Despite this primarily sinus node activity 
and evidence of a more predominant neuronal function, a reduction in ventricular HCN2 in 
rat models was associated with a prolongation of the QT and reduced heart rate 
variability230. 
4.3.2.8. SERCA2A down-regulation in type 1 diabetes 
SERCA2A is the predominant Ca2+  transporter from the cytosol to the lumen of the SR, after 
ECC thus replenishing the luminal stores for RYR2 to release and allow the next round of 
ECC. Previous studies have shown a clear reduction in SERC2A expression in the STZ rat 
model231 and in many other animal models of the diabetic cardiomyopathy 232 and we have 
found similar expressional change. While the major importance of SERCA2A will be assessed 
in the section on contractile function, reductions in SERCA2A are well reported in heart 
failure233 and this appears to lead to an increase in cytosolic leakage of Ca2+234. This excess 
leakage of Ca2+ leads to increased exchange via NCX1 which creates a late inward current, I
TI
, 
and can allow reactivation of the late Na+  current and this in turn leads to delayed Ca2+ 
sparks, and DADs235. These changes also lead to AP prolongation. 
While there is primary physiological data on the role of SERCA2A and 
arrhythmogenesis, interesting information on the role of SERCA2A and arrhythmias comes 
from gene transfer studies, where transfer of SERCA2A in a post infarct model has reduced 
Ca2+  leak and the incidence of ventricular arrhythmias236. Two other anti-arrhythmic 
functions have been shown to be related to replacement of SERCA2A, firstly, a reduction in 
Ca2+  level flux, which causes electrical alternans and is markedly pro-arrhythmic and 
secondly, by abbreviating the APD, through inactivation of I
C a-L
235.     
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The reduction we have seen in SERCA2A expression, would appear to be 
arrhythmogenic based on other work and in the Pandit et al. STZ experiment140, modelled SR 
Ca2+  loss led to AP prolongation. 
 
4.3.2.9. Cx43 down-regulation in type 1 diabetes 
Cx43, is the primary gap junction isoform present in the ventricle of humans and rats and 
so was analysed based on the fact the other gap junction isoforms are mainly atrially 
expressed or present in conduction tissue. The cardiac gap junction is located at the 
intercalated disk region of myocytes and is formed by two channels, made of hexamers of 
connexins connecting the cytoplasm of two myocytes to each other237. The role of gap 
junctions is important as signal conduction through the myocardium, depends of electrical 
coupling of cells mediated by gap junctions.  
In studies with a similar level of Cx43 reduction to that which we have observed, 
close to 20% of control levels in the mid-myocardial layer, conduction velocity is 50% of 
normal, suggesting a large reserve in the heart with a significant reduction in Cx43 levels 
being required to affect conduction velocities238. This level of Cx43 reduction has been 
shown to cause anisotropic reduction in conduction velocities and the creation of stable re-
entrant ventricular arrhythmias238.  The heterogenic reduction in Cx43, may also be 
significant as conduction heterogeneity is a significant risk for arrhythmia generation and 
anything that exacerbates this is likely to prove pro-arrhythmic.  
The second postulated mechanism by which a reduction in Cx43 may prove 
arrhythmogenic is that in areas of reduced Cx43 there seems to be reduced expression of 
Na
v
1.5 which is what we observed in the mid-myocardial layer of our STZ rats239. As shown 
above reductions in Na
v
1.5 are significantly arrhythmogenic on their own but the 
combination leads to marked conduction slowing, a reduced I
Na 
current and increased 
activation dispersal and an increase in VT 239. 
 
4.3.2.10. CLCN2 down-regulation in type 1 diabetes 
As mentioned earlier, CLCN2, generates a current (I
C l,ir
) similar to I
f
 and CLCN-2 has been 
shown to be contribute to cardiac pacemaking196, 197. Very little is currently known about the 
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role from an electrophysiological point of view about CLCN2 in the ventricle and no 
background literature was available to reference the reduction in ventricular CLCN2 
observed here. What is reported in the literature is that it may contribute to pacemaker 
activity as it becomes activated by hyperpolarisation and acts potentially as an inwardly 
rectifying current240, 241. What is expected from the basic physiology of the channel is that as 
it is mainly activated at more negative membrane potentials, the prolongation of the AP we 
would expect especially at phase 2/3 should lead to reduced Cl - efflux241 but this requires 
further confirmatory work. There has been no previous work reporting reduced CLCN2 in 
diabetes. 
 
4.3.2.11. Na+-K+ ATPase down-regulation in type 1 diabetes 
In this experiment, a reduction in Na+ -K+ ATPase isoforms, α1-3 was observed in the STZ 
group predominantly in the mid-myocardium but also for the α2 and α3 isoforms in the 
endocardium and reductions in Na+ -K+ ATPase isoforms has previously been experimentally 
reported in diabetes242.  
The function of the Na+ -K+ ATPases, is to actively transport Na+  out in exchange for K+  
and help repolarise the cell to resting membrane potential and allow restitution of the 
electrochemical gradients, for the next depolarization. From an arrhythmia perspective, 
there are two observed actions to review, firstly reduced Na+-K+ ATPase activity leads to 
increased intra-cellular Na+  activity which leads to reduced forward NCX1 exchange of Ca2+ 
and increased SR levels of Ca2+. This is the mechanism by which cardiac glycosides are 
positively inotropic243 but is also the mechanism by which digoxin toxicity leads to 
polymorphic VT. In contrast, contrary to earlier work, inhibition of Na+ -K+ ATPase isoforms 
appeared to shorten the AP in a biphasic approach by favouring reverse mode NCX1 activity 
and Ca2+  inflow and generation of an outward current- 3 Na+  for 1 Ca2+ 244, 245.  
Overall, the exact arrhythmogenic balance struck by reduced Na+-K+ ATPase is difficult to be 
certain of and is largely going to depend on the model used or clinical situation and how 
this may interact with our observed changes in SERCA2A and Na
v
1.5. 
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4.3.3. Contractility in type 1 diabetes 
As discussed in detail in the introduction, diabetes leads to significant impairment of 
contractile function of the ventricle and in animal STZ models this can be apparent after 
only two weeks246. 
Based on the gene expression changes we have seen, there are several potential explanations 
and these are reviewed now. 
Firstly, a reduction in Na
v
1.5 and the I
Na 
current, slows conduction through the ventricle and 
this results in an increase in QRS width on the ECG and an increase in markers of 
dyssynchrony with an accompanied reduction in contractile function247. Secondly, the I
Na
 
current whilst not directly linked to ECC, does have important effects on Ca2+  entry in the 
myocyte which are enough to induce contractile dysfunction. With reduced I
Na
 current 
amplitude, there is a knock on effect with reduced opening of the L-type Ca2+  channel and 
reduced plateau phase Ca2+ release 248. The other effect is via reduced reverse mode NCX1, 
which has an important role in priming the dyadic cleft with Ca 2+  to produce Ca2+ induced 
Ca2+  release and ECC249, 250. Clinically this syndrome is reproducible with flecainide which 
inhibits Na
v
1.5 and the I
Na 
current and produces a negative inotropic effect251. 
CX43 down regulation has predominantly been thought of as an issue primarily of 
conduction and arrhythmogenic significance but it is possible that through local variation in 
gap junction expression wavefront speed and homogeneity may be altered leading to 
dyssynchrony and reduced contractile function252. There has been some corroborative 
evidence for this theory using pacing induced heart failure, where the dyssynchronous 
pacing arm had much lower levels of Cx43 compared to the non-dyssynchronous arm with 
heart failure. 
The second major gene change which is likely to impact on cardiac contractility is 
the observed reduction SERCA2A which has been reported in many models of heart failure 
235. 
Reduced SERCA2A leads to accumulation of Ca2+ in the cytosol with prolonged 
relaxation times and reduced SR- Ca2+  levels and release for Ca2+  induced Ca2+ release which 
all lead to reduced contractile function. 
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In the STZ experiment here, similar to many other heart failure and contractility 
experiments there was an observed reduction in Na+ -K+ ATPases. As discussed in the 
arrhythmia section, this would be expected to result in potentially increased contractility via 
increased SR levels of Ca2+.  As modelled by Pandit140 and as we would expect based on our 
gene expression changes, there is prolongation of the AP and other work has shown that 
this is inotropic through increased Ca2+  accumulation253. 
From a clinical perspective, the last two changes described may be adaptive changes 
to increase contractile force in the setting of a diabetic cardiomyopathy. The majority of 
clinical data suggests that the predominant phenotype is reduced contractility254 and 
certainly we have observed several changes which would contribute to this. 
 
4.3.4. Cardiac energy production 
In this study we observed a significant reduction in the expression of GLUT-4, the major 
cardiac glucose transporter. GLUT-4 in its inactive state is found mainly in intracellular 
compartments and is translocated via Insulin mediated pathways and in response to 
contraction to the sarcolemma and to the T-tubules where glucose diffuses across a 
gradient255. 
Previously, in STZ models, expression of cardiac GLUT-4 has been shown to be 
reduced256 as it has been in type 2 diabetes models165 and in the human ventricle257. From the 
introduction section we know that glucose is a much more efficient energy source than fatty 
acids and any reduction in glucose transport to the sarcolemma is likely to impact energy 
production and in due course reduce cardiac contractile efficiency. GLUT-4 is known to be 
up-regulated in response to ischaemia in non-diabetics to increase glycolysis and in diabetes 
which is associated with a higher rate of coronary artery disease the observed reduction in 
GLUT-4 we and others have seen may lead to increased damage during ischaemia 258. 
 
4.3.5. Neuronal function 
While a peripheral and autonomic neuropathy is extensively reported in the STZ rat model 259 
and a cardiac neuropathy less so260, no significant differences in the neuronal genes tested 
was observed in this study. On review of the literature only one study directly measured 
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cardiac mRNA expression of a neuronal gene in diabetes, in this case calcitonin gene related 
peptide and general neuronal protein gene product 9.5 , with only one of these altered in 
their study261. One study did report a reduction in NGF1 expression in the ventricle of mice 
with cancer262 and while not significant, there appeared to be a trend towards reduced NGF1 
in our STZ animals.  
The expected reduction in neuronal gene expression that was not observed may be down to 
methodological flaws within the study potentially including: incorrect experimental 
technique, wrong rat model261, insufficiently long study duration and weight loss affecting 
neuronal gene expression 
Overall, this would certainly seem an area that requires further investigation based 
on the significant peripheral and central neuronal dysfunction seen in type 1 diabetes. 
 
4.3.6. Overall genotype 
Overall, our experiment similar to others suggest a genotypic change that would most likely 
result in a prolongation of the action potential and reduced contractility, primarily as a 
result of reductions in SERCA2A, Na
v
1.5, K
v
1.4, CX43, GLUT-4 and K
v
LQT1 expression. A 
possible compensatory reduction in Na+ -K+ ATPase expression which may have some 
positive effect of contractility and arrhythmogenesis. 
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5. HFD rat: obesity model 
 
5.1.  Animal characteristics 
Through the study HFD-fed rats consumed more energy (28.11.0x103 vs 23.70.9x103 kJ; 
+18%, p<0.01 vs controls) and increased their weight more than the control animals (+32%; 
p<0.01).  This led to an increase in levels of adipose tissue in HFD rats. (+40%; p<0.01). Due 
to the high energy content of the HFD, a smaller intake was required to cause weight gain in 
this group compared to controls (-10%; p=0.0165). These results are similar to previously 
reported experimental work on the induction of obesity using a high fat diet in rats 263. Mean 
energy consumption with final weight gain and percentage adiposity are shown below for 
control and HFD animals as mean ±SEM in Table 9:  
 
Diet Energy Consumed (kJ/g) Body Weight Gain (g)    Adiposity (%) 
Control 102.82.9 232.912.4 1.0320.081 
HFD 92.22.6* 308.618.5**    1.4490.010** 
Table 9: Baseline and final rat characteristics showing means ± SEM shown (n=8/group). 
**Significantly different from the control group (p<0.05). **Significantly different from the 
control group (p<0.01). 
 
5.2. HFD rat RT-PCR results 
In an identical manner to the STZ experiment, we analysed a wide range of genes we thought 
may be implicated in obesity cardiomyopathy for many of the same reasons as outlined in 
the STZ section. 
 
5.2.1.  Major ion channels active during the action potential 
Expression of ion channels in the left ventricle of the HFD rats (n=8) was measured at the 
mRNA level using quantitative PCR and compared to that in the control lean rats (n=8). 
Expression of the principle Na+ channel, Na
v
1.5 (SCN5A), tended to be greater in the HFD 
group (but not significantly so; p=0.127; Figure 23). However, expression of the principle L-
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type Ca2+  channel, Ca
v
1.2 (CACNA1C) was significantly increased in the HFD group (p<0.01). 
Expression of K
v
1.4 (KCNA4) and K
v
1.5 (KCNA5) tended to be greater in the HFD group but 
not significantly and similarly expression of K
v
4.2 (KCND2) and K
v
4.3 (KCND3) and the 
auxiliary subunit KChIP2 (KCNIP2) were not significantly different in the two dietary groups 
(but expression of K
v
4.2 and K
v
4.3 tended to be greater in the HFD group). In the HFD group, 
there was significantly reduced (p=0.029) expression of ERG but expression of K
v
LQT1 
(KCNQ1) tended to be greater (but not significantly so; p=0.128). 
 
 
Figure 23: Expression of mRNA for major ion channels active during the action potential in 
the left ventricle of the control and HFD groups displayed in arbitrary units referenced to 
expression of 18-s (housekeeper gene). Means ± SEM shown (n=8/group). *Significantly 
different from the control group (p<0.05). **Significantly different from the control group 
(p<0.01). 
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5.2.2.  Major ion channels active during diastole 
Expression of the three major pacemaker channel isoforms, HCN1, HCN2 and HCN4 tended 
to be greater in the HFD group, but only the increase in HCN4 was significant (HCN1, 
p=0.18; HCN2, p=0.089; HCN4, p=0.03; Figure 24). In the HFD group, there was significantly 
increased expression of K
ir
2.1 (KCNJ2) (p=0.032). Expression of K
ir
3.1 (KCNJ3) and K
ir
3.4 
(KCNJ5) tended to be greater in the HFD group (but not significantly so; p=0.77 and 0.20 
respectively).  
 
 
Figure 24: Expression of mRNA for major ion channels active largely during diastole in the 
left ventricle of the control and HFD groups displayed in arbitrary units referenced to 
expression of 18-s (housekeeper gene). Means ± SEM shown (n=8/group). *Significantly 
different from the control group (p<0.05). 
 
5.2.3.  Intracellular Ca2+-handling transcripts 
As stated earlier, given the key role intracellular Ca2+ plays, NCX1, SERCA2A and RYR2 were 
analysed in the HFD experiment. Expression of all three was significantly increased in the 
HFD group (p<0.01, <0.01 and 0.04, respectively; Figure 25). 
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Figure 25: Expression of mRNA for major Ca2+ -handling molecules in the left ventricle of the 
control and HFD groups displayed in arbitrary units referenced to expression of 18-s 
(housekeeper gene). Means ± SEM shown (n=8/group). *Significantly different from the 
control group (p<0.05). **Significantly different from the control group (p<0.01). 
 
 
5.2.4.  Other electrophysiological channels and associated proteins/enzymes 
Expression of all four Cl- channels tended to be greater in the HFD group, but only CLCN-3 
had a significantly increased up-regulation (CLCN-2, p=0.238; CLCN-3, p=0.029; TTYH-1, 
p=0.155; TTYH-3, p=0.056; Figure 26). There was a significant difference in expression 
between dietary feeding groups in ATPase mRNA levels, for the α1 and α2 isoforms tended 
in the HFD group but not the α3 isoform (Na+-K+ pump α1, p<0.01; Na+-K+ pump α2, 
p<0.01; Na+-K+ pump α3, p=0.758). Expression of Cx43 tended to be greater in the HFD 
group (but not significantly so; p=0.121). 
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Figure 26: Expression of mRNA for Cl - channels,  subunits of the Na+ -K+ pump and the gap 
junction Cx43 in the left ventricle of the control and HFD groups displayed in arbitrary units 
referenced to expression of 18-s (housekeeper gene). Means ± SEM shown (n=8/group). 
*Significantly different from the control group (p<0.05). **Significantly different from the 
control group (p<0.01). 
 
5.2.5.  Cardiac energy production 
The heart is one of the most energy intense organs in the body consuming requiring a 
significant amount of energy production to meet the requirements, given the effects of 
obesity on metabolism, once again GLUT-4, MT-ATP6 and MT-ATP 8 expression were 
analysed. We can see that there was no significant change in expression in GLUT-4, but 
significantly increased levels of mRNA in the ventricle of MT-ATP 6 and 8 (p<0.01; Figure 27)  
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Figure 27: Expression of mRNA for important cardiac energy production genes in the left 
ventricle of the control and HFD groups displayed in arbitrary units referenced to 
expression of 18-s (housekeeper gene). Means ± SEM shown (n=8/group). **Significantly 
different from the control group (p<0.01). 
 
5.2.6.  Neuronal genes 
In the final section for analysis, genes related to neuronal function, an analysis was made of 
the same 4 genes as in the STZ experiment. In the HFD group, an up-regulation of TH, which 
codes for tyrosine hydroxylase was observed (p=0.023; Figure 28) but no significant change 
was noted for the other gene transcripts, UCHL1, NGF1, TACR1 between groups. 
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Figure 28: Expression of mRNA for cardiac neuronal genes in the left ventricle of the control 
and HFD groups displayed in arbitrary units referenced to expression of 18-s (housekeeper 
gene). Means ± SEM shown (n=8/group). *Significantly different from the control group 
(p<0.05). 
 
5.3.  Immunofluorescence  
Primarily this study has been mRNA based study and the use of this methodology is based 
on the experience of the department with the TAQMAN™ system and the reliability and 
translatability of mRNA results in terms of function/protein correlation151, 152, 264.  
As a result, we decided to look at comparative protein analysis try and assess the reliability 
of our mRNA results as a predominantly quality assessment tool of the experimental mRNA 
techniques. As already there exists other confirmatory work available for several gene 
transcripts using the TAQMAN™ system265, a decision was made to look at one of the less 
expected results from the RT-PCR study. HCN4 being primarily an atrial based pacemaker 
gene, was not expected to be significantly altered at the ventricular level between groups 
and we could not find any previous work looking at the correlation between RT -PCR and 
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immunofluorescence. To show that the RT-PCR expression change of HCN4 should lead to a 
change in protein expression of HCN4 at the ventricular level, quantitative IF was 
undertaken of HCN4. 
Quantitative immunofluorescent labelling of HCN4 in the rat tissue samples showed a more 
than 2-fold increase in HCN4 labelling (p<0.01; Figure 29) in the HFD group. 
 
 
 
103 
 
Figure 29: Expression of HCN4 protein in the left ventricle of the control and HFD groups. A 
and B, representative images of HCN4 immunolabelling (white signal) in the left ventricle of 
eight control (A) and eight HFD (B) animals. C, mean (+SEM) intensity of HCN4 
immunolabelling in the left ventricle of the control and HFD groups (n=8/group). 
**significantly different from the control group (p<0.01). 
 
5.4.  AP Modelling  
To simulate the effects of obesity, the channel conductance for each of the presumed 
remodelled ionic currents in the Pandit et al.160 models was scaled according to the 
measured average percentage change of the corresponding mRNA between the control and 
the obesity groups (Table 10): 
Channel Current HFD group change 
Na
v
1.5 I
Na
 +163.60% 
Ca
v
1.2 I
C a,L
 +441.28% 
K
v
1.4, K
v
 4.2 and K
v
 4.3 I
to
 +240.45% 
K
v
1.5 I
K,ss
 +232.73% 
HCN4 I
f
 +222% 
K
ir
2.1 I
K,1
 +233.83% 
NCX1 I
NaC a
 +290.10% 
SERCA2A SR Ca2+  uptake +139% 
RYR2 SR Ca2+  Release +253.97% 
ATP1α1-3 I
NaK
 251% 
Table 10: Simulated changes in current density based on the mRNA expression differences. 
 
Figure 30 shows simulated action potentials (top row) of rat endocardial (Figure 30A) and 
epicardial (Figure 30B) ventricular cells in control and obesity conditions, accompanied by 
underlying ionic currents and the intracellular Ca 2+  concentration. In both cell models, 
remodelled ion channels in the obesity condition produced increased amplitude of the 
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action potential, elevation in the plateau phase and an increase in the action potential 
duration (APD; Figure 30 A and B). Notably, there was a pronounced slow tail of 
repolarization following the action potential; slow tails of repolarization following the rat 
ventricular action potential have been reported in experiments266. The changes in the action 
potential are attributable to the integral actions of increased I
Na
 (reflecting the increase of 
Na
v
1.5), I
to
 (reflecting the increase of K
v
1.4, 4.2 and 4.3), I
C a,L
 (reflecting the increase of Ca
v
1.2), 
sustained outward K+  current I
K,ss 
(reflecting the increase of K
v
1.5), I
K,1
 (reflecting the increase 
of K
ir
2.1), Na+ -Ca2+ exchange current (I
NaC a
; reflecting the increase of NCX1), Na+ -K+ pump 
current (I
NaK
; reflecting the increase of the 1, 2 and 3 subunits of the Na+ -K+ pump) and I
f
 
(reflecting the increase of HCN4). In the HFD condition, simulation results also showed that 
the amplitude of the intracellular Ca2+  concentration was increased (Figure 30 A and B). 
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Figure 30: Simulated rat ventricular endocardial (A; ENDO) and epicardial (B; EPI) action 
potentials and underlying ionic currents and intracellular Ca2+  concentration in control and 
HFD conditions. 
 
Potential effects of each of the remodelled ion channels on the ventricular action potential 
were investigated. Results are shown in Figure 31. The potential increase in I
Na
 alone had 
negligible effects on APD, but increased the amplitude of the action potential (Figure 31A). 
The potential increase in I
C a,L
 alone produced a dramatic increase in the duration of the 
plateau phase, leading to a failure of repolarization; consequentially, the models failed to 
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produce a full action potential (Figure  31B). The potential increase in I
to
 alone abbreviated 
APD and reduced the AP amplitude (Figure 31C). Modelled up-regulation of the I
NaK
 current 
led to marked abbreviation of the action potential. The potential increase in I
K,ss
 (Figure 31E), 
I
K,1
 (Figure  31F) isolated on their own resulted in small APD abbreviations. Up-regulation of 
in I
NaC a
 (Figure 31G) resulted in a small delay in phase 3 repolarization more obviously at the 
endocardial level. Changes in I
f
 (Figure 31H), Ca2+  release via RYR2 (Figure 31I) or Ca2+  uptake 
via SERCA2A (Figure 31I) alone produced negligible effects on the action potential. 
Therefore, the simulations suggest that the obesity-induced changes in ion channels could 
result in a prolongation of action potential primarily as a result of an increase in I
C a,L
 the 
effects of which are offset to a degree by increased in I
K,ss,
 I
NaK
 and I
K,1
. 
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Figure 31: Simulated rat ventricular endocardial and epicardial action potentials in control 
and HFD conditions when each of the remodelled ion channels/ionic currents was modified 
one at a time. A, only I
C a,L
 considered. B, only I
Na
 considered. C, only I
to
 considered. D, only I
NaK
 
considered. E, only I
ss
 considered. F, only I
K,1
 considered. G, only I
NaC a
 considered. H, only I
f
 
considered. I, only SR Ca2+  uptake and release considered (J -Up and J-Rel. respectively). 
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5.5. Discussion 
 
5.5.1. HFD rat: Whole animal data 
In our HFD group we were able to show clear weight gain and increased adiposity compared 
to the control group and using a simple dietary feeding method to induce obesity. Similarly, 
to our other animal experiment with the STZ rat, this type of homogenous feeding model is 
unable to fully reflect the heterogeneous methods by which humans become obese such as 
excessive fat and carbohydrate intake and reduced physical activity and as a result our data 
has to be interpreted with a degree of caution if attempting to translate directly to humans. 
Despite this experimental limitation, we did achieve our desired experimental model i.e. 
obese rats and we can say that our results reflect changes secondary to high fat intake 
induced obesity.  
 
5.5.2. Arrhythmogenesis 
As with our STZ experiment, reviewed below are the major mRNA changes and the AP 
modelling results and a discussion of how these relate to an arrhythmogenic phenotype in 
the obese rat. 
 
5.5.2.1. Ca
v
1.2 up-regulation in obesity 
 
The first major area of discussion from our results, was the increase in gene expression of 
the key Ca2+  channel, Ca
v
1.2 with a large modelled increase in current density   
with the effect of prolonging the AP through increased Ca2+ entry. This experimental finding 
is of importance as previously, clinical work has found a strong link between obesity and QT 
duration267. 
I
C a-L  
normally begins to activate at voltages more positive than -40mV and peaking in 
terms of activation at 0-10mV with an increase in activation speed at more positive voltages 
and is both voltage and Ca2+  inactivated268. An increase in the I
C a-L 
current leads to a 
prolongation of the APD mainly by extension of the plateau phase of the AP and this can 
create a window where there is a reduction in voltage inactivation and Ca2+  inactivation of I
C a-
L
. Reduction of I
C a-L 
inactivation allows some inactivated Ca
v
1.2 channels to re-open, which 
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can then generate a further inward Ca2+  current and upstroke in the AP creating EADs which 
can generate ectopic beats and arrhythmias269. As might be expected given an increase in 
Ca
v
1.2 channels and as we have seen from our modelling, this results in a much larger and 
prolonged Ca2+  current in our HFD group. Previous experimental work suggests a link to 
direct and indirect promotion of EADs and DADs, which can generate ectopic beats and 
arrhythmias269, 270 via increases in the Ca2+  current. Supporting evidence for the role of 
increased I
C a-L 
in arrhythmogenesis comes from the rare Timothy syndrome where a mutation 
in CACNA1C leads to gain of function in the Ca
v
1.2 channel, then subsequently to increased 
and prolonged calcium entry, a prolonged QT and a high incidence of ventricular 
arrhythmias271. As well as Timothy syndrome, patients with myotonic dystrophy where there 
is, similar to obesity, often signs of LVH, have been found to have an up-regulation in Ca
v
1.2 
again with an increase in arrhythmias272. 
Rat experimental work on I
C a-L 
current by other groups has revealed a reduction in I
C a-L 
inactivation and that this leads to QT prolongation though in their study this was not 
related to an increase in I
C a-L 
expression273, though while the prolongation of the QT in obesity 
between research groups seems ubiquitous not all have demonstrated changes in the I
C a-L 
current274, though it is possible some of this relates to variation in feeding models/animals 
used.  
  
5.5.2.2. NCX1 up-regulation in obesity  
In our HFD group, we observed an increase in NCX1 gene expression, which when modelled, 
suggests a large increase in the I
Na/C a 
current density leading to a small delay in late 
repolarization, generating a late transient inward current (I
Ti
) in phase 3 of the AP.  
In normal conditions, at -30mV and below NCX1 works in its forward mode (1 Ca2+  ion 
exchanged for every 3 Na+  ions) and above this in the reverse mode (small amounts of Ca 2+  
in). In situations of increased Ca2+, such as the increase in Ca
v
1.2  and Ca2+   transient we have 
seen, NCX1’s forward mode activity can be increased by up to 67% with generation of an 
inward current that prolongs the AP275 and may add to a small degree the AP prolongation 
we have seen in conjunction with I
C a-L .
 The other main current generated by NCX1 is the late 
I
TI
 current which despite the fall in Ca2+  levels during phase 3 of the AP, occurs when the 
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change in membrane potential outstrips the sodium-calcium exchange reverse potential 
forcing NCX 1 back into a forward mode276. The I
Ti
 current generated is bigger when the rate 
of membrane change is larger276 and in our modelled APs we can see a particularly sharp 
membrane potential drop followed by a later repolarization in the HFD group and when 
large enough this inward current can generate a delayed after depolarization (DAD) and can 
also cause Ca2+ mediated DAD via SR Ca2+ release in the Ca2+  overloaded state277. NCX1 when 
up-regulated has been shown to lead to an increase in Ca 2+   transient amplitude (as we have 
seen in our modelling) and an increase in SR Ca2+  levels all of which are likely to cause an 
overload of SR Ca2+ with oscillatory levels of Ca2+ and abnormal Ca2+ release generating 
DADs278. An arrhythmogenic role for NCX1 in obesity would be supported from work in 
other pathological states such as hypertrophy and heart failure which both demonstrate 
increased NCX1 levels279, 280. 
 
5.5.2.3. SERCA2A/RYR2 up-regulation in obesity and SR Ca2+ release
 
Similar to other groups looking at obesity281, we have seen an increase in SERCA2A and RYR2 
mRNA and increased SERCA2A expression has previously been explained as a response to 
oxidative damage in the SR caused by excess free radical generation in obesity 282. Several 
studies have suggested that increased SERCA2A activity leading to Ca2+  overload in the SR, 
can generate abnormal Ca2+  release and DADs leading to arrhythmias283, 284, although other 
work has shown increased SERCA2A to be anti-arrhythmogenic285. Despite the increase in 
mRNA content, an assumption that this leads to increased functional SERCA2A as other 
work has shown that in obesity SERCA2A activity was reduced through oxidative injury119, 
but this study revealed a prolonged Ca2+ transient within the rat ventricle as our modelling 
data suggests. In addition to the increase in SERCA2A mRNA in our HFD group, we saw an 
increase in RYR2 expression and as the main channel, for SR Ca 2+  release this would help 
explain the large modelled increase in SR calcium release we propose in conjunction with I
C a-
L
. Excess Ca2+   leak from RYR2 when the receptor is defective is a well described mechanism 
of I
Ti
 generation and then DADS, classically seen in catecholamingeric polymorphic 
ventricular tachycardia286. From other studies287, it is known that excess SR Ca2+   leads to an 
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increase in SR Ca2+  release via RYR2 and this again may contribute to the generation of the 
I
TI
. 
While the mRNA changes we have seen and the modelled AP is more 
arrhythmogenic, how much of the increase in NCX1/SERCA2A/RYR2 expression is 
pathological is still uncertain in obesity. Certainly NCX1 up-regulation is a normal response 
at higher heart rates in normal physiology288, a common finding in obese individuals. Also in 
the early stages of LV hypertrophy, SERCA2A has previously been shown to be up-
regulated289 and NCX1 similarly290, and so before the development of overt heart failure these 
may represent adaptive changes to maintain contractile function though at the cost of an 
arrhythmogenic phenotype and this is discussed in more detail in the section on 
contractility.  
 
5.5.2.4. K
ir
 2.1 up-regulation in obesity  
We have seen increased gene expression of KCNJ2 (K
ir
 2.1), which as stated before is 
responsible for part of the I
K,1 
current,
 
which repolarises the myocyte late in the action 
potential and helps maintains the resting membrane potential, allowing Na + channel 
recovery. Up-regulation of this would seem desirable for an arrhythmogenic perspective, as 
experimentally, over-expression of the I
K,1 
current results in acceleration of the final phase of 
repolarization and a shorter APD291. Despite, the theoretical advantage of increased I
K,1
, the 
physiological effect has been associated with familial short QT syndrome 292, familial atrial 
fibrillation293 and stabilisation and maintenance of re-entry arrhythmias leading to 
ventricular tachycardia294. Another mechanism by which up-regulated KCNJ2 has been seen 
in other studies to be arrhythmogenic is where an increase in the I
K,1 
current causes an 
increase in transmural dispersion of repolarization295 and this allows the formation of re-
entry arrhythmias296.   
Whilst many effects of increased I
K,1 
may be pro-arrhythmic two mechanisms may be 
compensatory, firstly, the AP prolongation caused by increased calcium transit may be 
opposed by increased I
K,1 
which will act to increase the K+  outward current accelerating phase 
3 repolarization and attempting to abbreviate the AP prolongation. Secondly, as I
K,1 
sets the 
membrane resting potential through the K+  outward current, it directly opposes any 
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pacemaker diastolic currents297 and in this case directly opposes the I
f  
increase we have seen 
to try and prevent ventricular ectopic activity.  
Experimentally, the simulated AP change we observed, appears relatively small 
despite the large increase in KCNJ2 and this is something previously observed by the group 
and by other groups with very large increases in I
K,1 
required to generate AP changes in 
simulation studies298. This may mean that some of the restorative effect of increased I
K,1 
on 
the modelled AP is lost and that in vivo the effect may be greater. 
 
5.5.2.5. ERG down-regulation in obesity  
In our HFD group, we observed a significant reduction in ERG gene expression, which is a 
rapid delayed potassium-rectifying channel that helps repolarise cells to their resting state 
and helps prevent prolongation of the APD, through the I
K,r 
current. As I
K,r
 does not play an 
important role in repolarization in the ventricle of the rat, its effect is difficult to discuss in 
this section, however it is a key channel in humans. Reduced expression or drug blockade of 
ERG is a well-known cause of human APD/QT prolongation and ventricular arrhythmias299.  
The arrhythmogenic risk of ERG blockade or reduction has shown to be reduced if 
there is a reduction of the inward calcium current300 and so the combination of reduced ERG 
and increased inward calcium may prove synergistically arrhythmogenic. 
 
5.5.2.6. Na+-K+ ATPase 1 and 2 up-regulation in obesity 
Na+ -K+ ATPases function to maintain a low intracellular Na+ and a high K+  and this is done in 
an ATP dependent manner, with 3 Na+  ions out for 2 K+  ions into the cell, this primarily helps 
to create a Na+  gradient for Ca2+  exchange by NCX1. This movement of current helps to 
generate a largely negative current and tends to hyperpolarise the cell 301. 
There have been many studies showing that a reduction in cardiac Na+-K+ ATPase is 
pathological and is found in other cardiomyopathies302. From an arrhythmogenic 
perspective, what we have modelled is an abbreviation of the action potential  and in other 
studies, increased Na+-K+ ATPase activity has limited Na+/Ca2+ overload reducing the rate of 
arrhythmias303.  
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It is important to note that this particular result in this study has not been 
reproduced in other work and Na+ -K+ ATPase was down-regulated in obesity304. 
 
5.5.2.7. Pacemaker currents up-regulation in obesity 
In our study, we found a significant up-regulation of HCN4 at the mRNA level and protein 
level in the ventricle of the obese rat. HCN4, forms the largest part of the I
f
 channel which is 
the major cardiac pacemaker current in the sinus node and knockout animals have been 
seen to suffer from severe bradycardias305.  To our knowledge this is the first time this has 
been demonstrated and represents a potential substrate for arrhythmias and ectopic activity 
in obesity. This would fit in with previously published results from rats with hypertrophy 
from pressure overload 306 and left ventricular hypertrophy; common problems in obese 
individuals307. In non-pathological states, there is low expression of HCN4 in the ventricle 
but after myocardial infarction ventricular up-regulation of HCN4 causes a high volume of 
ventricular ectopic beats and potentially prolonged ventricular arrhythmias22. 
Overexpression of HCN4, may represent a target for increased sympathetic drive 
within the heart308 and thus explain why there are higher resting heart rates and levels of 
ventricular ectopy seen in obese individuals. HCN4 protein levels have also been shown to 
be increased in the SAN in obese animal models and the total area of HCN4 tissue within the 
SAN increased264. The role of HCN4 in the ventricle compared to the SAN is likely to be much 
more pathological and represent an ectopic focus as opposed to organised pacemaker 
activity. Experimentally we were never able to show that the increase specifically in I
f  
on its 
own (even with the complete removal of I
K,1
) would be enough to generate diastolic 
depolarization though with all the other current changes combined there was a diastolic 
potential generated. This does cast doubt on a primary role for I
f
 in ectopic pacemaker 
activity though this may simply reflect that at a ventricular level I
f  
is only relevant in the 
context of other pathological changes as we have seen and in the other disease states listed 
above. 
We have been able to demonstrate an increase in CLCN3 gene expression in our HFD 
group and while the chloride channels are a group that is less well studied and also there is 
a lack of biophysical models to use, some information about the possible role of CLCN3 in 
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arrhythmias is available. CLCN3, codes for a volume activated large chloride channel, I
C l-vol
 
which has complex electrophysiological effects which are often different under stress 
conditions such as hypoxia and reperfusion309. There is some evidence that CLCN3 
contributes to the potassium independent I
to
 current310. In conditions of cell swell such as 
hypoxia, activation of CLCN3 leads to shortening of the APD and the refractory period 
causing a reduction in length of conduction needed to sustain a re -entry arrhythmia309, 311. 
Conversely, in heart failure, activation of CLCN3 has been shown to limit APD 
prolongation and reduce early after-depolarizations which are key methods of calcium 
overload activated arrhythmias312. One other potential area exists where up-regulation of 
CLCN3 may be pro-arrhythmic and that is in the SAN, where mechanical stretch has been 
shown to activate a chloride channel with similar characteristics to I
C l-vol 
and so this channel 
may in addition have a role in pacemaker activity196. We know also that other similar 
chloride channels have a potential role in pacemaker activity such as CLCN2 where 
knockout animals are bradycardic197. 
At this stage further functional studies would be required to look at the role of this 
channel in human obesity to look at its specific role and interaction with other channels. 
 
5.5.3. Contractility in obesity 
There are many studies showing that in obesity there is an increase in myocardial mass and 
left ventricular hypertrophy both concentric and eccentrically distributed 313 and that there is 
an increase in stroke volume and cardiac afterload314. To maintain output initially at least 
some compensatory mechanisms are required, such as increased circulating volumes, higher 
heart rates or increased contractility. 
In our discussion on arrhythmogenesis, we have predominantly seen an increase in 
and prolongation of Ca2+  entry with a subsequent prolongation of the action potential and 
an increase in expression of RYR2, the key channel for SR Ca 2+  release and excitation-
contraction coupling activation. 
In previous studies in humans mild to moderate obesity up to a BMI of 35kg/m2 
contractile function was noted to be increased by a variety of parameters315. It should be 
noted however that in animal models this change was not reproduced 316 and others have 
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shown a worsening of contractile function317. Much of this heterogeneity is related to leptin 
which is thought by many to cause suppression of myocardial contractility, though the exact 
mechanism is unclear. A key common area, in the wide variety of obesity models seems to 
be elevated intracellular Ca2+ , reduced extrusion and reduced sensitivity of the myocyte to 
Ca2+  318.  Increased levels of Ca2+ are key to the release of more troponin complexes from their 
resting state and the generation of more actin-myosin cross bridges and thus increased 
contractile force.  
Supportive evidence for the role of increased Ca 2+ as an early compensatory 
mechanism comes from studies in hypertensive rats, were an increase in Ca 2+  transient with 
APD prolongation has been associated with an increase in contractile function as an early 
response319. Our qPCR and modelling data suggest an increase in Ca 2+  levels, Ca2+  transient 
with reduced extrusion and this would fit in with these previously reported functional 
changes. Despite what we think may be an adaptive response, it is worth noting that despite 
the increase in Ca2 induced contractility, this response is smaller in obese animals than in 
lean animals318. In the study alluded to above, an early increase in systolic force has been 
shown in obesity315 at the expense of myocardial relaxation which leads to impaired filling 
times and excess energy consumption in the long run. 
Overall it would seem that at the expense of an arrhythmogenic phenotype, the 
changes in Ca2+  transient and APD may afford theoretically some increase in contractility, 
which may be important in obesity in maintenance of systolic function in the early phase. 
 
5.5.4. Cardiac energy production in obesity 
In our obesity experiment, we were able to show increased levels of mRNA for MT -ATP 6 and 
8 which, code for 2 of the 13 protein subunits which form complex V, ATP synthase 320. ATP 
synthase, uses the electrochemical energy created by the movement of H +  ions across 
mitochondrial membranes into the energy creating central matrix which then allows for 
oxidative phosphorylation of ADP. 
Most of our knowledge of the role of mitochondrial diseases comes from patients 
studied with infantile cardiomyopathies and mutations that causes loss of mitochondrial 
function320 and reduced cardiac energy production321 and translating these results to a more 
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general population is difficult. Looking at the impact of our results in our obese rats, we 
know that the heart is an organ with a high energy requirement and that in particular obese 
individuals myocardial 0
2
 (mV0
2
) consumption is significantly increased compared to normal 
controls322. While mV0
2
 consumption is higher in obesity, lots of this energy is wasted 
through mitochondrial un-coupling, generation of free radicals and just through supporting 
extra mass323. It would seem that up-regulation of MT-ATP 6 and 8 would appear to be 
appropriate responses in the face of increased myocardial 0
2
 demand and potentially one of 
the sources of increased free radical generation previously described as important in obesity 
generated cardiac dysfunction119. It is worth noting that these mitochondrial genes are not 
nuclear, so they do not wrap round protective histone proteins and therefore are more 
susceptible to damage, thereby potentially promoting or reducing their expression. 
We do know that as weight is lost there is a reduction in mV0
2
 and an improvement in LV 
diastolic function322, whether this is related to our observed changes in MT-ATP 6 and 8, 
deserves further study. Functionally it would appear that as weight is lost, energy efficiency 
improves324, energy demand drops325 and thus more energy can be diverted from maintaining 
systolic function to diastolic function326 and a longitudinal analysis of MT-ATP 6 and 8 
would help clarify this question. 
It would seem that the increase in MT-ATP 6 and 8 mRNA we have seen may be an 
early adaptive response to maintain cardiac energy production in the face of increasing 
energy demand created by adiposity and also a potent creator of free radicals that could 
prove pathological overtime.   
 
5.5.5. Neuronal function in obesity 
In our qPCR work we observed a trend towards an increase for all the neuronal genes we 
studied but a definite significant increase in tyrosine hydroxylase, which converts the amino 
acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), a key step in the production of 
noradrenaline and adrenaline, important catecholamines in the sympathetic nervous system. 
Obesity is a condition in which there is an increase in whole body and cardiac 
sympathetic activity327 and this increase in sympathetic activity is replicated in patients with 
heart failure328. Increased sympathetic drive may be pathological by several mechanisms 
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including development of LVH329, a common finding as already described, through direct 
toxicity and altered adrenoceptor activity. Chronic increased sympathetic nervous activity in 
the heart is directly toxic through stimulation of interstitial fibrosis, increased sarcolemma 
permeability with calcium overload and via the formation of oxidative metabolites which 
stimulate the ROS-TNF apoptosis pathway330.  
In the human there are 3 types of α1 adrenoceptor, 3 α2 receptors and 3 β receptors 
all with varying activities, with the heart predominantly containing β1 and β2 adrenoceptors.  
These receptors when stimulated increase contractility, relaxation, heart rate and 
conduction through the atrioventricular node all desirable effects and which are necessary 
to respond in normal situations such as exercise. As heart failure progresses, there is down 
regulation of β-adrenoceptor numbers and reduced sensitivity to stimulation331. Similarly, to 
some of the other changes we have seen and their postulated pathological effects, it would 
seem that an initial increase in tyrosine hydroxylase would be compensatory in obesity 
before eventually proving pathological via the mechanisms already outlined. 
 
5.6. Overall Genotype and modelled phenotype 
The overall genotype observed in this study was one with an up-regulation of the main 
calcium channel Cav1.2 and other important Ca2+  handling proteins such as RYR2, NCX1 and 
SERCA2A. We also observed an up-regulation in the majority of Na+ -K+ ATPase genes and K
ir
 
2.1 and the pacemaker gene HCN4, which was also confirmed to have increased at protein 
level. The modelled phenotype was for a prolonged AP with a much sharper repolarization 
slope compared to the control animals. We also observed increases in mitochondrial energy 
genes and an increase in tyrosine hydroxylase mRNA, both of which would appear to fit 
with the higher energy requirements and higher sympathetic activity observed in obesity. 
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6. Human type 2 diabetes experiment 
 
6.1.  Clinical characteristics 
Clinical characteristics for the two patient groups are shown below in Table 11 with 95% 
confidence intervals and show that both groups are comparable in terms of age, BMI, waist 
circumference with no significant differences between groups (p=ns for all) in Table 11.   
Table 11: Clinical characteristics of the control and diabetes groups 
 
Comparatively, the diabetes group had a tendency to more often be on cardiac medications 
than the control group but with no statistical significance in treatment differences (Table 
12).  
Group ACE/ARB Beta Blocker Statin Sulfonylurea Metformin 
Control 5 (55.5%) 3 (33.3%) 4 (44.4%) n/a n/a 
Diabetes 5 (71.4%) 3 (42.8%) 6 (85.7%) 2 (28.6%) 4 (57.1%) 
Table 12: Medication usage in each experimental group 
 
In our study only one a patient had a complication of diabetes with that patient suffering 
mild renal impairment as evidenced by an increased albumin-creatinine ratio but an eGFR 
well above 30 mls/min/1.73m2 and a normal serum creatinine level as measured by the 
hospital laboratory. 
 
6.2.  ECG analysis 
Comparison of the standard 12 lead ECG measured corrected QT interval was made between 
the two groups with a QTc in the control group of 451ms±6.58ms and 467ms±13.67ms in 
the group with diabetes which was significantly different (p=0.011: Figure 32).  Based on 
Group No. Age (Years) Male Waist (Cm) BMI (Kg/m2) HbA1c 
(mmol/mol) 
Control 9 78.8 (72.4-85) 6 35.8 (33.7-39.7) 27.8 (26-29.6) n/a 
Diabetes 7 74.9 (63-86.7)  4 39.7 (31.6-47.9) 31.2 (24.9-37.5)  57.9 (44.4-71.4) 
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previous experimental work we expected there to be arrhythmogenic changes in gene 
expression in the diabetes group and we planned to see if this might result in more positive 
late potentials but SAECG assessment of our two groups yielded only one patient in each 
group with a positive SAECG for late potentials with no difference between groups (p=ns). 
Measurements of the QRS width, HFLA signals, mean voltage in the terminal 40mSec of the 
QRS and the root mean square voltage in the terminal 40mSec were all not statistically 
different in the two groups (p=0.292, 0.28, 0.73, 0.814 and 0.63 respectively; Figure 32).  
 
Figure 32:  Key measurements from the standard 12 lead ECG and signal averaged ECG for 
the control (n=9) diabetes (n=7) groups. Means ± SEM shown. 
 
6.3.  Echocardiography 
 
6.3.1. Inter- and intra-observer variation 
As a measurement of quality control and reliability, inter- and intra-observer variability of 
some of the standard echocardiographic measurements used in this study were assessed 
and are shown below as Bland-Altman plots in line with previously published 
echocardiography studies and best practice (183): 
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Figure 33: Bland-Altman plots of intra- and inter-observer variability of some of the most 
important standard echocardiographic measurements with mean and standard deviation 
lines (n=5 for each assessment).A, Intra-observer variability of EF. B, Intra-observer 
variability of septal width. C, Intra-observer variability of MAPSE. D, Inter-observer 
variability of EF. E, Inter-observer variability of septal width. F, Inter-observer variability of 
MAPSE. 
 
As seen above, there is good agreement visually between observers and by the same 
observer repeating the analysis with no results outside the 95% lines. This suggests 
therefore reasonable validity in the measurements made and reliability in the reproducibility 
of the results obtained in this study.  This is in part due to the methodology used in this 
study which has come in large part from consensus guidelines based on multiple large 
studies. Also, both observers were trained in the same department which does in all 
probability help add to agreement between observers. A comparative t-test for each 
measurement between observers and intra-observer yielded no significant differences. 
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As with the standard 2D echocardiographic measurements made above methodological 
analysis of the global average strain rate data was made using Bland-Altman plots shown 
below: 
  
 
Figure 34: Bland-Altman plots of inter- and intra-observer variability of speckle derived 
longitudinal and circumferential stain with mean and standard deviation lines (n=5 for each 
assessment. A, Intra-observer variability of circumferential strain by speckle. B, Intra-
observer variability of radial strain by speckle. C, Intra-observer variability of longitudinal 
strain by speckle. D, Inter-observer variability of circumferential strain by speckle E, Inter-
observer variability of radial strain by speckle. F, Inter-observer variability of longitudinal 
strain by speckle. 
 
As we can see there is acceptable agreement in the strain analysis suggesting reasonable 
reproducibility of results obtained via strain analysis. Again, a t-test of each measurement 
between observers and intra-observer yielded no significant differences. 
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6.3.2. Standard echocardiographic measurements 
Prior to more detailed assessment of strain rates between the two groups, standard 
echocardiographic assessment was made of the patients in each group shown below in 
Table 13 with means, SEMs and  p value between the groups: 
 
Echocardiographic Parameter Control Group Diabetes Group p Value 
Ejection Fraction (%) 63.88 (2.31) 58.21 (1.16) 0.09 
LV Septal Width (Cm) 1.56 (0.08) 1.68 (0.02) 0.53 
End Systolic Volume (Mls) 31.55 (5.08) 37.80 (2.78) 0.39 
End Diastolic Volume (Mls) 76.19 (9.37) 89.60 (6.97) 0.33 
Mitral Annular Planar Systolic 
Excursion (Cm) 
1.57 (0.09) 1.12 (0.09) <0.01 
Left Atrial Area (Cm2) 20.42 (0.78) 26.94 (2.47)  0.01 
E/A ratio 0.88 (0.07) 0.918 (0.10) 0.81 
E/e’ Lateral 11.16 (1.33) 12.79 (1.53) 0.44 
Table 13: Standard echocardiographic measurements in each group 
 
Our results show that both study groups are not statistically different in terms of traditional 
measurements of left ventricular function (ejection fraction) and left ventricular wall 
thickness (septal width). Both groups showed significant hypertrophy of the left ventricle 
septum when compared to reference values185 as would be expected with significant aortic 
stenosis. We did see however that longitudinal function was depressed in the group with 
diabetes and there was an increase in left atrial size which are well recognised features of 
diabetes, thought to be due to sub-endocardial damage causing reduced longitudinal 
function and higher LV filling pressures resulting in increased LA size. These results show 
that we have a control group and an experimental group who would, by traditional 
assessment, have similar contractile performance and hypertrophic change, which we 
believe provides a useful comparison of the effect of type 2 diabetes on the human left 
ventricle over and above LVH. 
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6.3.3. Atrial function 
Following on from the higher LA size and published work on higher LA pressures in patients 
with diabetes332, measurement of active left atrial function between groups showed that 
there was no statistically significant difference in left atrial passive or active emptying (p=ns 
for both; Figure  35) but that the left atrial expansion index was significantly reduced by 
nearly 50% in the group with diabetes (p=0.035)  and this measures the LA reservoir 
function. 
 
Figure 35: Comparison of the left atrial expansion index (LAEI), left atrial passive emptying 
fraction (LAPEF) and left atrial active emptying fraction (LAAEF). Means ± SEM shown 
(Control; n=9/Diabetes; n=7). *significantly different from the control group (P<0.05). 
  
6.3.4. Strain analysis 
As discussed in the methodology section we have primarily focussed on the use of speckle 
tracking in this study because of easier use and superior reliability333 but to show that the 
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trends we obtained would be similar using TVI, comparison of longitudinal and 
circumferential strain was made between the two methods using the Bland-Altman method. 
 
 
Figure 36: Bland-Altman comparison of longitudinal and circumferential strain using TVI 
and speckle tracking. (n=5 for each assessment). A, TVI vs. speckle for longitudinal strain. B, 
TVI vs. speckle circumferential for longitudinal strain 
 
As mentioned earlier, radial strain is not well measured by TVI imaging179 and so was not 
included in the methodological comparison but as we can see in the two plots there is good 
agreement between the two methods and this has previously been reported 334 and helps 
supports the reliability/reproducibility of our strain rate trends measured in this study 
(Figure 36). In addition to this there was no significant difference in the measurements when 
they were analysed using a t-test for both groups. 
Both groups had a mean global longitudinal strain rate which is lower than previously 
published normal values of -21%+/- 2%184 and longitudinal strain measurements (below -18%) 
in the range associated with myocardial fibrosis in diabetes182 and in aortic stenosis alone168 
in previous studies. Both groups had strain values that are much lower than previously 
reported control values and strain values consistent with results correlating with myocardial 
fibrosis. These findings would support an indirect suggestion of interstitial fibrosis in both 
groups, and that the changes in the diabetes group are likely to relate to diabetes and not 
just interstitial fibrosis.  
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Comparative strain analysis between the groups to look for subtle left ventricular 
dysfunction was assessed in the circumferential, radial and longitudinal planes and shows 
that global circumferential (p=<0.01; Figure 37) and longitudinal strain (p=0.013) were 
markedly lower (by nearly 50% and 25% respectively) in the group with diabetes suggesting 
dysfunction specific to patients with diabetes over and above that expected in aortic valve 
disease (Figure 37).  
 
 
 
Figure 37: 2D Speckle derived measurements of strain in the longitudinal, circumferential 
and radial vectors. Means ± SEM shown (Control; n=9/Diabetes; n=7). *significantly different 
from the control group (p<0.05). 
 
6.4. RT- PCR results 
 
6.4.1. Main ion channels active during the action potential 
Expression of left ventricular ion channel genes in the diabetes group (n=7) was measured 
quantitatively at the mRNA level using PCR and compared to the non-diabetic control group 
(n=9). Expression of the primary cardiac Na+ channel, (Na
v
1.5) was slightly higher in the 
diabetes group but not significantly (p=0.50). Expression of the L-type voltage gated Ca2+ 
channels (Ca
v
1.2 and Ca
v
1.3) responsible for the I
C a-L 
current were not significantly altered in 
the diabetes group (p=0.98 and 0.92 respectively) compared to the control group. Expression 
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of K
v
1.4 and K
v
1.5, which are responsible for the slow transient outward K+  current (I
to-S
) and 
the ultra-rapid delayed rectifier K+  current (I
K,ss
), tended to be greater in the diabetes group 
(but not significantly so; p=0.77 and 0.73 respectively). Expression of K
v
4.2 (KCND2) and 
K
v
4.3 (KCND3) and the auxiliary subunit KChIP2 (Kcnip2), which are responsible for the fast 
transient outward K+  current (I
to-F
), were not significantly different between groups but 
tended to be higher in the diabetes group. In the diabetes patients, the major finding, was a 
significant reduction by 65% (p<0.01; Figure 38) in expression of ERG (K
v
11.1) responsible 
for the rapid delayed rectifier K+  current (I
K,r
). Expression of K
v
LQT1 (KCNQ1) was not 
significantly altered between groups (p=0.83). 
 
 
Figure 38: Expression of mRNA for major ion channels active during the action potential in 
the left ventricle of the control and diabetes groups displayed in arbitrary units referenced 
to expression of 18-s (housekeeper gene). Means ± SEM shown (Control; n=9/Diabetes; n=7). 
**significantly different from the control group (p<0.01). 
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6.4.2. Main ion channels active during diastole 
In our assessment of major channels active during diastole, we were able to see expression 
of KCNJ3 which encodes K
ir
3.1
, 
a G-protein activated subunit of the I
k,AC h 
channel 
(acetylcholine activated inward rectifying current), was reduced by nearly 50% in the group 
with diabetes (p=0.039; Figure 39). We also saw that there was an 85% and 68% increase in 
mRNA levels of KCNJ2 and KCNJ5 respectively (p=<0.01), which encode K
ir
2.1 and K
ir
3.4
 
respectively, in the group with diabetes. We did not observe any differences in gene 
expression of the major cardiac gap junction proteins, connexins Cx40 and Cx43 or in the 
Na+ /K+ hyperpolarisation activated cyclic nucleotide-gated channels 1, 2 and 4 (HCN1, 2 and 
4) which are responsible for the funny current (I
f
), an important pacemaker current, which is 
a current predominantly expressed in the foetal human ventricle or sino-atrial node. 
 
 
Figure 39: Expression of mRNA for major ion channels active during diastole in the left 
ventricle of the control and diabetes groups displayed in arbitrary units referenced to 
expression of 18-s (housekeeper gene). Means ± SEM shown (Control; n=9/Diabetes; n=7). 
*significantly different from the control group (p<0.05). **significantly different from the 
control group (p<0.01). 
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6.4.3. Cardiac Ca2+ handling Proteins 
In our group with diabetes we observed that ventricular expression of NCX1 (Na + -Ca2+ 
calcium exchanger) was 240% higher compared to the control group (p=0.047; Figure 40) but 
that expression of RYR2 (the sarcoplasmic reticulum’s – SR’s – Ca2+  channel) and SERCA2A 
(the sarcoplasmic reticulum’s – SR’s – Ca2+  pump) tended to be lower in the diabetes group 
but not significantly so (p= 0.78 and 0.75 respectively). 
 
 
Figure 40: Expression of mRNA for cardiac Ca2+ handling proteins in the left ventricle of the 
control and diabetes groups displayed in arbitrary units referenced to expression of 18-s 
(housekeeper gene). Means ± SEM shown (Control; n=9/Diabetes; n=7). *significantly 
different from the control group (p<0.05). 
 
6.4.4. Other channels and proteins 
Similarly, to the previous rat studies, a selection of Cl - channels was investigated: CLCN-2, 
CLCN-3, TTYH-1 TTYH-3 and BEST1 which is thought to encode for the I
C lC a
 current which 
allows Ca2+  mediated Cl - efflux. There was no clear pattern of chloride expression between 
the two groups with no significant difference between groups in expression (p=ns for all; 
Figure 41). There was no significant difference in expression between groups of Na + -K+ 
ATPases with very similar values for each isoform. Expression of Cx43 tended to be greater 
in the diabetes group (but not significantly so; p=0.237) and expression of Cx40, which 
encoded for gap junction alpha 5, another connexin important in cardiac conduction was 
slightly lower in the diabetes group but not significantly (p=0.394). 
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Figure 41: Expression of mRNA for Cl - channels,  subunits of the Na+ -K+ pump and the gap 
junctions Cx43/Cx40 in the left ventricle of the control and diabetes groups displayed in 
arbitrary units referenced to expression of 18-s (housekeeper gene). Means ± SEM shown 
(Control; n=9/Diabetes; n=7).  
 
6.4.5. Cardiac energy production 
As in the previous experiments, GLUT-4, MT-ATP6 and MT-ATP 8 expression were analysed 
again to look for an effect of type 2 diabetes on cardiac energy production. No observed 
significant difference in expression of GLUT-4 or MT-ATP8 was noted but a 17% reduction in 
MT-ATP 6 was noted (p=0.042; Figure 42) in the diabetes group. 
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Figure 42: Expression of mRNA for important cardiac energy production genes in the left 
ventricle of the control and diabetes groups displayed in arbitrary units referenced to 
expression of 18-s (housekeeper gene). Means ± SEM shown (Control; n=9/Diabetes; n=7). 
*significantly different from the control group (p<0.05). 
 
6.4.6. Neuronal genes  
As the final section for analysis, genes related to neuronal function, TH, UCHL1, NGF1, 
TACR1 were once again measured for differences in qPCR expression. There was no 
observable significant difference in expression for any of the 4 genes between the di abetes 
and control group (Figure 43). 
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Figure 43: Expression of mRNA for important cardiac neuronal genes in the left ventricle of 
the control and diabetes groups displayed in arbitrary units referenced to expression of 18-s 
(housekeeper gene). Means ± SEM shown (Control; n=9/Diabetes; n=7).  
 
6.5. Action Potential Modelling 
Using the results from our RT-PCR experiment we were able to use this to model the effect 
this would have if translated at the protein level to their respective channels that are 
testable using the O’Hara-Rudy model. Based on the testable currents available from the 
O’Hara-Rudy model, the quantitative qPCR data for these currents were converted to relative 
expression changes shown below in Table 14 and then converted to current conductance 
changes: 
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Channel Current Expression change in diabetes group 
Na
v
1.5  I
Na
  +21.08% 
Ca
v
1.2 and 1.3 I
C a-L
  +14.18% 
K
v
1.4, 4.2 and 4.3 I
to
  +26.04% 
ERG I
K,r 
-65.24% 
K
v
LQT1 I
K,s
 -5.38% 
K
ir
2.1  I
K,1
  +85.23% 
NCX1 I
NaC a
  +243.83% 
RYR2 SR Ca2+  release -10.07% 
ATP1a1-3 I
Na-K
 0% 
Table 14: Relative current expression changes based on mRNA change in the diabetes group 
 
Using this data in a similar manner to the HFD experiment, the Figure shows simulated 
action potentials (top row) from the human endocardial (Figure 44A) and epicardial (Figure 
44B) ventricular cell in the control and diabetes groups, accompanied by the cardiac 
currents and the intracellular Ca2+  concentration fluctuation. In both the endocardial and 
epicardial cell models, remodelled ion channels based on gene expression change in the 
diabetes group produced an increase in the amplitude of the action potential, elevation of 
the plateau phase and an increase in the APD. In particular, at the endocardial level, there 
was generation of an early-after depolarization which was not reproduced in the epicardial 
cell. APD prolongation is potentially attributable to the increase in many of the currents 
observed in the diabetes group and to elucidate which of these genes were most 
responsible, each current was separately tested to identify which were the drivers of  the AP 
changes seen. 
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Figure 44: Simulated human ventricular endocardial (A; ENDO) and epicardial (B; EPI) action 
potentials and underlying ionic currents and intracellular Ca2+  concentration in control and 
diabetes groups 
 
When each channel was tested singularly, (shown in Figure 45) the modelled increases of I
C a-L
, 
I
Na
 and I
to
 independently had negligible effects on APD and the amplitude of the action 
potential (Figure 45A-C). Modelling of the small decrease in I
K,s 
had no noticeable effect on 
the AP as might be expected from the very minor mRNA change(Figure 45D). The modelled 
reduction of I
K,r 
led to a dramatic prolongation of the AP in both simulated muscle layers and 
an increase in the maximum membrane potential (Figure 45E). The increase in I
K,1 
(Figure 
32F) alone resulted in APD abbreviation especially in phase 3, where I
K,1
 sharpens the rate of 
descent. The increase in I
NaC a
 led to prolongation of the AP, elevation of the resting 
membrane potential and failure to fully repolarise (Figure 45G). Ca2+  release via RYR2 (Figure 
45H) which was modelled to be reduced by a small amount, produced negligible effects on 
the action potential and very little change in calcium level change. Therefore, the 
simulations suggest that the diabetes induced changes in ion channels could result in a 
prolongation of APD primarily as a result of an increase in I
NaC a
 and a reduction in I
K,r 
with 
generation at the endocardial layer of an EAD.
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Figure 45: Simulated human ventricular endocardial and epicardial action potentials in 
control and diabetes groups with each of the remodelled ion channels/ionic currents 
modified singularly. A, only I
C a,L
 considered. B, only I
Na
 considered. C, only I
to
 considered. D, 
only I
K,s
 considered. E, only I
K,r
 considered. F, only I
K,1
 considered. G, only I
NaC a
 considered. H, 
only SR Ca2+  release considered (J-Rel. respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
6.6. Discussion 
 
6.6.1. Human study-type 2 diabetes: Clinical characteristics  
In this study we were fortunate to have two very similarly matched groups in terms of age, 
BMI, waist circumference and the diabetes group only had 1 person with a reported 
complication from their diabetes (minor nephropathy-evidenced by a slightly increased 
albumin-creatinine ratio). Overall, we consider that this, compared to many studies, gives a 
small but comparable cohort. 
 
6.6.2. Arrhythmogenesis 
As with our previous 2 experiments, reviewed below are the major mRNA changes and the 
AP modelling results and a discussion of how these relate to an arrhythmogenic phenotype 
in the diabetes patient. 
 
6.6.2.1. Down-regulation of ERG in type 2 diabetes 
In our group with diabetes, we have seen a marked reduction in ventricular mRNA 
expression of ERG which encodes the pore forming subunit of the I
K,r 
channel, the major 
outward delayed rectifying current with a marked prolongation of the AP. 
Functionally I
K,r
 causes K+  efflux with slow activation and fast recovery from 
inactivation, creating a positive feedback loop to help keep the AP duration appropriate 335 
and prevent AP prolongation, one of the prime steps in arrhythmogenesis. This function of 
the ERG channel is very important as in the context of an ectopic waveform, quick recovery 
from inactivation allows a short, high transient outward current to be generated by the 
ectopic waveform through the ERG channel  and prevents the waveform generating a 
current large enough to promote an ectopic beat336. I
K,r
 also has a secondary function which 
is to remain open during the resting phase of the AP for a period and this helps to maintain 
cell refractoriness.   
Our AP modelling shows that down-regulation of ERG creates early after 
depolarizations at the endocardial level at the plateau phase of the AP, which is a previously 
reported phenomena in the context of normal cellular coupling337. This is thought to be due 
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to reactivation of the I
C a-L
, created by extension of the plateau phase
  
and occurs in the 
endocardium predominantly as the sharper electrical gradient between the epicardium and 
mid-myocardium allows formation of a ‘sink’ for excess current in the epicardium reducing 
EADs in the mid- and epicardial layers337.  As well as the other pro-arrhythmic consequences 
of reduced ERG we know from previous studies that down-regulation of ERG leads to a 
reversal of the repolarization gradient from apex to base and increased dispersion and thus 
the formation of re-entrant circuits and arrhythmias338.  
The role of reduced ERG expression and or ERG blockade clinically in 
arrhythmogenesis 339 is well reported and particularly so in patients with diabetes130. In 
previous studies it has been shown that both myocardial hypertrophy340 and myocardial 
fibrosis341 leads to reduced ERG and it is not clear that diabetes had a specific effect on ERG 
expression within the myocardium or whether down-regulation of ERG was a function of 
hypertrophy/fibrosis. By comparing our group with diabetes to a control population with 
hypertrophy and likely fibrosis, we have shown that there may be a specific effect of 
diabetes on ERG expression within the myocardium and that this may go some way to 
explaining higher arrhythmia rates in patients with diabetes.  
 
6.6.2.2. Up-regulation of K
ir
2.1 in type 2 diabetes 
In our group with diabetes, there was an up-regulation of KCNJ2, which is the gene 
responsible for the main component of I
K,1
 channel, which sets the resting membrane 
potential at more negative potentials allowing for increasing potassium efflux. Our AP 
modelling has shown that this probably has only a small effect on the AP (again this maybe 
a function of AP simulations), most obviously in acceleration in phase 3 of repolarization to 
give a sharper terminal part of the curve. Other experimental work has suggested that 
increased or gain function, mutations in KCNJ2, leads to a more negative membrane resting 
potential, shorter terminal phase 3 and shorter action potential, similar to what we have 
observed, when testing this current only. 
Clinically an association between increased I
K,1 
 has been seen with atrial 
fibrillation213, ventricular tachycardia292 and elimination of the slow T wave in the ECG293. 
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Experimentally, if over-expression of I
K,1
 is not pro-arrhythmic on its own, studies have 
shown that it renders the heart more susceptible to arrhythmias342.   
Whilst, lots of evidence points to a pro-arrhythmic action, as discussed above it may 
be that the up-regulation of KCNJ2 we have seen is compensatory with an increase in I
K,1 
an 
attempt to balance the increase in APD and try to counter the effect of reduced ERG. This 
appears to be a consistent finding from our obesity experiment which as noted in the 
introduction is a major risk factor for type 2 diabetes. 
 
6.6.2.3. Down-regulation of K
ir
3.1 in type 2 diabetes 
We have also seen that there is comparatively reduced expression of KCNJ3 in the group 
with diabetes, which codes for a tetrameric, acetylcholine responsive rectifying channel that 
predominantly is expressed in atria. Due to the fact that this is mainly an atrial channel we 
were not able to incorporate this into our biophysical model and thus look at a potential 
effect on the AP and so theoretical information on how it may contribute comes from other 
studies. 
In atrial studies inhibition of the I
K,AC h 
channel, resulted in prolongation of the action 
potential in the atria with a change in the APD repolarization curve343 with similar findings 
in the single human ventricular cell228 . Interestingly this effect with the atria was protective 
with reduced arrhythmogenesis. Expression of the I
K,AC h 
channel tends to be in an opposite 
manner to I
K,1
, with mainly ventricular expression of I
K,1
344. It has previously been shown that 
there is a regional variation in the effectiveness of the I
K,AC h 
channel and that in epicardial 
cells within the left ventricle, activation of this channel is negatively inotropic 345. 
Whether these effects would be directly reproduced in the human ventricle would 
require physiological testing but if the down-regulation did produce the effects noted above 
such as prolongation of the AP or reduced contractility, this would be consistent with our 
observed functional findings on the EGG (prolonged QTc) and echocardiogram (reduced 
strain). 
Interestingly we observed the same changes in the STZ experiment in the ventricle of 
the rat, whether this represents a diabetes specific process linked to nervous system 
function could be explored further.  
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6.6.2.4. Up-regulation of K
ir
3.4 in type 2 diabetes  
Opposite to KCNJ3, we saw an up-regulation in expression in KCNJ5, which codes for the 
other two of the four subunits of the I
K,AC h 
channel and has stretch related properties, which 
provide electro-mechanical feedback and inhibit the channel, in high stretch situations213. 
This up-regulation of the stretch sensitive subunits would suggest, that the higher LV filling 
pressures (our diabetes group did have larger left atria which often correlated with higher 
LV end diastolic pressures) commonly seen in diabetes, may present a mechanism for 
further I
K,AC h
 channel inhibition and QT prolongation. 
 
The I
K,Ach 
channel is an important 
therapeutic target in the treatment of human arrhythmias, ventricular and atrial, with 
blockade of this channel prolonging the action potential , but any potential role in 
ventricular arrhythmias in diabetes is unclear, though this channel has been shown to be 
down-regulated in chronic atrial fibrillation346. Again as with K
ir
2.1 further experimental 
work would be needed to look at the role of K
ir
3.4 in the ventricle and its functionality in the 
obese individual. 
 
6.6.2.5. Up-regulation of NCX1 in type 2 diabetes 
We have seen an increase in NCX1 mRNA expression and this finding has been repeated in a 
wide variety of cardiac disease states such as heart failure and ventricular tachycardia 347 as 
we have discussed already in the obesity section. 
While many of the mechanisms of arrhythmia generation will be the same in the two 
disease states, obesity and diabetes, several particular areas require specific review.  Firstly, 
hyperglycaemia is known to inhibit the sarcolemma Na +–K+ exchanger with resulting higher 
levels of intracellular Na+ , which results in increased reverse flow of NCX1, leading to Ca 2+  
overload within the cell and sarcoplasmic reticulum. This excess of Ca2+, can cause spark 
formation leading to generation of DADs and to triggered activity and ventricular 
arrhythmias. Secondly, NCX1 over expression may tie in with the other changes we have 
seen, as prolongation of the action potential, leads to stimulation of the NCX1 forward 
mode and reactivation of I
C a-L
 which then can generate DADs, through generation of I
Ti
 in 
phase 4 of the action potential, which is something we were able to model at the endocardial 
level. Finally, in identical fashion to our animal obesity model we have been able to show 
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down regulation of I
K,1 
with as expected a sharper membrane potential drop in the terminal 
phase of repolarization which synergistically may potentially lead to creation of the 
arrhythmogenic I
Ti 
current.  
NCX1 expression has been seen to be increased in LV hypertrophy 348 and by 
comparing our group with diabetes who traditionally have been seen to have increased LV 
mass, with a control with LV hypertrophy, we can see that diabetes on its own does seem to 
stimulate NCX1 overexpression. There seem to be many mechanisms as discussed here 
whereby an increase in NCX1, is arrhythmogenic and whilst this study cannot prove the 
validity of each postulated mechanism, there is enough evidence elsewhere to suggest an 
important role for NCX1. 
 
6.6.2.6. ECG-correlation with qPCR 
Similarly, to many other studies349, 350 we were able to observe a prolongation of the QTc in 
our group with diabetes compared to the control subjects. This is supportive of the  
arrhythmogenic changes we have seen at the mRNA level and with our AP modelling. By 
looking at two comparable groups, it would appear that this change is primarily a function 
of their diabetes. 
In our study we have seen that in 2 similar groups of patients that the presence of 
type 2 diabetes did not cause any significant differences in the QRS width, late voltages or 
positive signal averaged ECG assessment. On review of the literature we did find reports of 
increased prevalence of positive SAECGs in patients of all ages with diabetes351, though the 
level of diabetic complications352 was not always stated and this has made comparing our 
data difficult. We know from previous work that there is an increased incidence of positive 
SAECGs in patients with aortic stenosis353 and it may be that a potential difference here has 
been removed because our control group unlike other studies also had a disease process 
causing LVH and potentially myocardial fibrosis.  
 
6.6.3. Contractility 
The qPCR data obtained predominantly reflects a genotype that leads to a modelled increase 
in AP duration and this normally would lead to an increase in duration of the calcium 
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transient and thus the SR Ca2+  load which is then linked to Ca2+  induced ECC. Looking at our 
AP modelling this would certainly seem to be the case and by allowing for increased time, an 
increase in Ca2+  entry may compensate in the early stages for deficient contractile function 
or larger LV mass354. Whether as the disease progresses the altered Ca2+  load leads to 
abnormal handling and impairment of the Ca2+  linked ECC has not been fully proven. The 
only gene change which may prove directly negatively inotropic was our observed increase 
in the I
K,AC h
 channel gene which in turn are stimulated by vagally released acetylcholine. 
Previous work has shown that there may be a directly negatively inotropic action of I
K,AC h 
but 
also that this may oppose sympathetic mediated β-adrenoceptor positive inotropic activity355, 
356. We do know that the majority of the I
K,Ach 
current is expressed in the atria, so any 
reduction in function is likely to be primarily in the atria compared to the ventricle , 
interestingly we did observe a significant reduction in one active atrial function parameter, 
LAEI and a trend for all others to be reduced. The left atrium exists under similar conditions 
to the left ventricle and the Frank-Starling’s law applies similarly to the LAEI’s reservoir 
function and this phase of atrial function is characterised by passive enlargement allowing 
filling from the pulmonary veins in ventricular systole. This function is characterised firstly 
by atrial relaxation, then compliance and a stretchable left atrium but as we might expect 
with increasing left atrial size and in a condition marked by fibrosis, hypertrophy and 
vascular stiffness (diabetes) as compliance falls, so does the LAEI. This result would be 
consistent with previously published worked on age related reductions in the LAEI with 
complimentary increases in LA area357. 
Previous studies suggest that much of the impaired ventricular contractile function 
relates to changes in the structure of the diabetic heart with changes in collagen deposition 
and marked fibrotic change within the ventricle. 
As expected, we did see that both groups had significant levels of left ventricular 
hypertrophy and that despite a normal ejection fraction value, both groups had strain 
values below the normal reported range and consistent with myocardial fibrosis. As outlined 
above reduced contractile function in diabetes is thought in large part to be due to 
structural abnormalities such as myocardial fibrosis with increasing fibrosis linked to 
poorer function and lower strain rates to higher rates of fibrosis358.  
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Our group with diabetes comparatively had larger atrial areas and lower longitudinal 
function and this is a commonly reported 359 phenomena potentially due to increased 
collagen deposition and fibrosis leading to subclinical dysfunction and lower compliance for 
LV filling.  
Further work would be needed to longitudinally track the prolonged AP gene 
changes we observed and the relationship to ventricular function to see whether this truly 
represents an early adaptive phase prior to clinical symptoms. 
 
6.6.4. Energy production in type 2 diabetes 
Despite the wide ranging metabolic effects of diabetes, the only observable change seen in 
gene expression was a down regulation in MT-ATP6.  
MT-ATP6 dysfunction is commonly seen as Leigh’s syndrome , a severe multi-system 
disorder with severe neurological features as well as energetic disorders. What we do know 
from some animal studies is that a lack of MT-ATP6 leads to a loss of complex V function 
which is important in the normal oxidative phosphorylation process leading to an increase 
in atypical energy pathway use360 which is less effective. Previous studies have shown clear 
energy production abnormalities in type 2 diabetes within the heart relating to 
mitochondrial dysfunction361. 
Interestingly MT-ATP6 polymorphisms have been linked to the development of type 
2 diabetes362 and to inherited cardiomyopathies363 increasing the likelihood of there being a 
common pathological themes.  
 
6.6.5. Neuronal function in type 2 diabetes 
In this study, whilst neuropathy of varying degrees is a well reported consequence of 
diabetes there was no significant change in any of the gene targets tested between groups. 
This is somewhat surprising given the background information summarised in the 
introduction but given the heterogeneity of the human population compared to animal 
controls may be simply a result of our patient group. Overall, by trying to find a cohort with 
diabetes without confounding complications such as renal failure our population had little 
in the way of complications which may mean a phenotype not severe enough yet to cause 
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autonomic or neuronal dysfunction. It also has to be borne in mind that while we did not 
observe changes in classical neuronal genes, we did not measure clinically or biochemically 
for signs of neuronal dysfunction and therefore a lack of gene changes does not mean no 
neuronal dysfunction in our diabetes group. In a future study, clinical and biochemical 
testing for neuronal dysfunction coupled with a larger cohort for gene expression testing 
would certainly be worthwhile.  
Given, the lack of positive results it is difficult to comment further, though whether 
the increased I
K,AC h 
is a response to the commonly found increased sympathetic drive 
observed in patients with diabetes maybe an area for exploration364. 
 
6.6.6.  Overall genotype/phenotype 
In this study, we observed a marked downregulation in the diabetes group of ERG mRNA 
production along with increases in K
ir 
2.1, 3.1, 3.4 and NCX1. These changes overall were 
modelled to lead to a significant increase in the AP duration with the formation of EADs at 
the endocardial layer, which has previously shown to be a pro-arrhythmogenic phenotype. 
Phenotypically, we observed an increase in the QT time in our diabetes group which would 
be supportive of the gene changes we observed. Also, in our diabetes group we observed an 
increase in left atrial area and reduced left atrial expansion index with reduced longitudinal 
ventricular function. We also observed a reduction in the diabetes group of circumferential 
and longitudinal strain compared to the control arm. 
Overall, these findings would suggest a diabetic cardiomyopathy with 
arrhythmogenic genotypic and phenotypic changes along with reduced ventricular/atrial 
function and that these changes were not apparent in a control group with similar LV 
hypertrophy or possible fibrosis. 
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7. Limitations 
As with all experiments there are limitations to this study which have to be reflected upon 
when reviewing the results presented and the major limitations of this study are discussed 
below. 
As a small exploratory study, we did not perform a preliminary power calculation prior to 
beginning the work and relied on the experimental experience of the groups in Liverpool 
and Manchester; hence there is the possibility that some variations in the data or lack of 
difference may relate to a lack of power in the study. It was the intention that this study 
may be used to identify areas of interest for a further larger targeted study and the results 
here are not presented as definitive final findings but areas of interest that do merit further 
work.  
One major limitation to all our sub-studies, is that we only have mRNA data and not 
quantitative protein measurements to corroborate the mRNA findings except in the case of 
HCN4 in our obesity study. As stated above, this study was conceived as an initial 
exploratory study and so we wished to identify areas in a further study for quantitative 
analysis of protein. Allowing for this, results using the TAQMAN™  system have proved 
reliable in terms of translation from mRNA to protein150, 152 and we did observe that when 
HCN4 mRNA was increased so was the protein expression. In a similar fashion, in this study 
it is impossible to claim mRNA changes lead to altered functional protein expression and 
even in the case of HCN4 protein up-regulation, it is not claimed with certainty that this 
protein is functional protein.  
Initially, this study was conceived without the aid of action potential modelling and 
as such we would have to interpret the data based on other experiments. While the 
modelling is illustrative of how mRNA changes if translated would play out, modelling is not 
the same as direct electrophysiological measurements such as patch clamp testing or 
intracardiac electrograms. It is not the claim of this study that the modelling data should be 
considered directly equivalent and directly translatable to intracardiac electrophysiology 
measurements. In the part of our study where there was corroborative electrophysiology, in 
the shape of 12 lead ECGs, the AP modelling, which suggested a prolonged QT was borne 
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out in the shape of the 12 lead ECG, where the diabetes group did have a longer QT 
compared to control. 
Overall, while there are several limitations in this study, we do believe that this study 
does highlight areas of interest for further investigation based on methods that have been 
shown to be reproducible by several other groups.  
 
8. Common themes  
A summary of the significant gene expression changes in the experimental groups 
compared to the control groups from the three experiments in this study are  shown below 
in Table 15: 
Gene Current STZ HFD Type 2 diabetes 
SCN5A I
Na
 Reduced: mid myocardium No change No change 
CACNA1c I
Ca-L
 No change Increased No change 
KCNA4 I
to-s
 Increased: all wall layers No change No change  
KChIP2 I
to
 Increased: mid and epicardial layers No change No change  
ERG I
K,r
 Reduced: mid myocardium Reduced  Reduced 
KCNQ1 I
K,s
 Reduced: mid myocardium No change No change  
KCNJ2 I
K,1
 No change Increased Increased 
KCNJ3 I
K,ACh
 Reduced: mid myocardium No change  Reduced  
KCNJ5 I
K,ACh
 No change  Increased Increased 
HCN2  Increased: all wall layers No change No change  
HCN4 I
F
 No change  Increased No change  
NCX1 I
NaCa
 No change  Increased Increased 
SERCA2a SR-Ca2+ uptake Reduced: endo and mid myocardium Increased No change  
RYR2 SR-Ca2+ release No change  Increased No change  
CLCN-2 I
Cl,ir
 Reduced: mid myocardium No change  No change  
CLCN-3 I
Cl,vol
 No change  Increased No change  
ATP1a1 I
Na-K
 Reduced: mid myocardium Increased No change  
ATP1a2 I
Na-K
 Reduced: endo and mid myocardium Increased No change  
ATP1a3 I
Na-K
 Reduced: endo and mid myocardium No change  No change  
Cx43  Reduced: mid myocardium No change  No change  
GLUT-4  Reduced: all wall layers No change  No change  
MT-ATP6  No change  Increased Reduced   
MT-ATP8  No change  Increased No change  
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TH  Not recorded Increased No change  
Table 15: Summary gene changes from the three experiments in this study 
 
Across all three experiments there was only consistent finding in the qPCR data, which was 
a reduction in expression of ERG and subsequently in AP modelling prolongation of the 
APD. Changes in ERG expression and the APD, are important in two major areas, 
electrophysiologically and contractile function and below, common themes are discussed. 
Firstly, as discussed previously, a reduction in ERG leads to prolongation of the AP and a 
failure of repolarization with a concomitant increase in rates of ventricular arrhythmias in 
many disease states. Other pro-arrhythmic consequences of reduced ERG include: an 
increase in transmural dispersion of repolarization, reduced ability to prevent ectopic beat 
generation-following an ectopic waveform, maintenance of cell refractoriness and reversal 
of the repolarization gradient  
All of these effects would potentially be sufficient to explain the higher rates of 
ventricular arrhythmias observed clinically in diabetes and obesity and may suggest a 
common pathological process, though whether it is a final downstream effect of 
diabetes/obesity or primarily part of both conditions is difficult to elucidate based on this 
study. 
Secondly, all three experimental subject groups have been shown to have impaired 
contractile function, as reported in other studies and seen in this study in our 
echocardiographic analysis. When ERG is reduced and the AP is prolonged there is reported 
to be a compensatory small increase in Ca2+  transient and an attempt to maintain excitation-
contraction coupling via this mechanism, though with a long term cost of maladaptive gene 
change365, 366. Whilst this compensatory change is likely to have a small beneficial effect on 
systolic function, prolongation of the AP, leads to a shorter diastolic filling time and 
eventually a reduction in output due to inadequate filling367, 368. The significant increase in LA 
size we observed and the reduction in the LAEI in our diabetes group could potentially be 
related to this to some degree. 
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Whilst, we only observed a common change in ERG across all three experiments, we 
did see some similar themes as one might expect between the obesity experiment and the 
human type 2 group, with both groups having an increase in NCX1 and increased K
ir
2.1. 
Increased NCX1 activity as outlined before, is likely to lead to an increase in SR -Ca2+  levels 
and probably along with the reduced ERG we have seen a prolonged AP which similar to ERG 
leads to a small compensatory potential increase in systolic function at the cost of increased 
arrhythmias and reduced diastolic time. Increased K
ir
2.1, looking at many of the other gene 
changes is probably a small compensatory mechanism to try and abbreviate the AP 
prolongation caused by many of the other changes such as reduced ERG/increased NCX1. 
Overall, it would appear that all three conditions are characterised by gene 
expression changes that prolong the AP possibly as a compensatory mechanism for 
structural changes that affect systolic function at the cost of an increased rate of 
arrhythmias and reduced diastole. Further work would be required to look at the role of AP 
prolongation/ERG reduction in diabetes and obesity as to the role of this as a primary 
function of the conditions as a consequence of the conditions. 
 
9. Future directions 
This study has described several interesting changes in mRNA expression in the STZ rat 
model, the HFD rat model and a human group with type 2 diabetes, which may have 
implications for arrhythmogenesis and contractile function and we discuss now some 
aspects which may merit future study. 
One of the first areas for future work would be to perform detailed protein quantification of 
the key altered genes in this study firstly in the rat models and then in a  similar human 
study. The lack of confirmatory protein expression has been a major limitation of this study 
and when performed would need to be accompanied by direct electrophysiological 
assessment of the channel/current function, which may then prove the importance of the 
measured mRNA changes we have seen. 
Moving forward from the models and results presented here, several interesting future 
avenues of investigation present themselves from an obesity perspective including whether 
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obesity from carbohydrates induces the same cardiac changes as obesity related to the high 
fat diet we used here. Following this, adding an exercise component to see whether high fat 
or high calorific diets lead to pathological cardiac changes if an animal does not develop 
obesity would be of great interest. 
In human research, a complimentary study using obese patients with aortic stenosis 
compared to lean controls would potentially provide further insight and be very interesting 
to look at overlap/differences with the type 2 diabetes population we have investigated 
here. The heterogeneity of the human population in terms of exercise/diet offers many 
opportunities for further work on the effect of obesity and diabetes on the cardiac system. 
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11.  Appendix 
11.1. Presentations 
Presentations of data from this study are reproduced below. Some of the data presented 
was provisional and has subsequently been revised for final presentation in this thesis. 
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